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Abstract 
Amid a substantial rise in gabapentin and pregabalin (gabapentinoid) prescribing and 
increasing concerns with their potential for misuse and diversion, there are anecdotal 
reports of their use for osteoarthritis. The aim of my thesis was to understand whether 
osteoarthritis may have contributed to the general rise in the use of the gabapentinoids. 
A series of scoping literature reviews summarised the context and potential rationale for 
the off-label use of gabapentinoids for osteoarthritis. An original analysis of data from the 
Clinical Practice Research Datalink (CPRD) was then undertaken.  
383,680 patients aged over 40 years with a new diagnosis of osteoarthritis recorded 
between 1995 and 2015 were identified and followed for a median of 5.1 years to their first 
gabapentinoid prescription or other censoring event. 35,031 (9.1%) cohort members 
received a gabapentinoid prescription. The crude incidence rate of first gabapentinoid 
prescription among this cohort of osteoarthritis patients increased from 1.71 (95% CI: 1.37, 
2.11) per 1,000 person-years in 2000 to 27.92 (27.06, 28.81) in 2015. Age-standardisation 
resulted in little change to these estimates. Whilst differences in incidence rates were seen 
by attained age, time since index osteoarthritis consultation, gender, and geographical 
region, the increasing trend over time was seen in all strata. The proportions of first 
gabapentinoid prescriptions in this cohort that could be attributed to osteoarthritis, a 
licensed indication, or an unlicensed indication were estimated as 9-10%, 11-12%, and 1-
2%, respectively. This proportion of attribution remained relatively stable throughout the 
study period. 
Patients with OA have become increasingly likely to be prescribed a gabapentinoid in the 
past two decades. Whilst this analysis found that the proportion of first prescriptions 
attributed to OA is approximately 9-10%, an unknown proportion of unattributed 
prescriptions may also be for OA. With growing concerns regarding their use, 
gabapentinoid prescribing in this condition requires careful justification.
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1 The Epidemiology and Management of Osteoarthritis 
 
1.1 Introduction 
Osteoarthritis (OA) is the most common form of arthritis, and as one of the most prevalent 
chronic diseases worldwide, is associated with substantial healthcare demand. This thesis 
investigates the off-label use of a class of drugs, the gabapentinoids, in patients with 
osteoarthritis presenting to primary care in the United Kingdom. Specifically this work aims 
to understand the risk of a patient with OA receiving a gabapentinoid. To set this work in 
context, this chapter aims to provide a brief overview of the epidemiology and current 
management of the condition. 
 
1.2 Defining Osteoarthritis 
In epidemiology, it is imperative to identify the definition of the disease to be studied 
(Bhopal, 2008). Disease definitions influence estimates of the frequency of the disease in 
populations and the nature of cases recruited into observational studies and clinical trials. 
Current opinion is that OA is a complex set of disorders (Driban et al., 2010) and, similar to 
other chronic non-communicable diseases, several definitions are used within 
epidemiological studies. The multiple definitions of OA reflect the lack of a ‘gold-standard’ 
diagnostic investigation, differences in the nature, risk factors and prognosis of the disease 
across different joint sites and the various sources of available data for epidemiological 
research. Another contributor to the variety of OA definitions used may be the different 
perspectives on how OA is most usefully characterised, for instance as a clinical syndrome 
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of joint pain and associated symptoms (Thomas et al., 2004), or as a biomechanically-driven 
disease affecting synovial joints (Brandt et al., 2008). 
Methods to define OA include using published classification criteria, such as those of the 
American College of Rheumatology (ACR), and other clinical guidance such as that provided 
by the United Kingdom’s National Institute for Health and Care Excellence (NICE). NICE’s 
guidance recommends the use of clinical criteria for diagnosing OA, based upon the 
presence of symptoms, such as stiffness and pain, in patients aged older than 45 years 
(National Institute for Health and Care Excellence [NICE], 2014). The ACR classification 
criteria for the diagnosis of knee, hip and hand OA are similar. Together with evidence of 
symptomatic disease, their diagnostic criteria also include signs elicited from physical 
examination, such as joint crepitus, as well as x-ray and laboratory findings (Altman et al., 
1986, 1990, 1991). Large population studies have used doctor-diagnosed OA, or the self-
reporting by study participants of persistent pain in joints commonly affected by OA, as 
indicative of the condition (Steel et al., 2014; Thomas et al., 2014). Some studies have relied 
upon evidence of disease found at post-mortem (Wallace et al., 2017). Electronic patient 
records and administrative healthcare records have increasingly been used to identify 
diagnoses for numerous conditions (Casey et al., 2016), and have been used in the study of 
osteoarthritis in the UK and internationally (Jackson et al., 2017; Jordan et al., 2007, 2014; 
Yu et al., 2015). Joint arthroplasty, a common endpoint for patients with severe OA, has 
also been used as a case definition, for example in genome-wide association studies 
(GWAS) (Zeggini et al., 2012).  
Joint imaging is commonly used to define OA in epidemiological research. The Kellgren-
Lawrence system, which utilises plain x-rays, is the most common method for defining OA 
radiographically (Braun & Gold, 2012). This system, approved by the World Health 
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Organisation (WHO), ranges from grade 0, with no radiographic evidence of joint pathology 
present, to grade 4, a joint with evidence of significant structural disease. Kellgren-
Lawrence grade 2, defined by the presence of a definite osteophyte (Figure 1.1), is most 
commonly used by studies as their threshold to define OA (Lawrence, 1977; Schiphof et al., 
2008). However, the use of the Kellgren-Lawrence system in epidemiological research has 
recognised limitations. Firstly, the use of grade 2 may result in conservative estimates of 
the prevalence of OA compared to clinical diagnoses, as patients who are judged to be 
grade 1 will be excluded, irrespective of their pain status. In the United Kingdom (UK) these 
patients could have a doctor-diagnosis of OA, as this can be made clinically without the 
need for radiographic investigations (NICE, 2014).1 Secondly, the definitions, particularly of 
grade 2, have been used inconsistently in the literature, including by the original authors 
(Schiphof et al., 2008). In other studies, whilst many use the presence of an osteophyte in 
their grade 2 definition, the presence of joint space narrowing features inconsistently 
(Arden & Nevitt, 2006; Cross et al., 2014; Culvenor et al., 2015; Parsons et al., 2015). The 
dependence on osteophyte formation has also been reported to be a limitation, as patients 
with joint space narrowing who have no osteophyte development rarely fulfil the criteria 
to be defined as having OA (Kohn et al., 2016). The reliance on osteophyte formation has 
also been reported to be of limited use for the assessment of the disease progression of 
OA, leading to other intermediate grades being proposed (Felson et al., 2011). In summary, 
not only could studies be significantly under-reporting the prevalence of OA, but estimates 
of the prevalence of radiographic OA may be heterogeneous due to the inconsistent 
definitions used by epidemiological studies. 
 
                                                     
1 The term ‘doctor-diagnosis’ describes a diagnosis provided by any healthcare professional. 
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A limitation of the use of plain radiography is that the articular cartilage, one of the main 
tissues affected early in OA, is poorly visualised. Potentially in response to this, studies have 
explored the use of magnetic resonance imaging (MRI). A 2014 study found that a grading 
system for OA using MRI had better content validity and was more sensitive than the 
Kellgren-Lawrence system, and this increased sensitivity had a higher association with knee 
pain (Schiphof et al., 2014). However, currently MRI scans are costly, time-intensive and 
can cause anxiety in some patients, and as a result have seldom featured as the method of 
defining OA in large-scale epidemiological studies.  
Whilst each of the definitions mentioned has strengths and limitations, they cannot be 
assumed to be directly comparable. A systematic review found the proportion of those with 
knee pain, who also had radiographically defined OA, ranged from 15 to 76% (Bedson & 
Croft, 2008). More recently, a systematic review reported that in asymptomatic adults aged 
≥40 years, the prevalence of knee OA based on MRI ranged from 19-43% (Culvenor et al., 
2018). As a result there may be vast differences between studies that use purely 
symptomatic or radiographic evidence versus those that use a combination of both 
definitions. It has also been demonstrated that a radiographic definition of OA leads to the 
Figure 1.1 Knee X-rays to 
Demonstrate a Kellgren-Lawrence 
Grade 2 Knee  
Image A depicts a normal knee 
(Radiopaedia, 2017), while B depicts 
a Grade 2 Kellgren-Lawrence knee, 
with a definite osteophyte, indicated 
by the arrow (Hayashi et al., 2016). 
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highest prevalence estimates, whilst self-reported and symptomatic definitions of OA 
produce similar results (Pereira et al., 2011).  
To account for the inconsistencies in the definition used to estimate the prevalence of OA, 
the 2010 Global Burden of Disease (GBD) study used statistical modelling techniques to 
adjust for prevalence figures reported by studies that used definitions different from their 
reference standard. In this study their reference definition was symptomatic OA confirmed 
using radiography (Kellgren-Lawrence grade 2), perhaps the most commonly used 
definition (Cross et al., 2014). 
 
1.3 Measures of the Frequency of Osteoarthritis 
 
1.3.1 Prevalence 
Using data from the Global Health Data Exchange, hosted by the Institute for Health 
Metrics and Evaluation, the worldwide age-standardised prevalence of symptomatic 
radiographic OA in 2016 was estimated as 4.5% (Institute for Health Metrics and Evaluation, 
2017). As demonstrated by Figure 1.2, the estimated prevalence of OA is highest in high-
income countries, such as the UK. The prevalence is also higher in females than males 
across all age groups and geographical locations, except in 30-39 year olds in high-income 
countries. The prevalence of symptomatic radiographic OA is strongly age-related, with 
prevalence negligible in children and adolescents and increasing in frequency across 
adulthood to exceed 5% after 45 years of age. As a result, many studies provide prevalence 
estimates within older age groups rather than in the whole population. For instance, an 
analysis of a Swedish healthcare register found that 26.6% of patients aged ≥45 years, 
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residing in the Skåne region in 2012 (n = 531,254), had received a doctor-diagnosis of OA 
affecting any joint (excluding the spine) at least once within the preceding 14 years. 13.8% 
of the population aged over 45 years had a diagnosis of knee OA, making it the most 
commonly affected joint (Turkiewicz et al., 2014). Although OA often affects the spine and 
hands, amongst other joints, the knee and the hip are the most frequently studied. Indeed, 
these two joints were the only sites analysed by the 2010 GBD study, which found the 
global age-standardised prevalence of knee and hip OA to be 3.8% and 0.85%, respectively 
(Cross et al., 2014). The focus on hip and knee OA may be justified by their frequency, 
debilitating nature, and relevance to joint replacements (National Joint Registry, 2017). 
However, it is likely that prevalence estimates based on these two joints alone will under-
estimate the prevalence of OA due to the lack of accounting for spinal OA and other 
peripheral joint OA, which are often categorised as ‘other musculoskeletal disorders’.  
One of the first studies to assess the prevalence of knee OA was conducted by Felson et al. 
(1987), using the Framingham Heart Study cohort. The age-standardised prevalence of 
radiographic knee OA within this cohort was found to be 19.2% in patients aged ≥45 years, 
although, as pointed out by the authors, this may be limited by a lack of ethnic diversity 
within the population studied. Since a 2001 review compared the prevalence of knee pain 
with and without disability and radiographic changes (Peat et al., 2001), published 
prevalence studies specific to the UK are sparse. However, albeit slightly out of date, data 
can be obtained from Arthritis Research UK (ARUK). ARUK’s Musculoskeletal Calculator, 
which utilises data from the Office for National Statistics (ONS), provides an estimate of 
10.9% and 18.2%, respectively, for hip and knee OA in England in 2012, in patients aged 
≥45 years (Arthritis Research UK, 2012). This translates to 2.5 million and 4.1 million 
sufferers of hip and knee OA in England in 2012, respectively (Public Health England, 2017). 
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Figure 1.2 2016 Worldwide OA Prevalence, of Males (Top) and Females (Bottom), by Age and 
Location (Institute for Health Metrics and Evaluation, 2017)  
The general consensus is that the prevalence of OA is increasing. Although this was not 
found in the 2010 GBD study, the authors noted that this finding was potentially due to the 
modelling software used to predict the prevalence of OA in countries where data were 
sparse, or due to the length of the study period (Cross et al., 2014). A recent analysis of 
more than 2,500 cadavers demonstrated that the prevalence of knee OA in those aged ≥50 
years in the United States (US) has more than doubled between the early industrial (up to 
early 1900s) and post-industrial (late 1900s onwards) periods (Wallace et al., 2017). 
Between 2005 and 2015, the global prevalence count of knee OA for all ages increased 
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32.9%, although this increase reduced to 2.2% after the population was age-standardised 
(Vos et al., 2016). This may demonstrate the effect of the ageing population on the 
prevalence of OA. With both life expectancy and the proportion of the population who are 
elderly expected to increase, this growth is only expected to continue.  
An increase in key determinants of OA may also contribute to its rising prevalence. Obesity 
is an important risk factor for the development and progression of OA, particularly of the 
knee (Allen & Golightly, 2015; Arden & Nevitt, 2006), and if projections are correct, the rise 
in prevalence of obesity will further compound the increasing prevalence of OA (Wang et 
al., 2011). After accounting for the projected changes in sex, age and obesity, Turkiewicz et 
al. (2014) predict that in Skåne, the region in Sweden, the prevalence of OA in patients aged 
≥45 years will increase from 26.6% in 2012 to 29.5% by 2032, and over half of this total 
figure will remain accounted for by OA of the knee (13.8% in 2012, 15.7% in 2032). 
 
1.3.2 Incidence 
Estimates of incidence, the number of new cases within a population during a certain 
period of time, are much less commonly published than those of prevalence for a condition 
such as OA. One factor that may contribute to this is that identifying the precise time of 
onset may be difficult, and there may be a ‘pre-clinical’ phase before changes in 
radiography and symptoms manifest (Ryd et al., 2015). Alongside this delay between 
disease onset and the development of symptoms or radiographic changes, there may also 
be a delay between the development of symptoms and patients receiving a diagnosis of 
OA. A case-control study within North Staffordshire (UK) found that the median time 
between a patient’s first knee symptom and their first diagnosis of knee OA in electronic 
healthcare records was 10.0 years (Bedson et al., 2005). OA was not assessed as part of the 
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incidence analysis of the 2015 GBD study, as they focussed instead on acute conditions 
such as infectious diseases (Vos et al., 2016). However, the reporting of incidence can be 
useful for chronic conditions such as OA as, without the influence of disease duration, it 
allows the temporal sequence of exposure and outcome to be studied. This allows the 
potential identification of risk factors, and the possible modification of these factors is 
extremely important from a public health perspective.  
A study within British Columbia, Canada, reported that within the fiscal year 2008/2009 the 
crude incidence rate of OA in the total population was 14.6 cases per 1,000 person-years. 
Whilst the crude incidence rate had increased from 1991/1992, the age-standardised 
incidence only increased slightly in males and no change was observed in the incidence of 
OA in females (Rahman et al., 2014). As with prevalence, the definition used has a large 
effect on the incidence rates of OA reported by studies. For instance within the UK, a study 
of primary care data between 1992 and 2013 found that the age-sex standardised incidence 
rate of OA in any joint, recorded using clinical terms such as joint pain, in those aged ≥45 
years, increased from 29.2 to 40.5 cases per 1,000 person-years. However, this increase 
was contrasted by incidence rates of consultations recorded as definitive, diagnostic OA, 
where the incidence rate fell from 8.1 to 6.3 cases per 1,000 person-years during the same 
period (Yu et al., 2017). This discrepancy in rates demonstrates the effect of different codes 
used in electronic healthcare databases, however NICE’s clinical definition may also be a 
factor, leading to more diagnoses, irrespective of the incidence rate of OA diagnosed using 
prior criteria. Within Europe, a Spanish five-year cohort study of electronic healthcare 
records conducted between 2006 and 2010 reported the incidence rate of OA, stratified by 
joint. The incidence rate of hand, hip and knee OA was 2.4, 2.1 and 6.5 per 1,000 person-
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years, respectively. This demonstrates again that, much like prevalence, knee OA is the 
most commonly affected joint (Prieto-Alhambra et al., 2014). 
 
1.4 Risk Factors 
Risk factors for OA can be general to all joints or joint-specific. Increasing age has been 
associated with the development of OA in all commonly affected joints (van Saase et al., 
1989). However, the two may be independent processes, with ageing associated with 
factors such as impaired sensory innervation function (Arendt-Nielsen, 2017) as well as 
inflammation and oxidative stress, which in turn may contribute to the susceptibility of the 
joint to the development of OA (Loeser et al., 2016). There is also evidence that increasing 
age may be associated with OA due to the longer time frame for cumulative exposures, 
such as knee loading, to have an effect. This accumulation of excessive or repetitive 
mechanical loading may be influenced by occupation and activity (Andersen et al., 2012; 
Ratzlaff et al., 2012; Verbeek et al., 2017), and by an increased body mass (Wills et al., 
2012). 
There is evidence that certain risk factors have stronger associations with certain joints. For 
example knee OA is strongly associated with an increased body mass index (BMI), but this 
relationship is not seen in hip OA (Dieppe & Kirwan, 1994). This may explain why the BMI 
of patients tends to be higher in those undergoing knee arthroplasty, compared to those 
awaiting hip arthroplasty (Culliford et al., 2015). Evidence of the role of certain risk factors 
remains poorly understood, and in some cases, contradictory. For instance Visser et al. 
(2015) found that an increase in weight was associated with knee OA, after adjustment for 
metabolic factors, but no relationship between knee OA and metabolic factors was found 
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after adjusting for weight. Whilst the opposite was seen when studying hand OA, 
interestingly the relationship seen in knee OA was also found when studying patients with 
both knee and hand OA, suggesting there may be a more complex underlying relationship 
present. However, others have found an association between metabolic syndrome and 
knee OA (Wang et al., 2016), and a cumulative effect of increasing metabolic conditions 
and their association with knee, but not hip, OA (Monira Hussain et al., 2014).  
 One of the most recent systematic reviews of OA risk factors reported that knee OA was 
associated with having previous joint trauma, an increased BMI, and being female (Table 
1.1). Previously studied risk factors, including smoking and concomitant hand OA, were not 
found to be associated (Silverwood et al., 2015). The effect of occupation on OA has also 
been studied. Manual labour is associated with knee OA, especially in males, whilst 
agriculture and farming has a strong association with hip OA (Andersen et al., 2012).  
Table 1.1 Pooled Odds Ratios of Knee OA Risk Factors with 95% Confidence Intervals (CI) 
(Silverwood et al., 2015)  
 
Evidence on the genetic contribution to OA is also expanding. Analysis has evolved from 
loci mapping (Zeggini et al., 2012) to functional analysis (Loughlin, 2015), although larger 
studies are required, especially as heterogeneity has been found between the studied joint 
sites. 
Risk Factor 
Number 
of Studies 
Total number 
of participants 
Pooled 
Odds Ratio 
Lower 
CI 
Upper 
CI 
Overweight 22 398,251 1.98 1.57 2.20 
Obese 22 401,119 2.66 2.15 3.28 
Overweight or Obese 25 415,613 2.10 1.82 2.42 
Previous knee injury 13 27,326 2.83 1.91 4.19 
Female Gender 11 28,133 1.68 1.37 2.07 
Hand OA 6 5,232 1.30 0.90 1.87 
Smoking 13 362,061 0.92 0.83 1.01 
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1.5 Impact 
As OA is a prevalent chronic painful condition, the impact it has on patients, healthcare 
services and wider society is large. In 2010, OA represented 2.2% of all years lived with 
disability (YLD), of which 83% were due to knee OA. Hip and knee OA combined ranked 11th 
out of the 291 conditions studied. This was an increase from rank 15th in 1990, 
demonstrating that the impact of OA is growing at a rate above that of other conditions 
(Cross et al., 2014). 
On a personal level, OA can have a variety of effects on the patient. The most debilitating 
symptom is pain, and this is one of the ‘need factors’ that results in patients seeking medical 
advice (Paskins et al., 2013). The large impact OA may have on a patient’s mobility may 
have large consequences in terms of work, but also on their general activities of daily living. 
Potentially because of this, as well as the physical impact, OA can also have psychological 
and emotional effects (Litwic et al., 2013). This emotional aspect to OA is important, as not 
only are anxiety and depression common in patients with OA, but both can negatively 
contribute to the experience of pain (Neogi, 2013). The wide range of effects of the 
condition results in patients with knee OA reporting lower health-related quality of life 
scores compared to age-matched controls and this relationship strengthens as the disease 
progresses (Farr II et al., 2013).  
Prevalent diseases, especially those with high levels of disability, would be expected to 
impact heavily on healthcare providers. More than one third of patients aged 45 years or 
older consulted for OA during a seven-year prevalence study in North Staffordshire, 
England (Jordan et al., 2014). A Swedish study assessed the proportion of patients with OA 
who present to a doctor due to their osteoarthritis. Using a cohort of patients with 
symptomatic knee OA, they found that more than 74% consulted a doctor and received a 
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consultation code of knee OA or joint pain between 2004 and 2011. 63% of the same 
population consulted during this time period and received a consultation of knee OA 
specifically, after search terms were restricted (Turkiewicz et al., 2015). With many patients 
seeking medical attention for such a prevalent disease, this results in a large burden on 
health providers, both within primary and secondary care. As could be expected due to its 
increased prevalence compared to any other joint, knee OA results in the most recorded 
consultations in primary care (Yu et al., 2015). For secondary care, the number of 
admissions to consultant care is published by ARUK, using data from Hospital Episode 
Statistics (HES). In 2016/2017, they reported that musculoskeletal conditions accounted for 
1.4 million admissions to consultant care, resulting in more than 2.2 million bed days 
(Arthritis Research UK, 2018). Whilst ARUK’s information is not broken down by specific 
disease, such as OA, the National Joint Registry (NJR) may be a useful resource. This is a 
database of all joint replacements performed in England, Wales, Northern Ireland and the 
Isle of Man. Their published annual reports present the number of joint replacements, as 
well as other information, such as indications for surgery. In 2016, 98,147 primary knee and 
87,733 primary hip arthroplasties were performed, of which greater than 96% and 90% 
were for the management of OA, respectively (National Joint Registry, 2017). This not only 
gives an idea of OA’s impact on secondary care, but may give an indication of the 
prevalence of more severe OA within these nations. However, its use for this may be limited 
as it does not account for those patients that do not require, decline, or who are not 
deemed suitable for surgery. Secondly, although data is published on ‘primary knee 
arthroplasties’, which excludes surgical revisions, it is possible patients are included twice 
if they have had arthroplasties on both knees.  
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The debilitating nature of the condition also results in a large impact on the economy, 
estimated by a systematic review to be between 0.25 and 0.5% of a country’s gross 
domestic product (Puig-Junoy & Ruiz Zamora, 2015). This burden can be divided into direct 
and indirect costs. Direct costs, such as the pharmacological treatment and surgery, have 
been estimated to account for 86% of the total economic burden of OA (Chen et al., 2012). 
A large proportion of the direct costs are due to the expensive surgical procedures and their 
associated expenditure, as a recent American study found that the marked rise of knee 
replacements now costs their economy $10.2 billion (£8.3 billion) annually (Ferket et al., 
2017). Indirect costs incorporate days lost off work, and the associated loss of productivity 
and potential disability payments. Although data directly related to OA are sparse, 
musculoskeletal disorders resulted in 30.8 million days lost off work in 2016, representing 
22.4% of the total (Office for National Statistics, 2017d). It should be noted that if, for 
instance, pharmacological therapies are cost-effective and allow a patient to return to 
work, direct costs may reduce indirect costs. However for a condition such as OA, current 
treatments are not always effective and the experience of adverse effects can result in 
further expenditure. The cost to the Canadian economy of these effects was estimated to 
be $316 million (~£200 million) in 2010, and is predicted to rise to $665 million by 2031 
(Sharif et al., 2015). In the UK, a 1999 study assessed the cost of gastro-intestinal adverse 
effects experienced by patients prescribed non-steroidal anti-inflammatory drugs (NSAIDs). 
They estimated that the annual cost of adverse effects in this group of patients was £251 
million, or £48 per individual (Moore & Phillips, 1999). More up to date information related 
to the UK is lacking, of both studies assessing the cost of the adverse effects of 
pharmacological OA management, or of the medications individually. 
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Whilst there has been increasing interest in the study of the economic costs of OA over the 
last decade, several issues remain. For instance, Chen et al. (2012) highlighted that current 
estimates may be conservative, due to factors such as there being no recognised way to 
identify indirect costs effectively, as well as a lack of accounting for alternative therapies in 
direct cost estimates, which are commonly used and result in large expenditure. There are 
also large differences between studies in their estimates of direct and indirect costs, 
potentially due to inconsistent methodologies. This not only makes the evaluation of the 
global impact of OA challenging, but means attempts to apply other country’s data to the 
UK, where information remains sparse, are difficult. The review article by Chen et al. (2012) 
found no published studies regarding the direct and indirect costs of OA to the UK 
economy, and there has been little development. One of the most recent systematic 
reviews included 32 studies, of which none were from the UK (Salmon et al., 2016). As a 
result, obtaining data again relies on sources such as ARUK. Using information from an 
unpublished report, they estimate that the total combined direct costs of OA and 
rheumatoid arthritis (RA) will be £10.2 billion in 2018 alone (Arthritis Research UK, 2018). 
As could be expected due to the predicted increase in prevalence of OA, the costs 
associated with this condition are also projected to increase. This will largely be driven by 
increasing direct costs, and over the next decade, ARUK predict that the cumulative 
healthcare costs of OA and RA will be £118.6 billion (Arthritis Research UK, 2018). 
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1.6 Current Management 
Within the UK, guidelines for clinical practice and patient management are published by 
NICE. The current guidelines for the management of osteoarthritis were released in 2014 
(NICE, 2014). They recommend the treatment of OA be a holistic approach, with non-
pharmacological, pharmacological and surgical options offered by the healthcare provider, 
alongside self-management by the patient (Figure 1.3).  
The core elements of patient self-management are exercise and weight loss, if appropriate, 
as well as being provided with appropriate information. For lower limb arthritis advice 
regarding the use of appropriate footwear is also recommended. Non-pharmacological 
options are offered as adjuncts to the core treatments, and examples include 
thermotherapy, electrotherapy and the use of assistive devices.  
Figure 1.3 Management of Osteoarthritis, as Recommended by NICE (NICE, 2014) 
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Current pharmacological guidelines for OA advise the use of paracetamol or topical non-
steroidal anti-inflammatory drugs (NSAIDs) as first line analgesic options. If required, they 
can also be used in combination. If this proves insufficient the introduction of an oral 
NSAID, COX-2 inhibitor or opioid is advised, if not contraindicated. Other options 
recommended for OA include intra-articular steroids, and for hand and knee OA, topical 
capsaicin (NICE, 2014).  
Total joint arthroplasty is the definitive surgical treatment for OA. Arthroplasty is both 
clinically and cost effective, especially for knee and hip arthroplasty, the two most 
commonly replaced joints (Daigle et al., 2012; National Joint Registry, 2017; Pinedo-
Villanueva et al., 2014). Arthroscopy with lavage was previously indicated for use in knee 
OA, but its routine use was found to have limited benefits that did not outweigh the risks, 
such as surgical complications (Reichenbach et al., 2010; Siemieniuk et al., 2017; Thorlund 
et al., 2015). As a result NICE do not recommend its use unless the patient has a specific 
clinical history, such as the knee locking or giving way (NICE, 2014).  
 
1.7 Problems with the Current Management Options for Osteoarthritis 
Problems with the current management approach of OA have been highlighted by recent 
literature. These include questions regarding the efficacy of pharmacological options, 
worries about their safety profiles, and the frequency at which they are contraindicated 
due to comorbidities (Machado et al., 2015; Roberts et al., 2016; Van de Laar et al., 2012; 
Vergne-salle, 2015). This may result in patients receiving suboptimal pain control, or being 
exposed to adverse effects.  
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Although patient self-management is central to the recommended management of OA, 
there is clear scope for improvements in supported behaviour change. Whilst studies have 
suggested that the role of exercise should be further encouraged for patients with 
conditions such as back pain and OA (Mallen & Hay, 2016), there is evidence that patients 
do not perform the recommended levels of exercise, and that clinicians also under-utilise 
provided services, such as physiotherapy. A study of data from the European Project on 
Osteoarthritis (EPOSA) reported that patients with knee OA, compared to those without, 
are more inactive and less likely to follow physical activity recommendations 
(Herbolsheimer et al., 2016). A study of general practices in the West Midlands of the UK 
reported that only 36% of applicable OA consultations resulted in a consideration of a 
referral to physiotherapy, compared to the 63% which were considered for pain 
assessment (Edwards et al., 2014). Similarly, a Danish study of general practices in the UK, 
Denmark, Portugal and Norway reported that only 11% of applicable OA consultations 
resulted in a referral to services to assist in losing weight (Østeras et al., 2015). It is 
therefore clear that this core treatment approach is not fully optimised. Potentially in 
response to this under-utilisation and lack of effective communication between healthcare 
professionals and patients, studies have explored the effect of using the internet or 
telephone consultations to increase the information that patients receive (Lane et al., 
2017).  
Within the pharmacological guidelines for managing OA, there is no explicit mention that 
the approach taken by doctors should be step-wise. However, the concept of the 
guidelines, whereby if one step proves insufficient it is replaced by a stronger analgesic, 
could be viewed as such. Some have deemed the use of this approach to analgesia 
inadequate for chronic pain. Compared to acute and end of life pain, chronic pain tends to 
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have a very unpredictable trajectory, affected by factors such as mood and circumstance 
(Ballantyne et al., 2016). As a result a ladder, where the majority of patients often only 
move up to a more potent analgesic, does not take into account the variations in pain 
experienced. It has therefore been proposed that a stratified, rather than stepwise, 
approach may better accommodate for these fluctuations in pain. 
Alongside the management approach of OA, there are growing concerns with the individual 
pharmacological medications recommended for use in patients with OA. It should be noted 
that whilst all therapies mentioned are effective in some patients, their use does not come 
without risk. Although paracetamol is the most widely used and prescribed drug in the UK 
(Dear et al., 2015), there have been growing concerns with its use. Classically viewed as an 
effective analgesic for a variety of conditions, until recently very few studies had assessed 
its effectiveness for chronic pain. A 2016 systematic review found that it had “negligible 
efficacy with doubtful clinical relevance” for chronic pain (Ennis et al., 2016, p. 188). 
Another found that irrespective of dose, paracetamol did not exceed the effect size 
threshold for chronic pain of -0.37, and thus had no role as a single agent in the treatment 
of OA (da Costa et al., 2017). Secondly, there are growing safety concerns with 
paracetamol. Although it is often seen as safe, especially compared to NSAIDs which it is 
commonly compared against, a systematic review reported that four trials had 
demonstrated a dose-response relationship between paracetamol and cardiovascular 
adverse effects. Of two studies that reported mortality, both demonstrated an increased 
risk with paracetamol use compared to placebo, and one trial found there to be a dose-
response relationship present (Roberts et al., 2016). As highlighted by the authors of this 
systematic review, a common limitation for studies such as these is channelling bias. This 
inequality arises as patients are often started on a certain medication due to their risk of 
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adverse effects with other treatments. As a result it is challenging to compare intervention 
and control group participants, making inferences difficult. An adverse effect commonly 
associated with paracetamol use is hepatic damage. Although this is often a result of 
overdose, recent studies have demonstrated that this can occur when paracetamol is used 
at therapeutic doses. A 2015 systematic review reported that patients taking paracetamol 
were nearly four times more likely than those taking placebo to have elevated liver function 
test results, although the clinical importance of this was unclear (Machado et al., 2015). 
Another potential issue with paracetamol is its presence in a wide variety of over the 
counter products, including combination medications. This may lead to patients not being 
aware of the cumulative dose of ‘hidden paracetamol’ that they are taking (Van de Laar et 
al., 2012), resulting in an increased risk of adverse effects, due to taking a higher dose than 
the recommended daily maximum of four grams. Amid researchers concluding that the 
recommendation of paracetamol in guidelines should be reconsidered (Machado et al., 
2015), the concerns with paracetamol have not gone unnoticed. In the drafted guidelines 
for the management of OA, NICE recommended that paracetamol should not be routinely 
used due to the uncertainty of the clinical benefit and possible adverse effects (National 
Clinical Guideline Centre, 2013). However, due to worries that this would lead to an 
increase in prescribing of NSAIDs and opioids, this was revised for the published guidelines, 
and paracetamol continues to be recommended. 
There are also concerns with the use of NSAIDs, another class of drugs commonly used in 
patients with OA. Although a meta-analysis demonstrated that many NSAIDs are effective 
compared to placebo (da Costa et al., 2017), concerns remain regarding their use in OA. 
These are primarily related to adverse effects and them regularly being contraindicated 
due to the wide variety of comorbidities experienced by patients with OA. Common 
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adverse effects associated with NSAID use include cardiovascular and gastrointestinal 
events, as well as abnormal renal function (Bhala et al., 2013; Moore, Pollack, et al., 2015). 
The high risk of gastric ulceration in patients with OA prescribed an NSAID results in NICE 
recommending co-therapy with a proton pump inhibitor (PPI) to act as a protective agent 
(NICE, 2014). The risk, or having a history of, one of these adverse effects, as well as the 
potential for drug interactions, often results in NSAIDs being used with caution or 
contraindicated. As the number of medications prescribed to the elderly population rises 
(Melzer et al., 2015), this may result in the use of NSAIDs in many patients with OA 
becoming increasingly problematic. Interactions with aspirin, antihypertensives, 
antidepressants and corticosteroids have been reported by studies (Moore, Pollack, et al., 
2015). Potentially due to the risks of NSAID use, NICE recommend that they be used at the 
lowest dose and for the shortest possible time (NICE, 2014). With recommendations such 
as these for drugs used as commonly as NSAIDs, it would appear that the current guidelines 
and treatment approach may not be congruent with the natural history of the disease.  
Potentially due to NSAIDs not representing a suitable long term therapy, there has been a 
decrease in their use for patients with OA, and instead, patients have increasingly been 
prescribed opioids such as tramadol (Yu et al., 2017). Whilst opioids remain recommended 
by NICE for the management of OA (NICE, 2014), there are serious concerns with their use. 
Due to the high incidence of withdrawals in trials, Osteoarthritis Research Society 
International (OARSI) deem opioids of “uncertain appropriateness” for specific subgroups 
of patients with OA (McAlindon et al., 2014, p. 376). Although the Cochrane review of 
opioid use in hip and knee OA reported that patients benefitted marginally from their use, 
this observation was of questionable clinical significance. They also found an increased risk 
of severe adverse effects and dependency (da Costa et al., 2014). A 2018 randomised 
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controlled trial of patients with back pain or OA of the knee or hip found that opioid 
analgesics did not significantly improve pain-related function over the course of 12 months. 
Of the secondary outcomes, only anxiety improved for the patients taking opioids. This lack 
of analgesic efficacy resulted in the authors concluding that there is little support for the 
initiation of opioids in these chronic pain conditions, as the advantages did not outweigh 
the risk of harms, as medication-related adverse effects were more common in the group 
of patients taking opioids (Krebs et al., 2018). There are also concerns with the misuse 
potential of opioids, with the increase in opioid related overdoses and deaths becoming 
widely known in the US as the ‘opioid epidemic’ (Manchikanti et al., 2012). Misuse is 
defined as the use of a medication either without one’s own prescription or with a 
prescription but not using the medication as instructed. The 2015 National Survey on Drug 
Use and Health in the US reported that, of the 91.8 million (37.8%) US adults who were 
prescribed an opioid in 2015, more than 10% misused them. However, as almost 60% of 
patients who misused opioids did not receive them from a doctor, the authors highlighted 
the common diversion of opioids, with patients who misuse them often receiving them free 
from relatives or friends (Han et al., 2017). 
Whilst arthroplasty is viewed by many as an effective, definitive treatment, issues do 
remain. Firstly, it does not result in adequate pain relief in all patients, with a large number 
reporting persistent pain post-operatively. After adjusting for losses to follow-up, a 
systematic review estimated the prevalence of post-operative pain following hip 
arthroplasty as between 7 and 23%, and between 10 and 34% for knee arthroplasty 
(Beswick et al., 2012). Secondly, the incidence of OA diagnoses in younger patients, such as 
in those aged 35-44 years, is increasing (Yu et al., 2015). As more than 10% of total knee 
arthroplasties require revision within 15 years (Niinimäki et al., 2014), the increasing 
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incidence of OA in younger patients, combined with increasing life expectancy, may 
become problematic unless changes are made to the prosthesis. These concerns, as well as 
the number of patients for whom surgery is not suitable, mean that analgesia will continue 
to be significantly important in the management of OA. 
In conclusion, whilst more can be done to potentially optimise core treatments and surgical 
approaches, the main concerns are with the recommended pharmacological options for 
OA. Whilst some patients may gain some benefit from paracetamol, NSAIDs or opioids, this 
tends to be modest, and this must be balanced against the risk of harms, such as adverse 
effects. With studies demonstrating that patients are unwilling to risk adverse effects to 
potentially reduce pain (Hauber et al., 2013), there have been reports that clinicians are 
resorting to non-recommended therapies for conditions such as OA. There is also a growing 
number of studies exploring the possible pain mechanisms of OA, whilst others are studying 
the efficacy of other, non-guideline, therapeutic options for the pain of those with the 
condition. 
 
1.8 The Pain Mechanisms Involved in Osteoarthritis Pain 
Within the field of OA research, there has been a growing number of studies exploring the 
potential effectiveness of novel treatments, such as platelet rich plasma, as well as the use 
of therapies used for other conditions but not recommended for OA, such as 
bisphosphonates, calcitonin, and the supplements glucosamine and chondroitin (Lane et 
al., 2017). However, to date very few trials have demonstrated consistent effects on clinical 
outcomes of OA, and potentially due to trials not providing clear therapeutic solutions, 
there has been an expansion of the literature regarding the mechanisms of OA pain, which 
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some believe should be central to the focus of management guidelines (Van de Laar et al., 
2012). 
Historically, OA pain was viewed as purely nociceptive, arising from the damaged joint. 
Studies have demonstrated associations between pain and bone marrow lesions, synovitis 
and joint effusions (Fu et al., 2017; Thakur et al., 2014). However, the lack of response by 
some patients to conventional therapies, as well as the large discrepancy between the 
radiographic severity of OA and the intensity of pain experienced by the patient (French et 
al., 2017; Lee et al., 2011) has resulted in other mechanisms of pain being proposed. These 
include peripheral and central sensitisation, as well as neuropathic pain.  
Whilst the affected joint is clearly the original source of pain in OA, there is evidence that 
abnormal pain processing by the nervous system may amplify or augment these signals, in 
a process known as sensitisation. Sensitisation can occur both centrally and peripherally, 
due to the neuroplasticity of the nervous system. The repetitive nociceptive stimuli arising 
from an osteoarthritic joint is thought to be the “main driver” of processes resulting in 
centralised sensitisation (Arendt-Nielsen, 2017, p. S-68). O’Driscoll and Jayson produced 
one of the earliest articles suggesting the presence of central sensitisation in OA. In their 
study they reported that patients with hip OA had a reduced pain threshold at the 
forehead, a site typically unaffected by OA (O’Driscoll & Jayson, 1974). More recently, 
Gwilym et al. (2009) utilised Quantitative Sensory Testing (QST) and neuroimaging in 
patients with and without OA. They found that patients with OA had lower thresholds to 
punctate stimuli, and MRI imaging demonstrated greater activation in the brainstem of 
patients with OA in response to noxious stimuli. Features of central sensitisation include 
allodynia (pain arising from typically non-painful stimuli), hyperalgesia (an increased 
sensitivity to pain) and alterations in the intensity and duration of pain. The use of pain 
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drawings has also demonstrated the altered extent to which patients with central 
sensitisation may experience pain (Fu et al., 2017; Lluch Girbes et al., 2016). 
The development of peripheral sensitisation has been associated with inflammatory 
mediators in joints with OA, and tissues thought to be involved in this process include the 
articular cartilage and subchondral bone. Although the articular cartilage, one of the main 
tissues affected in OA, lacks innervation and vascularity in a normal joint (Dimitroulas et 
al., 2014), it has been proposed that the inflammatory process of OA may alter its structure. 
There is evidence to suggest that the cartilage of an osteoarthritic joint is infiltrated by 
neurons, and at arthroplasty, when compared to healthy joints, an increased presence of 
immune cells, growth factor expression and angiogenesis has been reported in 
osteoarthritic knees (Thakur et al., 2014). The cytokines and mediators responsible for the 
occurrence of angiogenesis in chronic inflammation may also cause sensitisation of local 
nerves, and this relationship between vascular growth and neural sensitisation has been 
proposed as a source of OA pain (Dimitroulas et al., 2014; Walsh, 2016). Support for the 
theory that sensitisation of peripheral nerves may also occur in the subchondral bone 
includes the fact that this densely innervated tissue is not affected until later in the disease, 
when OA pain is typically more severe (Ohtori et al., 2013).  
Neuropathic pain has been proposed as a component in the pain experienced by some 
patients with OA. The International Association for the Study of Pain (IASP) define 
neuropathic pain as “pain arising as a direct consequence of a lesion or disease affecting 
the somatosensory system” (French et al., 2017; Jensen et al., 2011; Treede et al., 2009, p. 
1361). By definition this lesion can occur both centrally and peripherally, and examples 
include spinal cord injuries and following joint surgery, respectively. A 2017 systematic 
review of 9 studies found that, within a population of patients with hip or knee OA, from 
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both the community and healthcare settings, the prevalence of neuropathic pain 
characteristics was 23% (95% CI: 10, 39). They did however express concerns with the 
variety of methodologies present, and believe certain studies may considerably 
overestimate the prevalence (French et al., 2017).  
Whilst studies have attempted to detect neuropathic pain characteristics in patients with 
OA, the concept of neuropathic pain in OA needs to be viewed cautiously. IASP’s definition 
of neuropathic pain was changed in 2008, removing the previously used word ‘dysfunction’, 
to distinguish ‘true’ neuropathic pain from pain arising from a dysfunctional somatosensory 
nervous system, for instance due to central sensitisation (Treede et al., 2009). 
Consequently, in order to be defined as neuropathic pain according to the latest definition, 
OA must be capable of causing a lesion of the somatosensory system. Whilst ATF-3, a 
protein marker of neuronal injury, has been detected in the dorsal root ganglions of rat 
models of OA induced by monoiodoacetate (Ivanavicius et al., 2007), a clear lesion to the 
somatosensory system has not been definitively identified. As a result, the symptoms 
reported by patients would be characteristics of, rather than indicative of, neuropathic pain 
– most likely resulting from central and peripheral sensitisation. This is often overlooked in 
studies, where conclusions are made that a certain proportion of patients with OA ‘have 
neuropathic pain’ (French et al., 2017). This would result in OA being viewed similarly to 
conditions such as fibromyalgia, where a definitive lesion is not always identified, or 
complex regional pain syndrome type 1, which by definition has no nerve lesion. The 
distinction created by the latest definition may be a reason for the separation of the 
previously combined Cochrane systematic reviews analysing the efficacy of the 
neuropathic pain medications gabapentin and pregabalin in neuropathic pain from their 
effectiveness in fibromyalgia. It should be noted that the latest Cochrane review studying 
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gabapentin in neuropathic pain made no mention of OA in the context of neuropathic pain. 
Indeed, they used an “arthritic knee” as an example of non-neuropathic pain (Wiffen et al., 
2017, p. 2). As Cochrane reviews are often seen as the pinnacle within the literature 
hierarchy, and bearing in mind the prevalence of OA and the recent expansion of the field 
of research regarding neuropathic pain in OA, this omission is interesting.  
Whilst there is no current gold standard for identifying patients with neuropathic pain 
(French et al., 2017), QST is often used, especially in research settings. However, this time-
intensive approach is impractical clinically due to the large number of patients with OA, 
leaving a questionnaire as a more viable alternative. Questionnaires assessed by studies 
include the Douleur Neuropathique 4 (DN4) and the modified painDETECT (mPD-Q) (Aşkin 
et al., 2017). The mPD-Q, prior to modification for OA, was used to identify characteristics 
of neuropathic pain in patients with chronic low back pain (Hochman et al., 2011). It uses 
the presence of features such as allodynia and hyperalgesia to indicate the likelihood of the 
patient having neuropathic pain. Attempts have also been made to correlate risk factors 
with questionnaire scores, however no association has been found between high 
painDETECT scores and age or duration of disease (Mesci et al., 2016). 
Whilst debate remains regarding the extent to which certain patients with OA have ‘true’, 
or merely characteristics of, neuropathic pain, the identification of these individuals may 
be beneficial for several reasons. Firstly, for patients with OA, the presence of neuropathic 
pain characteristics can negatively affect a patient’s function, quality of life and experience 
of pain (French et al., 2017; Valdes et al., 2014). Scores that have been used to assess the 
association been neuropathic pain characteristics and reduced quality of life include the 
Short Form-36 (SF-36) and the Western Ontario and McMasters Universities Osteoarthritis 
Index (WOMAC) (Aşkin et al., 2017). The identification of these patients would then allow 
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more targeted medications to be prescribed for these pain mechanisms, where 
conventional OA management options such as NSAIDs and paracetamol are known to be 
of limited efficacy (Moore, Chi, et al., 2015). Examples of possibly effective analgesic 
therapies include some antidepressants and anticonvulsants, collectively known as 
neuromodulators. Identifying patients with neuropathic pain characteristics may also be 
important in the context of trials evaluating the efficacy of medications. Therapies such as 
the neuromodulators are rarely being studied with the view that they will be used for all 
patients with conditions such as OA and as a result it is critical to study their use in specific 
subgroups of patients. Without clearly identifying the study population, it is possible that 
the heterogeneity of patients within the study is nullifying the studied drugs’ effectiveness, 
rather than the lack of observed efficacy being due to the ineffectiveness of the drug itself 
(Thakur et al., 2014). Further still, as recent neuropathic pain studies have attempted to 
stratify patients into different phenotypes to identify those best suited to certain therapies 
(Holbech et al., 2016), identifying those with a potential neuropathic element may be a 
minimum requirement. 
In summary, there has been an expansion of the literature suggesting that the pain 
experienced by some patients with OA may have features of neuropathic pain. However, 
the lack of a clear somatosensory lesion means that OA may not fulfil the criteria to be 
defined as ‘true’ neuropathic pain, and as a result the features elicited by QST or 
questionnaires such as the painDETECT are most likely a consequence of central and 
peripheral sensitisation, which have similar characteristics. The presence of sensitisation 
may explain why certain groups of individuals do not respond to the analgesia currently 
recommended by NICE for the management of OA, and thus there may be a role for 
medications more tailored to these pain mechanisms, known as neuromodulators. 
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1.9 The Use of Neuromodulating Medications in Osteoarthritis 
Neuromodulation is defined as “the alteration of nerve activity through targeted delivery 
of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites 
in the body” (The International Neuromodulation Society, 2018). There is a variety of 
chemical neuromodulating medicines that can be used, not just as analgesia, but to provide 
symptomatic relief in a variety of conditions, such as Parkinson’s disease. Neuromodulating 
medicines currently recommended for neuropathic pain include the antidepressants 
duloxetine and amitriptyline and the anticonvulsants gabapentin and pregabalin (National 
Institute for Health and Care Excellence, 2013). Although there has been a growing body of 
evidence suggesting that the neuromodulators may be effective for some patients with OA, 
to date only the serotonin-noradrenaline reuptake inhibitor (SNRI) duloxetine is 
recommended by OARSI for knee OA (McAlindon et al., 2014), and no neuromodulators are 
currently recommended by NICE for the management of OA (NICE, 2014). 
As one may expect clinicians to explore recommended options prior to prescribing a non-
guideline medication, any use of such medications could be expected in patients with more 
severe OA. A potential marker of this is the period prior to arthroplasty. In a Norwegian 
study of patients prior to and following hip arthroplasty, Blågestad et al. (2016) reported 
that 8% of patients were prescribed an antidepressant three months prior to their 
arthroplasty. Other medications assessed were anxiolytics and hypnotics, which were 
collectively grouped with antidepressants as ‘psychotropics’, due to their effects on a 
patient’s mental state. In total, 25.8% of patients were prescribed a psychotropic three 
months prior to their arthroplasty, and this increased in the three month period 
immediately post-operatively before returning to pre-operative levels. Although this study 
did not necessarily identify patients with OA, we know that this is the primary indication 
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for hip arthroplasty, and often comprises greater than 90% of the caseload (National Joint 
Registry, 2017). 
Another class of medications with neuromodulating properties are the gabapentinoids 
gabapentin and pregabalin. In recent years within the UK, concerns have arisen regarding 
the substantial increase in gabapentinoid prescribing and their potential to be misused. 
Whilst it is thought that painful conditions are a large determinant of their increased 
prescribing, data regarding their use in OA are sparse. In a similar study to the one 
conducted by Blågestad et al. (2016), Inacio et al. (2018) assessed the proportion of 
patients who received a prescription for a gabapentinoid in the year prior to their joint 
arthroplasty. Gabapentin and pregabalin were analysed with the tricyclic anti-depressant 
(TCA) amitriptyline and collectively grouped as ‘neuropathic pain medications’. They 
reported that the prevalence of patients (n = 15,517) prescribed a neuropathic pain 
medication in the one year prior to their knee arthroplasty increased from 5.2% in 2001 to 
11.4% in 2012. A very similar trend during this time was also seen in patients before hip 
arthroplasty. This may point to a potential increase in the use of the gabapentinoids in 
patients with more severe OA. However, it is not understood whether OA is the reason for 
the prescribing of the gabapentinoids, and the prevalence of the use of such medications 
before and after arthroplasty, as assessed by Blågestad et al. (2016), may be accounted for 
by different patients. 
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1.10 Conclusion 
OA is one of the most prevalent chronic health conditions worldwide, with most forecasts 
projecting further increases in the crude, if not age-standardised, prevalence of the 
condition in populations. A range of recommended management options currently exists, 
but few confer substantial benefits and there are particular problems with access to non-
pharmacological treatments, the long-term safety of some pharmacological options, and 
the future affordability of the continued increases in demand for joint arthroplasty. These 
concerns have resulted in clinicians and researchers looking towards existing treatments 
not currently licensed (nor recommended) for OA. The rationale for the use of the 
neuromodulators in OA may have strengthened due to the proposed neuropathic 
component of the pain experienced by some patients with the condition. The high 
prevalence of OA means that such use has the potential to involve a large number of 
patients. Amid concerns regarding the substantial rise in prescribing and misuse potential 
of the gabapentinoids, the remainder of this thesis will focus on the use of gabapentin and 
pregabalin in OA. The next chapter will provide a brief overview of their history, followed 
by the possible rationale and efficacy of their use in this common, painful condition.
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2 The Gabapentinoids 
 
2.1 Introduction 
The gabapentinoids gabapentin and pregabalin are analogues of the inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA). Whilst their precise mechanism of 
action is not completely understood, they do not exert their effects on the GABA receptor. 
Instead, they are thought to act on the α2-δ-1 subunit of voltage gated calcium channels 
(Stahl et al., 2013). This results in them having several effects, acting as an anti-convulsant, 
anxiolytic and analgesic (Cappuzzo, 2009). Although other gabapentinoids are in trials or 
have been approved, such as mirogabalin and gabapentin enacarbil, respectively (Vinik et 
al., 2014), pregabalin and gabapentin are the only gabapentinoids currently prescribed in 
the UK and as a result these two medications will be the focus of this thesis.  
 
2.2 History of the Licensing and Use of Gabapentin and Pregabalin 
Gabapentin, branded as Neurontin, first entered the market in the United States (US) in 
1993, manufactured by the Warner-Lambert subsidiary Parke-Davis. At this time it was 
initially licensed by the Food and Drug Administration (FDA) as an adjuvant in the therapy 
of the treatment of partial seizures in patients aged older than 12 years. Its use was 
extended to patients older than three years in 2000, before being licensed for post-herpetic 
neuralgia in 2002 (U.S. Food & Drug Administration, 2018). In Europe, the European 
Medicines Agency (EMA) first approved gabapentin in 2006, for use in epilepsy and 
peripheral neuropathic pain syndromes, such as painful diabetic neuropathy and post-
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herpetic neuralgia (European Medicines Agency, 2006). In the UK, the latest British National 
Formulary (BNF) indicates that as of June 2018 gabapentin is indicated for epilepsy, 
peripheral neuropathic pain, migraine prophylaxis and for menopausal symptoms in 
women with breast cancer (Joint Formulary Committee, 2018).  
Pregabalin, commonly branded as Lyrica, was produced after gabapentin, again 
manufactured by Parke-Davis. It was first licensed in July 2004 in Europe for use in epilepsy 
and as an analgesic in post-herpetic neuralgia and diabetic neuropathy. In 2006 its licence 
within Europe was extended to generalised anxiety disorder (Baldwin et al., 2015; 
European Medicines Agency, 2009a). The BNF lists pregabalin’s indicated uses in the UK as 
generalised anxiety disorder, focal epilepsy and for both peripheral and central neuropathic 
pain (Joint Formulary Committee, 2018). Examples of central neuropathic pain include the 
pain experienced by patients following a stroke or spinal cord injury. Pregabalin was first 
approved in the US in December 2004 for peripheral neuropathic pain (Dworkin & 
Kirkpatrick, 2005), followed by an approval for fibromyalgia in 2007 (Cascade et al., 2008; 
Pfizer, 2016). Interestingly, an application for a license for pregabalin’s use in fibromyalgia 
was refused by the European Medicines Agency in 2009. This was due to a lack of trial 
evidence in European populations, and concerns regarding pregabalin’s clinical efficacy and 
safety (European Medicines Agency, 2009b).  
A timeline of both gabapentinoids in Europe and the US is visually represented in Figure 
2.1. 
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Figure 2.1 Timeline of Gabapentin (Top) and Pregabalin (Bottom) in the United States (US) and 
Europe (EU). Events Shaded Green Apply to Both Gabapentinoids  
Data of all community issued prescriptions, from each of the four countries of the UK 
(England, Northern Ireland, Scotland and Wales), are published annually. Since 2004, the 
total number of gabapentinoids prescribed in the UK has risen sharply (Figure 2.2). In 2004, 
just over 1 million gabapentin prescriptions were issued. By 2010 this number had risen to 
almost 3 million prescriptions, and by 2016 was 7.8 million. Pregabalin has followed a 
similar trend. Since its approval in 2004, the number of items prescribed has risen from 
24,640 to just over 6.7 million in 2016. To provide comparison, prescriptions of tramadol, 
an opioid analgesic included alongside the gabapentinoids in a recent report on 
dependence-forming medicines (Cartagena et al., 2017), have increased from 8.5 million in 
2010 to 9.3 million in 2016 (Business Services Organisation, 2018; ISD Scotland, 2018; NHS 
Digital, 2017; Welsh Government, 2017). Using population data from the Office for National 
Statistics (Office for National Statistics, 2017c), the absolute number of gabapentinoid 
prescriptions can be presented as a rate per 1,000 individuals. When prescriptions of 
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gabapentin and pregabalin are combined, gabapentinoid prescribing has increased from 
almost 20 gabapentinoid prescriptions per 1,000 individuals (of any age) in 2004 to over 
220 prescriptions per 1,000 individuals in 2016. The increase in gabapentinoid prescribing 
has also been observed in other countries. As of September 2017, gabapentin was the 
seventh most commonly prescribed medication in the US (GoodRx, 2017), with the total 
number of prescriptions rising 64% between 2012 and 2016. In the same period spending 
on pregabalin more than doubled (Goodman & Brett, 2017).  
Figure 2.2 Annual Gabapentinoid Prescriptions in the UK, 2004-2016 (Business Services 
Organisation, 2018; ISD Scotland, 2018; NHS Digital, 2017; Welsh Government, 2017)  
The observed increase in prescribing may be accounted for by several factors. Firstly, a 
change in the prevalence of the conditions for which the gabapentinoids are licensed may 
explain an increase in prescribing. For instance it is likely that the prevalence of painful 
diabetic neuropathy has increased, as the prevalence of diabetes in the UK increased from 
3.2% to 5.3% between 2004 and 2014 (Zghebi et al., 2017). As the incidence of newly 
diagnosed diabetes decreased during this time, the observed rise in prevalence must be 
accounted for by greater disease duration. Secondly, the increasing number of licensed 
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indications of the gabapentinoids may also explain an increase in prescribing. For instance 
in Europe, pregabalin’s license for generalised anxiety disorder (GAD) came two years after 
its approval as both an analgesic for neuropathic pain and anti-convulsant for epilepsy. As 
the lifetime prevalence of GAD has been estimated as almost 3% in Europe (Alonso et al., 
2004), a license for this condition may have contributed to an increase in prescribing. 
Although there may be some delay between drug approval and its uptake in medical 
practice, it is felt that this change in licensing is unlikely to account for the dramatic rise in 
prescriptions witnessed since 2012, as most indication changes occurred before 2007. 
Changes in the population of patients prescribed a gabapentinoid may also influence 
prescribing, for instance if prescribing practices changed and the gabapentinoids were 
prescribed more commonly to older age groups. However, information regarding patient 
demographics is not readily available in national prescribing data. Even though all the 
above may contribute, expert consensus is that it is not felt that any of these factors can 
completely explain the substantial rise in prescriptions (Goodman & Brett, 2017). Instead, 
it has been postulated that the rising number of prescriptions for gabapentinoids reflect 
their increasing off-label use, i.e. for conditions for which they are not licensed. 
There is evidence to suggest that the off-label use of the gabapentinoids could be 
substantial. A 2002 American review estimated that the off-label use of gabapentin was as 
high as 95% in a Medicaid population. Unlicensed conditions for which the drug were 
commonly used at this time included bipolar disorder and restless legs syndrome (Hamer 
et al., 2002). More recently, a study of patients with chronic non-cancer pain attending 
tertiary care centres in Canada found that 73% of pregabalin prescriptions were for 
unlicensed conditions, such as lumbar back pain with or without radiculopathy (Giladi et 
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al., 2015).2 Whilst some variation exists between studies, potentially due to differences in 
methods and varying prescribing practices by geographical location, it is clear that both 
gabapentin and pregabalin have been prescribed for conditions beyond their respective 
licenses. A perspectives article assessing the reasoning for off-label prescribing by clinicians 
in Canada found that they rarely differentiated between licensed and non-licensed 
indications, and that this distinction was made difficult by the inconsistencies between 
product licensing and clinical guidelines (Fukada et al., 2012). Other contributors to this 
lack of clarity may be the differences in licensing between gabapentin and pregabalin, as 
well as between regions. Whilst pregabalin is not licensed for fibromyalgia in Europe, unlike 
the US, it is recommended by the European League Against Rheumatism (EULAR) 
(Macfarlane et al., 2017), and often features in the pharmacological repertoire used by 
clinicians in the UK (Public Health England, 2014). It is also likely that the lack of objective 
criteria for licensed and off-label uses such as neuropathic pain and fibromyalgia, 
respectively, allows for the expansion of their use to other conditions with common 
presenting symptoms, such as pain. 
There is growing evidence that the use of the gabapentinoids in off-label painful conditions 
may be a large determinant in the increase of both gabapentin and pregabalin prescribing. 
Whilst a 2013 study of The Health Improvement Network (THIN), a UK primary care 
database, concluded that the majority of pregabalin use between 2004 and 2009 was for 
licensed indications, more than 60% of prescriptions were unattributable to licensed 
indications in their primary analysis. Their conclusion was most likely drawn from their 
sensitivity analyses, whereby they assumed that the pain of patients prescribed pregabalin 
                                                     
2 Unlike in the UK, pregabalin is not licensed for peripheral neuropathic pain such as lumbar radiculopathy in 
Canada. 
39 
 
was neuropathic (Asomaning et al., 2016). A 2015 article analysing trends in UK primary 
care prescribing proposed that the increased prescribing of the gabapentinoids between 
2004 and 2014 was “probably due to their use for pain” (Chaplin, 2015, p. 14). This is not 
only true of the UK, as in a recent editorial in the New England Journal of Medicine, 
Goodman and Brett (2017, p. 411) remarked that in both inpatient and outpatient settings 
in the US they had observed clinicians “increasingly prescribing gabapentin and pregabalin 
for almost any type of pain”. A study of prescribing in Ontario, Canada, reported that 
greater than 80% of patients prescribed pregabalin between April 2013 and March 2014 
had a diagnosis of a musculoskeletal condition. Although a smaller proportion of this group 
of patients had a musculoskeletal condition diagnosis without the presence of a 
neurological or fibromyalgia diagnosis (approximately 20%), the common use of NSAIDs 
and opioids in the year prior to first pregabalin prescription may point to the use of 
pregabalin in musculoskeletal conditions in which these medications are commonly used 
(Kwok et al., 2017). This may also reinforce the belief that the diagnoses of suspected 
fibromyalgia or neuropathic pain can be used for a large number of patients presenting 
with pain. A Spanish cross-sectional primary care study found that 45.2% of patients 
prescribed pregabalin had a diagnosis of bone and joint pain (Viñas-Bastart et al., 2017). 
Whilst this study did not specify conditions in this category, OA is likely to be the most 
prevalent. In summary, despite a substantial increase in gabapentinoid prescribing, and the 
growing consensus that they are being used for pain, an understanding of which conditions 
are contributing to this increase is lacking. This resulted in the development of the 
hypothesis that OA may be a contributor to this increase.  
It is highly likely that the gabapentinoids are being used in patients with OA, largely due to 
the prevalence of the condition and common comorbidities. For instance diabetes is a 
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condition that more than 14% of sufferers of OA also experience (Louati et al., 2015). The 
resulting complication, diabetic neuropathy, is estimated to occur in roughly 21% of 
diabetic patients (Abbott et al., 2011). As a result, many patients would have a licensed 
indication for a gabapentinoid prescription. However, there is anecdotal evidence that the 
gabapentinoids may be being used for OA, rather than solely in patients with the condition. 
Goodman and Brett (2017, p. 412) also proposed in their editorial that clinicians in the US 
may use the fibromyalgia license of pregabalin to prescribe pregabalin off-label for “ill-
defined pain… but also for more defined conditions such as low back pain and pain from 
osteoarthritis”. However, as was illustrated in the opening chapter of this thesis, OA is not 
as clearly defined in practice as might be expected, but instead there exists a spectrum of 
severity which can result in a large variation in prevalence estimates. Within the UK, there 
is a belief that general practitioners may be willing to use these drugs in chronic joint pain 
(J Bedson, personal communication, 2017). The British Pain Society suggests that doctors 
prescribing a medication off-label for pain should “be satisfied that there is sufficient 
evidence… to show its safety and efficacy” and that the “reasons for the choice” of such a 
medication should be recorded (The British Pain Society, 2012, p. 8). As a result, further 
exploration of the rationale for the use of the gabapentinoids, as well as of the potential 
benefits and harms to patients prescribed a gabapentinoid, is required. 
 
2.3 Possible Rationale for the Use of the Gabapentinoids in OA 
There may be many reasons why gabapentin and pregabalin are being used for the pain 
experienced by patients with OA. Primarily among these are the concerns of the prescriber 
with current pharmacological options (with a lack of effective alternatives), the central 
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mechanisms involved in the pain of some patients with OA and the potential effects of 
illegal pharmaceutical marketing. 
When gabapentin first entered the market in the US its manufacturer, Warner-Lambert, 
advertised its use for numerous non-licensed indications. These included bipolar disorder, 
migraine and pain (Kaufman, 2004; Petersen, 2008; Steinman et al., 2006). Although 
prescribing a medication for a non-licensed indication is legal, advertising is not, and a 
reported $430 million settlement was reached in the 2004 Franklin v Pfizer (who had since 
acquired Warner-Lambert) case (Department of Justice, 2004). Whilst the direct effect of 
this marketing strategy on the behaviour of clinicians is unknown, there may have been 
effects on the subsequent research, which could influence prescribing. There is evidence 
that industry-sponsored trials of the gabapentinoids in off-label conditions were not 
reported fully, or had altered primary outcomes, when the results were not significant 
(Vedula et al., 2009). This bias may have affected clinical practice as the 2010 NICE 
guidelines on neuropathic pain only included published studies, as highlighted by a 
response to an article summarising the recommendations (Tan et al., 2010). Advertising 
practices of pregabalin have also resulted in a lawsuit. In 2012 Pfizer were fined $2.3 billion 
for inappropriate advertising of pregabalin and three other medications up until 2009 (The 
New York Times, 2009).  
The concerns, as mentioned in Chapter 1, of the clinician with current pharmacological 
options for OA pain management may also lead them to prescribe alternative medications, 
such as the gabapentinoids. In the US it has been hypothesised that clinicians may lower 
their threshold to prescribe the gabapentinoids to avoid the prescription of opioids, in 
response to concerns about their use and clinical guidelines recommending considerations 
of non-opioid treatments (Goodman & Brett, 2017). If concerns with the currently 
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recommended treatment options for OA are a contributing factor to the prescription of the 
gabapentinoids, any current use may be expected to increase alongside the growing 
number of patients with OA, unless changes are made to treatment guidelines. 
Although the comorbidities of the patient may result in the gabapentinoids being indicated 
in patients with OA, they may also have other effects on prescribing behaviours. For 
example a doctor may have found their use in a patient with diabetic neuropathy 
significantly improved this patient’s OA pain, and thus decided to use the drug for non-
diabetic patients. It is likely that interviewing clinicians would be required to further 
appraise this. 
Finally, central mechanisms involved in OA pain, as mentioned in Chapter 1, may also be a 
reason for the use of the gabapentinoids in patients with OA. Authors of a trial of pregabalin 
in OA patients suggested that the effectiveness of pregabalin in combination with an NSAID 
is due to both inflammatory and neuropathic pain components (Ohtori et al., 2013), and 
authors of another trial, who assessed the efficacy of pregabalin in hand OA due to possible 
central pain mechanisms, concluded that pregabalin may present a “realistic alternative to 
pain management in OA” (Sofat et al., 2017, p. 2448). It has been stated that when 
challenged with ineffective treatments, “physicians may try new approaches that have 
some theoretical basis” (Klein & Tabarrok, 2004, p. 61). Could this be the theoretical basis? 
Although questions remain regarding the presence of ‘true’, definitive, neuropathic pain in 
patients with OA, patients with evidence of central sensitisation may still experience 
benefit from the gabapentinoids due to their effects on α-δ-1 subunits in the spinal cord 
and at other sites in the nervous system (Stahl et al., 2013). Equally, the anxiolytic 
properties of the gabapentinoids may also contribute to a reduction in the pain 
experienced by some patients, irrespective of the presence of neuropathic pain.  
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In summary, whilst there may be numerous reasons for the use of the gabapentinoids in 
OA, including a lack of effective treatment options and potential central mechanisms in OA 
pain, definitive information regarding the rationale for the prescribing of gabapentinoids 
in patients with OA is lacking. 
 
2.4 The Efficacy of the Gabapentinoids in Osteoarthritis 
Whilst anecdotal evidence suggests that the gabapentinoids may be being used in patients 
with OA, there is limited efficacy of their use in the management of the condition. Trial data 
remain limited to several animal studies (Kim et al., 2011; Ogawa et al., 2016; Rahman et 
al., 2009), and four published human trials of pregabalin in OA (Filatova et al., 2018; Ohtori 
et al., 2013; Sofat et al., 2017; Wright et al., 2017). There remains a paucity of data studying 
gabapentin in both clinical trials and drug utilisation studies in the context of OA.  
Prior to trials with human participants, literature focussed on the effect of the 
gabapentinoids in animal models of OA. Rahman et al. (2009) reported that pregabalin may 
be beneficial in OA as it inhibited neuronal responses in rats that had been injected with 
monoiodoacetate (MIA), a substance used to chemically induce rapid and extensive joint 
destruction. However, Thakur et al. (2012) noted that a dose of 2 milligrams (mg) of MIA, 
as used by Rahman et al., induced what appeared to be axonal injury, as well as the same 
level of cartilage disruption when induced at lower doses. As a result the medication trialled 
in certain animal models may prove effective due to its effect on the manifested 
neuropathic pain, rather than the induced OA. This is compounded by the fact that animal 
models, such as MIA-induced joint destruction, may not accurately represent the typical 
post-traumatic or spontaneous processes of OA in humans (Arendt-Nielsen, 2017). 
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Current research on the efficacy of the gabapentinoids in humans remains sparse, with only 
four small (n<100) registered trials published to date. In 2013 Ohtori et al. (2013) conducted 
a randomised controlled trial with 89 knee OA participants, who received either pregabalin 
(25mg daily), meloxicam (an NSAID; 10mg daily) or a combination regime of the two 
treatments. When in combination, both drugs were significantly more effective at lowering 
patients’ pain than either drug as monotherapy at the conclusion of the four week trial. 
Although not compared with placebo, no significant difference was observed between the 
two drugs when used separately. However, their analysis was limited by low dosages, a 
small sample size and a short period of follow-up. Sofat et al. (2017) conducted their trial 
with 65 hand OA participants. The participants were randomised to pregabalin (150mg 
daily), duloxetine (30mg daily), or placebo. At thirteen weeks, pregabalin was significantly 
more effective than placebo on a Numerical Rating Scale (NRS) and two of the three 
domains of the Australian and Canadian Hand Osteoarthritis Index (AUSCAN) in both the 
intention-to-treat and per-protocol analyses. In comparison, duloxetine was only 
statistically more effective than placebo on the NRS of the per-protocol analysis. As 
highlighted by the authors, again this trial was limited by small group sizes, and the findings 
may not be applicable to other joints, for instance due to the differences in pain 
characteristics and structure of large weight-bearing joints such as the hip and knee. In 
contrast to these two trials in OA, Wright et al. (2017) conducted their trial on 90 patients 
with knee OA who were selected with characteristics of neuropathic pain. Neuropathic pain 
was identified based upon the presence of an elevated cold pain threshold and a 
painDETECT questionnaire (PD-Q) score of ≥13. It should be noted however that a PD-Q 
score of 13-18, according to the original creators of the questionnaire, represents an 
uncertain result, “i.e. a neuropathic pain component can be present” (Freynhagen et al., 
2006, p. 1915). Upon the conclusion of their four week trial period pregabalin (titrated to 
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a maximum daily dose of 300mg) was associated with greater reductions in WOMAC and 
painDETECT scores, and an increase in pressure pain thresholds, compared to paracetamol 
(maximum daily dose: 4g). This conference abstract did not present mean differences or 
equivalent figures, instead solely p-values of significance. It should also be noted that four 
of the five authors of this abstract received ‘grant/research support’ from Pfizer. Most 
recently, a Russian team of researchers published a conference abstract of a trial of 
pregabalin in 60 female patients with knee OA. As with the trial conducted by Wright et al. 
(2017), all patients had a neuropathic pain component, detected using the Douleur 
Neuropathique 4 questionnaire. Upon conclusion of the trial at five weeks, both patients 
prescribed pregabalin (dose unknown) or pregabalin and aceclofenac (an NSAID), had a 
significant improvement in pain and function, assessed using the DN4 and painDETECT 
questionnaires as well as the WOMAC and a visual analogue scale. However, between-
group outcomes were not reported, and as a result the individual effect of pregabalin’s use 
in OA is unclear (Filatova et al., 2018). 
In summary, whilst four trials have suggested a possible role for pregabalin as an analgesic 
in the management of OA, there is a lack of data from large trials with long periods of 
follow-up. As a reason for the use of the gabapentinoids in OA may be the suggested 
centralised pain mechanisms, their efficacy in neuropathic pain conditions requires further 
evaluation.  
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2.5 The Efficacy of the Gabapentinoids in Neuropathic Pain Conditions 
As the gabapentinoids feature on national treatment guidelines for neuropathic pain 
conditions such as post-herpetic neuralgia and painful diabetic neuropathy, one could 
suspect there is favourable evidence for their use. Both have clear somatosensory lesions, 
and thus fulfil the latest criteria to be defined as neuropathic pain. A 2014 systematic 
review found that gabapentin 1800mg daily was effective in reducing patients’ post-
herpetic neuralgia pain (Fan et al., 2014), whilst a 2013 meta-analysis found that both 
gabapentin and pregabalin were superior compared to placebo at improving patients’ 
diabetic neuropathy pain (defined as ≥50% reduction in pain), with odds ratios of 3.98 (95% 
CI: 2.29, 7.68) and 2.78 (95% CI: 1.72, 4.62), respectively (Rudroju et al., 2013). The latest 
Cochrane review for the use of gabapentin in neuropathic pain was published in 2017. They 
reported that gabapentin doses of 1800mg and 3600mg daily could provide meaningful 
benefit to certain patients, although roughly half of patients experienced no improvement 
(Wiffen et al., 2017).  
Although Giladi et al. (2015) reported that the patient-perceived efficacy of pregabalin was 
not statistically different between licensed and unlicensed indications, it may be more 
relevant to assess the efficacy of the gabapentinoids in conditions that have no clear lesion, 
such as fibromyalgia and low back pain. A 2017 systematic review found that both 
gabapentin and pregabalin, when used in low back pain, were associated with a significant 
increase in risk of adverse effects, with very limited evidence of benefit (Shanthanna et al., 
2017). In fibromyalgia, it is clear as of 2009 that the European Medicines Agency believed 
there was a lack of favourable evidence for the licensed use of pregabalin in fibromyalgia. 
More recently, a 2016 Cochrane review of pregabalin in patients with fibromyalgia found 
that although there may be some benefit compared to placebo, this occurred only in a small 
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number of patients (approximately 10% more than placebo) (Derry et al., 2016). The 2017 
Cochrane review of gabapentin found that data available was limited and of poor quality, 
and as a result they had insufficient evidence to provide a conclusion regarding its potential 
benefit in patients with the condition (Cooper et al., 2017). In those patients that do 
experience some benefit, this may be due to the previously mentioned anxiolytic 
properties of the gabapentinoids. This may particularly be the case in patients with 
fibromyalgia, as the odds ratio of having any comorbid anxiety disorder has been reported 
to be more than six times that of those without the condition (Bernik et al., 2013). 
In summary, there appears to be a greater body of evidence of the efficacy of the 
gabapentinoids in conditions where there is a clear lesion of the somatosensory system 
than in those without. However, this data predominantly comes from studies of two 
neuropathic pain conditions, painful diabetic neuropathy and post-herpetic neuralgia. As 
reported by the Cochrane review of gabapentin, evidence for other neuropathic pain 
conditions is limited (Wiffen et al., 2017), and in conditions with no clear somatosensory 
lesion, such as low back pain, the potential efficacy of the gabapentinoids occurs only in a 
small minority of patients, and rarely outweighs the risk of harm. 
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2.6 The Potential Risks of Gabapentinoid Use 
Whilst there is limited evidence of benefit of the gabapentinoids, particularly beyond 
clearly defined neuropathic pain conditions, the prescribing of gabapentin and pregabalin 
for OA may not be without risk. These risks include adverse effects experienced by the 
patient, interactions with other medications regularly prescribed to patients with OA and 
the possibility for diversion and misuse, whereby the drugs are not used as they were 
intended at the time of prescription. 
 
2.6.1 Adverse Effects 
Information regarding the safety of the gabapentinoids is primarily based on trial data. A 
systematic review assessing the safety of anticonvulsants and antidepressants in painful 
diabetic neuropathy reported that, in trials, pregabalin resulted in more than three times 
the number of withdrawals than placebo. Although gabapentin also resulted in more 
withdrawals, this was not statistically significant, and gabapentin was viewed as the safest 
compared to the other antidepressants and anticonvulsants studied.3 However, the 
authors noted that all studies were shorter than four months in duration, meaning safety 
beyond this point could not be evaluated (Rudroju et al., 2013). The better safety profile of 
gabapentin compared to pregabalin was also reported by a systematic review assessing the 
tolerability of 12 anti-epileptic drugs (Zaccara et al., 2017). In the Cochrane review of 
gabapentin in neuropathic pain, although there was no evidence gabapentin caused a 
higher rate of serious adverse events, there was high quality evidence that withdrawals 
arising due to adverse events were more common with gabapentin than with placebo. They 
                                                     
3 Assessed medications: Amitriptyline, Duloxetine, Gabapentin, Pregabalin, Valproate, Venlafaxine, Placebo. 
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also reported that the risk ratio of any adverse effect, compared to those taking placebo, 
was 1.3 (95% CI: 1.2, 1.4). More than 10% of participants experienced dizziness, drowsiness 
or gait disturbance (Wiffen et al., 2017).  
Perhaps due to their very similar mechanisms of action, the adverse effects associated with 
pregabalin use are very similar to those associated with gabapentin. Pfizer’s Summary of 
Product Characteristics (SmPC) for pregabalin indicates that the most common adverse 
effects include dizziness, drowsiness, weight gain and peripheral oedema (Pfizer, 2016). 
Other adverse effects of the gabapentinoids that have been reported by trials include 
cognitive and visual disturbances (Shanthanna et al., 2017), nausea and dry mouth 
(Cappuzzo, 2009). 
Giladi et al. (2015) assessed the safety of pregabalin using questionnaires in a population 
of current and former users of pregabalin. To reduce inaccurate recall, they excluded 
former users of pregabalin that had not used the drug in the previous 12 months. In their 
study 70% of responders reported adverse effects associated with the use of pregabalin, 
and 70% of former users stated these effects were the reason for them discontinuing their 
therapy regime. One patient discontinued pregabalin due to suicidal ideation, a clearly 
dangerous potential adverse effect, but one that is rarely mentioned in the trial data 
reviewed for this thesis. 
The safety of the gabapentinoids was assessed in two of the human OA trials (Ohtori et al., 
2013; Sofat et al., 2017). Although no adverse effects were reported by Ohtori et al. (2013), 
the study was only four weeks in length, and the 25mg dose used is far below the 150mg 
recommended by NICE for neuropathic pain, which, based on the presence of nerve 
damage in animal trials, was the rationale for them trialling pregabalin in patients with OA 
(National Institute for Health and Care Excellence, 2013). Whilst this may have reduced the 
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analgesic efficacy, it may also have reduced the number of adverse effects. The thirteen 
week trial in hand OA conducted by Sofat et al. (2017) was with a higher dose and they also 
reported that adverse event occurrences were no more likely with pregabalin than placebo. 
However, the long-term safety of gabapentinoid use in OA remains poorly understood. 
Efforts have been made to reduce the incidence of adverse effects experienced by patients 
taking the gabapentinoids. In practice, NICE recommend that the dose of gabapentin and 
pregabalin be titrated slowly to desired levels (National Institute for Health and Care 
Excellence, 2013), whilst trials have assessed combination regimes that therefore require 
a lower dose (Senderovich & Jeyapragasan, 2018), or topical therapies, which tend to cause 
fewer central adverse effects (Martin et al., 2017).  
 
2.6.2 Misuse Potential 
Initially, it was thought that gabapentin and pregabalin had a low potential for misuse and 
addiction. In one of the earlier studies of gabapentin use, Hamer et al. (2002, p. 269) 
reported that it was “a treatment option that has relatively few serious side effects and 
drug interactions”. However, in 2010, years after its release on the market, studies of the 
possible abuse potential of pregabalin emerged (Filipetto et al., 2010; Schwan et al., 2010). 
Since then, concerns that the gabapentinoids may have the potential to be used as drugs 
of abuse have grown, and there has been a growing body of evidence that the abuse of 
these drugs is becoming increasingly common and problematic (Chiappini & Schifano, 
2016; Smith et al., 2012).  
A 2017 systematic review of gabapentin and pregabalin misuse reported that among the 
general population, the abuse of the gabapentinoids was much lower than traditional drugs 
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of abuse, such as cannabis. However, among patients with substance use disorders, this 
risk was more comparable, as up to 68% of opioid misusers also misused pregabalin (Evoy 
et al., 2017). Furthermore, whilst another 2017 systematic review concluded that there was 
no convincing evidence that the gabapentinoids possess substantial addictive power, they 
also highlighted that the risk of misuse was highest in patients with a current or historic 
substance use disorder (Bonnet & Scherbaum, 2017). Another population at an increased 
risk of gabapentinoid misuse appears to be those in prisons. The rate of gabapentinoid 
prescribing in UK prisons has been reported to be almost double the rate of prescribing in 
the community. Whilst this could be due to differences in the prevalence of licensed 
indications in this population of patients, this seems unlikely, and 56.1% of prisoners 
prescribed a gabapentinoid had a history of substance misuse, again demonstrating that 
this group of patients are a high-risk group that are liable to misuse these medications 
(Farmer, 2013). There is also an increasing number of patients transitioning from a 
gabapentinoid to other dependence forming medications, such as z-drugs and 
benzodiazepines (Cartagena et al., 2017), suggesting that the gabapentinoids may act as 
gateway drugs to other illicit or prescribed medications. 
Features of the gabapentinoids that may point to their possible dependence-forming 
nature include a tolerance necessitating increasing doses for the same effect (Bonnet & 
Scherbaum, 2017), and a withdrawal syndrome of symptoms such as sweating, fatigue, 
insomnia and diarrhoea (Chiappini & Schifano, 2016). Gabapentin has been referred to by 
drug users as a “cheap man’s high” (Smith et al., 2016, p. 9) and a ‘euphoria-like’ state has 
also been reported by patients (Evoy et al., 2017; Goodman & Brett, 2017). It is thought 
that the appeal of the gabapentinoids to prospective abusers includes their low cost, ease 
of procurement and a misunderstanding of their abuse potential by prescribers (Evoy et al., 
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2017). In 2014 Public Health England did publish a report to highlight to prescribers the 
risks of the gabapentinoids (Public Health England, 2014). As well as highlighting the 
discrepancy in the number of gabapentinoids prescribed across regions of England, 
pointing to their potential misuse as this was not felt to be accounted for by differences in 
patient demographics, this document provided information to prescribers on tapering and 
reducing doses of the gabapentinoids to minimise dependence and stockpiling. 
There has been an increasing body of evidence that a growing black market of the 
gabapentinoids has enabled their abuse by patients not initially prescribed them (Kapil et 
al., 2014; Schifano, 2014). As is the case with opioids (Han et al., 2017), studies of the 
misuse of the gabapentinoids have reported that many patients who abuse these 
medications do not directly receive them from a doctor. A survey of those that misuse the 
gabapentinoids, as well as the GABA analogue baclofen, found that whilst many obtained 
them from health services, a similar proportion received them from family or 
acquaintances, or via the internet. 36.8% of the population misusing one of these three 
medications acquired them from multiple sources (Kapil et al., 2014). In Germany, the 
majority of patients who tested positive for urinary traces of pregabalin at opioid abuse 
treatment programmes were not prescribed the medication (Lyndon et al., 2017). The 
concerns regarding the growing diversion of the gabapentinoids has resulted in many 
studies concluding that efforts are required to reduce the diversion of these medications 
(Kapil et al., 2014; Lyndon et al., 2017; Schifano, 2014).  
A study estimating the lifetime prevalence of abuse of gabapentin and pregabalin amongst 
the UK population aged between 16 and 59 years found the prevalence to be 1.1% and 
0.5% for gabapentin and pregabalin, respectively (Kapil et al., 2014). Although the 
proportion of gabapentin abusers may be higher, this may be due to the higher rate of 
53 
 
gabapentin prescribing as of the two gabapentinoids, drug abusers display a clear 
preference for pregabalin. Reasons for this may include the desired effects occurring 
quicker due to its bioavailability of ≥90%, irrespective of dose, and its quicker absorption, 
with maximum plasma concentrations reached within one hour, compared to the three or 
four taken with gabapentin (Bockbrader et al., 2010).  
 
2.6.3 Gabapentinoid-Related Overdose 
One can speculate that the documented increase in the misuse of the gabapentinoids may 
be a factor in the increasing number of gabapentinoid-related overdoses and deaths being 
reported by studies. Due to the aforementioned pharmacodynamics of pregabalin, it 
features much more commonly in both emergency departments and at post-mortem than 
gabapentin, again reflecting that it may be the more dangerous drug of abuse, or merely 
preferred by at-risk drug users. A study of a National Self-Harm Registry in Ireland reported 
that between 2007 and 2015, 2,115 (2.9%) of all intentional drug overdoses were due to 
the gabapentinoids, and 92% of these were due to pregabalin. Although gabapentinoid-
related overdoses presented less frequently than the number of overdoses associated with 
other classes of medications, such as the analgesics, the proportion of all overdoses 
involving a gabapentinoid increased from 0.7% in 2007 to 5.5% in 2015 (Daly et al., 2017). 
The number of gabapentinoid-related deaths has also substantially increased. Within 
England and Wales in 2016, pregabalin was mentioned as a possible cause of death on 111 
death certificates, compared to 59 with gabapentin, although it was prescribed much less 
frequently. This was an increase from four and eight, respectively, in 2012, a 
disproportionate increase compared to their growing prescribing rates (Figure 2.3). During 
the same period of time deaths related to tramadol increased from 175 to 184, and deaths 
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related to antidepressants decreased (Office for National Statistics, 2017a). It should be 
noted that the annual estimates of gabapentinoid-related deaths may be conservative, as 
UK coroners selectively screen for gabapentin and pregabalin due to cost or lack of 
accreditation (Nahar et al., 2017), and not every drug detected may be reported on the 
death certificate (Lyndon et al., 2017). The proportion of gabapentinoid-related deaths 
involving opioids may point to the dangers of concomitant use, as their use in combination 
can have synergistic effects on sedation and respiratory depression (Gomes et al., 2017). In 
2015 79% of deaths registered in England and Wales involving a gabapentinoid also 
mentioned an opioid on the death certificate, and this rose to 89% in 2016 (Office for 
National Statistics, 2017b). Although this may be due to substance abusers commonly using 
multiple drugs simultaneously, it may also be due to the synergistic effects of the two 
substances leading to a higher risk of overdose. It should also be noted that the lack of an 
antidote for a gabapentinoid-related overdose, unlike for opioids, means that management 
is challenging (Bonnet & Scherbaum, 2017). 
 
Figure 2.3 Comparison of Annual Gabapentinoid-Related Deaths and Number of Items Prescribed, 
in England and Wales (NHS Digital, 2017; Office for National Statistics, 2017a; Welsh Government, 
2017)  
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2.6.4 The Potential Risks of Gabapentinoid Prescribing in the OA Population 
Due to short, small trials, data related to the risks of gabapentinoid prescribing in the OA 
population are sparse. However, current knowledge can be applied to the large population 
of patients with the condition. 
Firstly, adverse effects of gabapentinoid use may be particularly problematic in this 
population. Two common adverse effects, dizziness and drowsiness, may increase the risk 
of falls and lead to inactivity, respectively. As a risk factor for respiratory depression is 
increasing age, patients with OA may be at an increased risk of this severe adverse effect 
as a large proportion of the population of patients with OA is elderly (Gomes et al., 2017). 
The reporting by a pooled analysis of trials that euphoria occurred in 1.6% of patients 
prescribed pregabalin for peripheral neuropathic pain (Freynhagen et al., 2015), 
demonstrates that this adverse effect, which could potentially lead to misuse, may occur 
in the general population. The common use of opioids in patients with OA may also be a 
source for concern, not only due to the possible interaction, but due to patients becoming 
a source of diversion of both medications. Finally, as pain is a common motivation for 
patients to misuse opioids (Han et al., 2017), the nature of the condition may also be a risk 
factor for misuse, if reasons for misuse are similar between different medications. 
As the majority of drug misusers tend to be younger than the average patient with OA, one 
could argue that this group would appear at low risk of the mentioned risks of misuse of 
the gabapentinoids. Indeed in 2016, the highest rates of drug misuse deaths in England and 
Wales for all substances occurred in those aged 40-49 years and this group, along with 
those aged 30-39 years, were also at highest risk of gabapentinoid-related deaths (Table 
2.1). However, there were still many gabapentinoid-related deaths in the 50-69 years age 
group, when OA becomes more prevalent (Office for National Statistics, 2017c). 
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Table 2.1 Pregabalin and Gabapentin Deaths in 2016, by Sex and Age Group, with Corresponding 
Mortality Rates (Office for National Statistics, 2017c, 2017b) 
 
The high prevalence of OA may also be problematic, as even a small proportion of patients 
prescribed a gabapentinoid will result in many prescriptions being issued. Whilst the risk of 
misuse may be relatively low in the general population compared to high risk groups such 
as those with a history of substance use disorder, this increased community prescribing 
may be problematic as a recent research report published in Addiction demonstrated a 
strong correlation between the number of gabapentinoid prescriptions issued and related 
deaths. For every 100,000 prescriptions in England and Wales, deaths increased by 5% 
(Lyndon et al., 2017).  
 
2.6.5 Summary of the Potential Risks of Gabapentinoid Use 
There are growing concerns with the increasing use of the gabapentinoids, in particular 
with regards to their possible diversion and potential for misuse, resulting in an increasing 
number of gabapentinoid-related deaths. In light of this, the Advisory Council on the 
Misuse of Drugs recommended to the UK government in January 2016 that the 
gabapentinoids be classified as Class C medications under the Misuse of Drugs Act 1971 
Age 
Group 
Deaths 
Population 
Mid-2016 
Deaths per 
1,000,000 
individuals 
Pregabalin Gabapentin 
Total 
Males Females Males Females 
≤20 0 1 0 0 1 13,812,700 0.1 
20-29 6 1 3 1 11 7,783,500 1.4 
30-39 31 13 8 5 57 7,664,600 7.4 
40-49 28 9 9 9 55 7,812,600 7.0 
50-69 14 8 12 11 45 14,019,800 3.2 
≥70 0 0 0 1 1 7,288,000 0.1 
        
Total 79 32 32 27 170 58,381,200 2.9 
       111        59   
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(Advisory Council on the Misuse of Drugs, 2016). During 2017 the British Medical 
Association also called for them to become controlled medications. The UK government 
have accepted this proposal, pending a consultation assessing the effect the reclassification 
would have on the healthcare sector (Iacobucci, 2017). Opinion is that this implementation 
of Class C status on gabapentinoid prescribing is likely, and there are three potential 
outcomes of this legislation. One is that gabapentin and pregabalin be controlled as 
Schedule 3 medications according to the Misuse of Drug Regulations 2001, as well as being 
required to be stored securely. Implications of this control would include the requirement 
of a ‘wet’ signature for each gabapentinoid prescription. The second option is the same as 
option one but does not require safe custody of gabapentin and pregabalin. Whilst this is 
not as stringent, it is believed that the required regular auditing of gabapentinoid 
prescribing would prevent diversion. The last option is that pregabalin and gabapentin are 
controlled within Part 1 of Schedule 4. Although this would provide similar benefits to 
option two, the same safeguards against diversion would not be provided (Home Office, 
2017). 
 
2.7 Conclusion and Study Aims 
Prescriptions of the gabapentinoids gabapentin and pregabalin have risen sharply in recent 
years. Due to the large number of patients with OA and the prevalence of comorbidities 
that are licensed indications of the gabapentinoids, it is likely that the gabapentinoids are 
being used in this population of patients. However, anecdotal evidence both in the UK and 
US suggests that the gabapentinoids may be being used off-label specifically for the 
patient’s OA pain. Possible reasons for this off-label use include concerns with the current 
pharmacological options for the treatment of OA, a potential neuropathic component to 
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the pain experienced by some patients with the condition and illegal marketing. As 
suggested by the British Pain Society, use of off-label medications for painful conditions 
should offer the “best balance of benefit against harm for any given patient” (The British 
Pain Society, 2012, p. 11). With only four small trials to date, data of efficacy remain sparse. 
On the contrary, the risk of adverse effects, diversion and misuse are increasingly being 
reported. As a common painful condition such as OA could contribute to this increased 
prescribing and risk to patients, further research is warranted. 
As a result, the aim of the research in this thesis is to explore the trends over time in 
incident gabapentinoid prescribing in patients with OA. The Clinical Practice Research 
Datalink (CPRD) will be used to provide an understanding of whether the risk of patients 
with OA receiving a gabapentinoid has increased, and which patients with OA are most 
likely to receive a gabapentinoid prescription. This will be achieved by stratification of the 
incidence rate of gabapentinoid prescribing by calendar year, as well as by a patient’s 
gender, age, geographical region and time since diagnosis. As the rationale for the use of 
the gabapentinoids in patients with OA is not well understood, an attribution analysis will 
be performed to explore whether OA, or other comorbidities, are responsible for the 
observed increase in gabapentinoid prescribing.
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3 Methods 
 
As demonstrated by the background chapters, literature suggests that the gabapentinoids 
(gabapentin and pregabalin) may be increasingly being used as analgesics in painful 
conditions. The proportion of this use that is off-label, beyond the licensed indication of 
neuropathic pain, is poorly understood. There is anecdotal evidence to suggest that the 
gabapentinoids may be being used for the pain experienced by patients with OA, a common 
cause of pain in older adults. However, use of these drugs may be problematic. The analysis 
within this thesis will therefore ascertain the incidence rate of gabapentinoid prescribing 
in patients with OA. To provide a better understanding of the proportion of patients with 
OA who may be prescribed a gabapentinoid for this common, painful condition, the study 
will also attempt to identify those patients with no other licensed or unlicensed indication 
for the gabapentinoids, where pain associated with OA may be the indication for 
prescribing. 
 
3.1 Choice of Data Source 
There were several possible sources of data to analyse gabapentinoid prescribing in 
patients with OA. Whilst information gathering would have been possible by surveying 
patients with OA, or interviewing doctors about their prescribing behaviour, anonymised 
electronic health record data offered several advantages. Firstly, as the majority of OA care 
is provided by general practitioners within the UK, primary care electronic health records 
provide prospectively-gathered information of a patient’s OA consultations and 
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gabapentinoid prescriptions. These data points allow for both the construction of a cohort 
of patients who are diagnosed with OA and the estimation of the frequency of 
gabapentinoid prescribing in these patients. Secondly, as 90% of NHS consultations occur 
within primary care (Gregory, 2009), primary care data is a rich source of information, both 
in terms of the number of patients and length of follow-up. As a result, incidence rates 
could be estimated with an acceptable level of precision, even after stratification. Finally, 
the use of electronic health records was a time efficient and cost effective approach that 
did not require a new Health Research Authority application and approval. In summary, the 
use of electronic health records was thought to be an efficient, powerful and reliable source 
of data for this study’s research objectives.  
 
3.2 Primary Care Electronic Health Records 
There are currently five large UK primary care datasets available: The Clinical Practice 
Research Datalink (CPRD), QResearch, ResearchOne, The Health Improvement Network 
(THIN), and the Royal College of General Practitioner’s Research and Surveillance Centre 
(RSC). Whilst the different databases may compile information from different software 
packages used by general practices, all have a similar structure. 
 
3.2.1 Structure of Electronic Health Records within the United Kingdom 
Within the UK, primary care information is currently recorded using the hierarchical Read 
code system (NHS Digital, 2018), which was developed by Dr James Read in the 1980s 
(Benson, 2012). As well as patient demographics, Read codes are recorded for many 
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patient-related data points that occur in the practice, including diagnoses, symptoms and 
signs, prescriptions and immunisations (Herrett et al., 2015).  
Data can be inputted by general practitioners (GPs) as well as by other practice staff. Other 
staff may include both clinicians, such as nurses or physiotherapists, and non-clinicians, 
such as receptionists or other administrative staff. The proportion of data inputted by non-
GP staff is increasing. A study of QResearch revealed that of healthcare professionals, GPs 
entered 61.9% of Read codes in the financial year 2007/2008, a decrease from 75.7% in 
1995/1996. The remaining data were inputted by nurses or other clinical staff (34.5% and 
3.7% in 2007/2008, respectively) (Hippisley-Cox & Vinogradova, 2009). 
A patient’s primary care health records may also include data from other healthcare 
institutions. Such institutions that may diagnose conditions or prescribe medications in the 
UK include walk-in centres, accident and emergency departments, hospitals and mental 
health centres, as well as providers of private medical care. Information from the above 
institutions will still feature within a patient’s primary care records providing data from 
communicating letters received by the general practice are uploaded and recorded 
appropriately.  
For the purpose of this thesis, the Clinical Practice Research Datalink (CPRD) was chosen 
for several reasons. Firstly, compared to the other primary care electronic health record 
databases, the CPRD is by far the most frequently used in published studies (Mannan et al., 
2017). It has also been validated for a number of diagnoses, including musculoskeletal and 
connective tissue disorders (Herrett et al., 2010; Williams et al., 2012). Finally, the CPRD 
was chosen for convenience and efficiency - the Institute for Primary Care and Health 
Sciences at Keele University already held a CPRD GOLD license, and extensive experience 
of the dataset, in the form of prior analysis and publications, was readily available. 
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3.2.2 The Clinical Practice Research Datalink 
The Clinical Practice Research Datalink (CPRD) is an electronic primary care database 
overseen by the Medicines and Healthcare Regulatory Agency (MHRA) and the National 
Institute for Health Research (NIHR). It is a database of anonymised data, first collected in 
1987, which is uploaded monthly from participating general practices who are trained to 
record information appropriately using the Read code hierarchy. As of 2018 there are two 
datasets offered by the CPRD: CPRD GOLD and CPRD AURUM. CPRD GOLD comprises data 
from practices recording information using the VISION software system. CPRD AURUM is a 
separate database of data from practices using Egton Medical Information Systems (EMIS). 
Although they offer similar information, due to slight differences in coding and structure 
they are offered as two distinct datasets (CPRD, 2018).  
Prior to 2012, the CPRD included only primary care information and was known as the 
General Practice Research Datalink (GPRD). Since then, the incorporation of linked data 
allows patient information from primary care to be linked to other sources, such as Hospital 
Episode Statistics, as well as to death and cancer registries (provided by the Office for 
National Statistics and Public Health England, respectively). To ensure anonymity of 
patients, the linkage process is undertaken by the CPRD team before the linked data is 
released to researchers (CPRD, 2018).  
In June 2017 a Primary Care Working Group Datasets Project released information about 
several datasets, including CPRD GOLD. At this time there were 693 practices contributing 
data of 14.2 million patients to the CPRD, of which 2.8 million were active (The Farr 
Institute, 2017). The CPRD has been shown to be representative of the UK population. 
Potentially due to 98% of the UK population being registered with a general practice in 
2013, the patients within the CPRD at this time were representative of the 2011 UK census 
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according to age, sex, and ethnicity (Herrett et al., 2015). Coding of ethnicity was 
historically poor but has improved since its introduction in the Quality and Outcomes 
Framework (QOF) in 2006 (Mathur et al., 2014). Other studies of the CPRD have 
demonstrated that compared to the UK population, patients who do consult tend to be 
older, female and from areas of higher deprivation (Hobbs et al., 2016; Mukhtar et al., 
2018).  
The CPRD GOLD dataset was chosen as the Institute at Keele University already held a 
license. Permission was sought to use the GOLD dataset by completion of an application 
form (Protocol 18_007, available in Appendix 1.1 on page 158), submitted to the 
Independent Scientific Advisory Committee (ISAC) in December 2017. This application was 
approved in April 2018, following protocol clarification and amendments. No further ethical 
permission, such as that needed when gaining information from patients via 
questionnaires, was required due to the nature of the descriptive research performed on 
the anonymised data.  
  
3.3 Study Design 
This study analysed prospectively-collected data from a cohort of patients in the CPRD. To 
analyse prescription rates in patients with OA using a denominator of person-time, and to 
thus ascertain an accurate period of follow-up, the date of initial diagnosis of OA (i.e. 
incident cases), was used as a patient’s entry into the cohort. From this date onwards 
however patients could reconsult for OA, and could thus be viewed as ‘prevalent’ cases. 
The date of initial OA consultation was chosen as it was a clear starting point to the follow-
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up of patients who definitely had the condition prior to receiving a gabapentinoid 
prescription. 
The study period during which a patient could be recruited into the cohort ran from the 1st 
January 1995 to the 31st December 2015. Whilst the starting year of 1995 predates the 
likely use of the gabapentinoids, it allowed the identification of gabapentinoid prescriptions 
in patients who received their initial OA diagnosis several years before. 
 
3.3.1 Population 
All objectives below were analysed from the same cohort of patients with OA. The 
population used in this cohort were patients in the CPRD who were newly diagnosed with 
OA during the study period. In terms of Read codes, a patient’s initial diagnosis of OA may 
be coded no differently from follow-up appointments. As a result, identification of only 
those with a new OA diagnosis required the exclusion of prevalent consulters. Patients with 
prevalent disease were determined by identifying their first consultation for OA during the 
study period, and excluding those with a consultation within the three years prior to this 
date (Figure 3.1). Patients who had received a knee or hip arthroplasty, a common end 
point for patients with OA, during this three year period were also excluded. Read codes 
for joint arthroplasty, which can be found in Appendix 2.3 on page 182, were already held 
by the research institute, having been used in a prior CPRD ISAC protocol (ISAC 15_211). 
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Figure 3.1 Scenarios of the Inclusion (Blue) and Exclusion (Red) of Patients, Based on the Year of 
their OA Consultation 
The three year period prior to OA diagnosis was chosen as this has been shown to 
effectively exclude the vast majority of prevalent consulters with the condition (Yu et al., 
2015). Other criteria had to be fulfilled for a patient to be included in the study cohort 
(Figure 3.2). To establish temporality between exposure and outcome, and to ensure the 
diagnosis of OA preceded the prescription of a gabapentinoid, patients with a 
gabapentinoid prescription in the three years prior to their first OA diagnostic consultation 
were excluded. The patient also had to be aged 40 years or over on the date of this first 
consultation as used by prior studies of OA (Ho-Pham et al., 2014; Prieto-Alhambra et al., 
2014; Thiem et al., 2013). At the practice level, data uploaded had to be ‘up to standard’ 
(UTS) during the three years prior to, and the follow-up period since, diagnosis. UTS is a 
measure provided by the CPRD and whilst not a definite indicator of data quality, the CPRD 
recommends that it be used as a measure to select “research-quality patients and periods 
of quality data recording” (Herrett et al., 2015, p. 832).  
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3.3.2 Definition of Incident OA 
The case definition of incident OA, used as the cohort member’s index date, was the first 
occurrence within the study period of a definitive, diagnostic OA Read code in their health 
records. This approach has been used (Turkiewicz et al., 2014; Yu et al., 2017) and validated 
(Lix et al., 2006) by prior studies. This definition also rarely (1.3%) results in a different 
diagnosis (Prieto-Alhambra et al., 2014). The list of Read codes used for this definition of 
OA was taken from established code lists held by the research institute (available from 
www.keele.ac.uk/mrr). This code list has been used in prior research of the CPRD (Yu et al., 
2017 [ISAC 14_090]), and can be found in Appendix 2.1 (page 175). The requirement of a 
definitive OA diagnostic Read code is a relatively specific definition of OA, as many patients 
presenting to primary care with symptomatic OA may be managed under non-specific 
‘clinical OA’ Read codes (Jordan et al., 2014). The decision was made to use the specific 
definition, instead of the more sensitive ‘clinical OA’, primarily to provide a greater 
understanding of the attribution of a gabapentinoid to OA or other conditions. The use of 
‘clinical OA’ Read codes, such as ‘joint pain’, may have made it more challenging to 
distinguish OA from other common causes of pain and potential gabapentinoid indications, 
such as fibromyalgia. 
 
3.3.3 Censoring of Patients 
The follow-up of a patient came to an end on the date of their first censoring event. Possible 
censoring events were a patient receiving their first gabapentinoid prescription, 
transferring out of their GP practice, dying, or reaching the study end date (31st December 
2015). Follow-up also came to an end if the GP practice chose to no longer upload data to 
the CPRD. In the instance that a patient received their first gabapentinoid prescription on 
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the same date as another censoring event, the gabapentinoid prescription took priority, 
and was counted in the analysis. 
Details of the criteria of a patient’s index and censoring dates are displayed in Figure 3.2. 
 
Figure 3.2 Criteria of Index and Censoring Dates for Cohort Members (OA: osteoarthritis)  
3.3.4 Gabapentinoid Prescriptions 
Prescriptions are recorded in the CPRD as product codes. The code list of product codes 
used (presented in Appendix 2.2, page 178) was derived from a recent report on 
Dependence Forming Medications that included the gabapentinoids (Cartagena et al., 
2017). This was compared with code lists available online in the clinical codes repository 
(ClinicalCodes.org), provided by the University of Manchester (University of Manchester, 
2018).  
 
3.3.5 Possible Indications for Gabapentinoid Prescriptions 
Due to the structure of electronic primary care records, it is not possible to directly link a 
prescription to an indication or diagnosis. Whilst every cohort member had received a 
diagnosis of OA, it is possible that a gabapentinoid prescribed to a member of this cohort 
was due to a comorbidity. As a result, possible indications were identified. 
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As shown in Table 3.1, identified licensed indications of the gabapentinoids included 
epilepsy, generalised anxiety disorder (for pregabalin), and neuropathic pain. These 
conditions were identified using NICE guidelines and the BNF. Possible unlicensed 
indications of the gabapentinoids were identified using the BNF (Joint Formulary 
Committee, 2018) and by literature searches (Cartagena et al., 2017; Fukada et al., 2012; 
Mack, 2003; Wallach & Ross, 2018). Read code lists for the identified comorbidities were 
established using publically available code lists sourced from the University of 
Manchester’s repository (University of Manchester, 2018), as well as by searching the CPRD 
bibliography available online (methods and articles used specific to each condition are also 
available in Table 3.1). Codes were verified using the CPRD Code Browser (Version 3.0.0, 
copyright © 2012-2018 of Clinical Practice Research Datalink Medicines and Healthcare 
Products Regulatory Agency) and the NHS Clinical Terminology Browser (Version 1.04) was 
also used to detect any missing codes. Read codes for these conditions, available in 
Appendix 2.4 (page 184), were checked by two senior clinicians: JB, a senior academic 
general practitioner and JA, an academic consultant in pain management. 
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Table 3.1 Identified Licensed and Unlicensed Indications of the Gabapentinoids and the Sources 
Used in Code List Development 
 
 
 
 
 
 
GAD: generalised anxiety disorder; CRPS: complex regional pain syndrome 
 
  
                                                     
4 (Gorton et al., 2018; Horsfield, 2005; Kontopantelis et al., 2015). 
5 Generalised anxiety disorder is an indication for pregabalin only (Joint Formulary Committee, 2018). 
6 (Windfuhr et al., 2016). 
7 (Berger et al., 2012; Hall et al., 2013). 
8 (Fairhurst et al., 2016; Gorton et al., 2018; Horsfield, 2005; Khan et al., 2010; Kontopantelis et al., 2015; 
Zhong et al., 2018). 
9 (Doyle et al., 2016; Thompson et al., 2017). 
10 (Newlove-Delgado et al., 2018). 
11 (Windfuhr et al., 2016). 
12 Complex regional pain syndrome has two subtypes. Type 1 has no nerve lesion, and the syndrome was 
deemed non-neuropathic by a 2010 review (Naleschinski & Baron, 2010). 
13 Fibromyalgia is not a licensed indication within the UK, although is a licensed indication of pregabalin in the 
US and is seen as part of the repertoire for treatment within Europe (Public Health England, 2014). 
14 (Collin et al., 2017). 
15 Menopausal hot flushes and migraine are listed as indications of gabapentin by the BNF as of May 2018, 
but were not licensed during the study period (Joint Formulary Committee, 2018). 
16 (Gorton et al., 2018). 
17 (Windfuhr et al., 2016). 
18 Restless legs syndrome is not a licensed indication of gabapentin or pregabalin, but is a licensed indication 
of gabapentin enacarbil, the prodrug formulation (not analysed in this thesis). 
19 (Van De Vijver et al., 2004). 
Condition Source of Code List 
Licensed  
Epilepsy ClinicalCodes.org4 
GAD5 NHS Browser, ClinicalCodes.org6 
Neuropathic Pain CPRD Bibliography7, NHS Browser, ClinicalCodes.org8 
  
Unlicensed  
Alcohol Withdrawal ClinicalCodes.org9  
Attention Deficit Disorder CPRD Bibliography10, NHS Browser 
Bipolar Disorder ClinicalCodes.org11  
CRPS12 NHS Browser 
Fibromyalgia13 CPRD Bibliography14 
Menopausal Hot Flushes15 NHS Browser 
Migraine15 ClinicalCodes.org16  
Panic Disorder ClinicalCodes.org17  
Restless Legs Syndrome18 CPRD Bibliography19, NHS Browser 
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3.4  Statistical Analyses 
This thesis includes descriptive analyses of the CPRD as well as estimations of rates, 
absolute rate differences, and rate ratios. All analyses were performed using IBM SPSS 
Statistics version 24. 
 
3.4.1 Objective 1: Incidence Rate of Gabapentinoid Prescribing in OA 
Objective 1 was to estimate the incidence rates of first gabapentinoid prescriptions in 
patients newly diagnosed with OA during the study period (1st January 1995 to 31st 
December 2015). Lexis expansion was used to estimate incidence rates along three 
different time axes: calendar year, a patient’s attained age, and time since index OA 
diagnosis. Attained age, used by prior studies of OA (Turkiewicz et al., 2016), was felt to 
provide a more relevant measure of age for the clinical decision to prescribe a 
gabapentinoid than age on the date of index OA diagnosis. The use of Lexis expansion 
allowed for the analysis of two or more time-dependent variables simultaneously (for 
instance calendar year and age, as demonstrated by Figure 3.3 and Figure 3.4), permitting 
the exploration of changing age as a confounding variable in the analysis of gabapentinoid 
prescribing over the course of the study period (Nitika et al., 2017). Time since index date 
can also be calculated using this method. However, this was not a key feature of the 
analysis in this thesis as the index date of diagnosis of OA is dependent on the definition of 
OA used, and as such the date of initial consultation can be viewed merely as an arbitrary 
time point at which follow-up within this cohort began. This is further discussed in Chapter 
6. 
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In this incidence analysis the numerator was the number of first gabapentinoid 
prescriptions occurring in the calendar year of interest. The denominator was the number 
of person-years contributed by cohort members in that year. Incidence rates throughout 
this thesis are presented as first gabapentinoid prescriptions per 1,000 person-years, and 
95% confidence intervals (CI) for incidence rates were calculated using a publicly available 
online Poisson regression calculator (Dean & Sullivan, 2018). Due to the anticipation of 
small cell sizes, particularly when stratified by calendar year, age was stratified into 10 year 
age groups (40-49, 50-59, 60-69, 70-79 and 80+ years). A patient’s age at index and at 
censoring was calculated based on their year of birth, the level of precision provided by the 
CPRD. The crude annual incidence rates were then age-standardised using direct 
standardisation (Naing, 2000). As the population of cohort members used in this study 
were those with an OA diagnosis based on the presence of a diagnostic Read code in their 
medical records, the reference population used for direct age-standardisation was cohort 
members present in mid-2015 of this study. The 30th June was used as the mid-year date, 
as this date is used by the Office for National Statistics for their mid-year population data 
(Office for National Statistics, 2018).  
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Figure 3.4 Lexis Expansion of Cohort from Figure 3.3, Demonstrating the Analysis of Calendar Year 
and Age Simultaneously 
3.4.2 Objective 2: Stratification of Incidence Rates 
Objective 2 stratified the incidence rates of gabapentinoid prescribing found in Objective 1 
by patient gender, geographical region and time since index OA diagnosis. Geographical 
region is stratified into 13 regions and is provided by the CPRD, based on the location of 
the GP practice to which the patient is registered. Time since OA diagnosis was calculated 
from a patient’s index date (their first OA consultation) until their time of censoring and 
was stratified into five-year age bands (<5, 5-9, 10-14, >15 years). The product codes of the 
gabapentinoids, provided by the CPRD, were used to identify the respective proportions of 
prescribing due to gabapentin and to pregabalin. 
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3.4.3 Objective 3: Attributing Prescriptions to OA and Licensed or Unlicensed Indications 
As previously mentioned, one limitation of the CPRD and other similar databases in 
pharmacoepidemiology studies is the inability to link a prescription directly to a specific 
indication. As a result, although prescriptions of gabapentinoids may occur in patients with 
OA, it is not possible to directly link this prescription to their OA, and the prescriptions could 
therefore be issued for a comorbid condition (either a licensed or recognised off-label 
indication for the gabapentinoids). The primary attribution analysis explored the 
proportion of patients with a first gabapentinoid prescription that had a diagnostic Read 
code of OA during the period from 14 days before to 90 days after (inclusive) the date at 
which the gabapentinoid was issued.20 This time window has been used in a previous study 
of the CPRD to identify musculoskeletal conditions in patients prescribed opioids (Bedson 
et al., 2016). Performing this attribution analysis within the time window around only the 
first gabapentinoid prescription, rather than including any subsequent prescriptions, may 
present less opportunities to assess the presence of diagnostic codes. However, this 
technique has been used in a prior study of pregabalin prescribing within the UK 
(Asomaning et al., 2016), and as the first prescription of a gabapentinoid would constitute 
a change in a patient’s management, this prescription, more so than any other, should be 
accompanied by a diagnostic Read code for the relevant indication (Lawson et al., 1998). 
To gain an understanding of the proportion of gabapentinoid prescriptions issued to 
patients with OA that may be due to a comorbidity, the presence of licensed and unlicensed 
indications (as displayed in Table 3.1 on page 69) were also assessed during this same time 
period. The primary analysis could therefore provide an estimate of the proportion of 
prescriptions attributable to OA as well as to other licensed and unlicensed indications. As 
                                                     
20 This date may or may not have been a patient’s first consultation of OA (i.e. their index date). 
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a result, the number of prescriptions unattributed to OA or the other identified indications 
could also be reported. 
As the consultation closest to the gabapentinoid prescription was chosen for each 
condition analysed, cohort members could only have one consultation date for OA as well 
as for the licensed or unlicensed indications. However, patients could have Read codes 
within the same time window for more than one condition. As a cohort member with OA 
around the time of their gabapentinoid prescription may also have had a licensed or 
unlicensed indication present in their electronic healthcare records, the identified 
proportion of patients with a prescription attributable to OA may overstate the role of the 
condition in the prescribing of a gabapentinoid in this cohort of patients. As a result, the 
proportion of patients with OA in their electronic healthcare records at the time of 
prescription, but with no presence of a licensed or unlicensed indication, was also explored. 
In other words, attribution to a licensed or unlicensed indication took precedence over OA, 
to provide a more conservative estimate. Within this analysis no priority was given between 
licensed or unlicensed indications, and as such this thesis presents the proportion of 
patients with first gabapentinoid prescriptions attributable to OA (irrespective of other 
indications), to licensed or unlicensed indications, as well as those prescriptions in patients 
with a Read code for OA but with no evidence of a licensed or unlicensed indication. 
The proportions of first gabapentinoid prescriptions attributed to OA or licensed and 
unlicensed conditions, as well as those prescriptions which remained unattributed, were 
stratified by patient age, gender and geographical region. The attribution of first 
gabapentinoid prescriptions was also stratified by calendar year and whether the 
prescribed gabapentinoid was gabapentin or pregabalin. 
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As the 105-day window (referred to in Chapter 5 as Window 1) surrounding the prescription 
date relies on the assumption that coding will be present at this time, the estimated 
proportion of first prescriptions attributable to OA may be conservative. Equally, as the 
presence of the Read codes for the licensed and unlicensed indications within this narrow 
time window may also be low, the proportion of first prescriptions that remains 
unattributed may be the upper estimate of the proportion of patients with OA prescribed 
a gabapentinoid with no indication. As a result sensitivity analyses, using the same 
technique, were undertaken to explore the effect of expanding the time period studied 
around the first prescription date (Figure 3.5). As in Window 1, the patient’s nearest 
consultation date (based on the presence of a Read code) to their gabapentinoid 
prescription was used and as a result those first prescriptions attributed in the narrow time 
window were also attributed in subsequent analyses. The order of precedence, whereby 
licensed or unlicensed indications took priority over OA to provide a more conservative 
estimate of attribution, was also used in the sensitivity analyses. Window 2 analysed the 
proportion of patients with an OA or licensed or unlicensed indication Read code within six 
months before to six months after the date of their first gabapentinoid. Window 3 further 
expanded upon window 2, by assessing a further six months before the gabapentinoid date. 
Finally, the extreme was window 4, where first prescriptions were attributed based upon 
the presence of a Read code in the period from one year prior to their initial OA 
consultation to six months following their gabapentinoid prescription. The time frame of 
six months following the first prescription was also used by a previous study of pregabalin 
prescribing in primary care (Asomaning et al., 2016). As in Objectives 1 and 2, as well as in 
the primary attribution analysis, all attributed and unattributed prescriptions in the 
sensitivity analyses were stratified by a patient’s age, gender and region, as well as by 
calendar year.  
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Figure 3.5 Time Periods Used in Attribution Analysis 
 
3.5 Summary 
The analyses in this study were designed to estimate the trends, by calendar year and 
patient age, in the incidence of first gabapentinoid prescriptions issued to members of a 
fixed cohort. Members of this study were UK patients aged 40 years and over newly 
diagnosed with OA between 1995 and 2015. Stratified analyses sought to further explore 
differences in the incidence of gabapentinoid prescribing among patients with OA, 
between men and women, as well as by geographical region. The above estimates describe 
the incidence of gabapentinoid prescribing in patients with a diagnosis of OA. Attribution 
analyses are then intended to allow the assessment of the proportion of OA patients 
prescribed a gabapentinoid for OA, as well as for comorbidities, including both licensed 
indications and other recognised off-label uses. 
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4 Results I 
 
4.1 Cohort Characteristics 
During the study period starting 1st January 1995 and ending 31st December 2015 there 
were 383,680 patients in the CPRD who were newly diagnosed with osteoarthritis (OA). Of 
these, 234,159 (61.0%) were female. Median age at first OA consultation was 66.0 years 
(IQR: 57.0, 75.0; range: 40, 107 years). The number of newly diagnosed cases of OA in each 
calendar year is shown in Figure 4.1, ranging from a minimum of 7,712 diagnoses in 1995 
to a maximum of 26,072 in 2005. Throughout the study period there was an annual average 
of 108,106 person-years contributed by cohort members. This was lowest in the first year 
of the study (3,849 person-years) and highest in 2012 (185,227 person-years). Table 4.1 
depicts patients at first OA diagnosis by the geographical region of their general practice. 
 
Figure 4.1 Number of Patients with a New Diagnosis of OA in the CPRD, by Year 
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Table 4.1 New OA Diagnoses by Geographical Region, 1995-2015 
 
 
 
 
 
 
4.2 Outcome Events 
Cohort members were followed for a median of 5.1 years (IQR: 2.3, 8.7; range: 0.0, 21.0) 
from the date of their index OA consultation to the occurrence of a censoring event. This 
provided a total of 2,270,238.8 person-years of follow-up. Censoring occurred when a 
cohort member reached the study end date (n = 122,518), transferred out of their practice 
(n = 62,973), died (n = 55,871) or received their first gabapentinoid prescription (n = 
35,031). 117,874 cohort members were censored due to their general practice no longer 
uploading data to the CPRD.21 
 
4.2.1 Cohort Members who Received a Gabapentinoid Prescription 
35,031 (9.1%) patients received at least one prescription for a gabapentinoid. Of this subset 
of the population, 23,607 (67.4%) were female, and the median age at their first 
                                                     
21 The number of censoring events (n = 394,267) adds to more than the number of members in the cohort (n 
= 383,680) due to the possibility of two or more censoring events occurring on the same day, such as a 
gabapentinoid prescription occurring on 31st December 2015, the study end date. 
Region Frequency Percentage 
North East 8,443 2.2 
North West 50,390 13.1 
Yorkshire & The Humber 17,710 4.6 
East Midlands 17,535 4.6 
West Midlands 41,205 10.7 
East of England 34,664 9.0 
South West 33,674 8.8 
South Central 36,843 9.6 
London 28,124 7.3 
South East Coast 32,998 8.6 
Northern Ireland 10,817 2.8 
Scotland 31,547 8.2 
Wales 39,730 10.4 
   
Total 383,680 100.0 
81 
 
prescription was 69.0 years (IQR: 60.0, 77.0; range: 40, 106). As could be anticipated by the 
date of marketing authorisation of the gabapentinoids in the UK, there were less than 100 
first gabapentinoid prescriptions annually during the period 1995-2000, and in the 
remainder of the study period the number of cohort members who received their first 
gabapentinoid prescription increased from 164 in 2001 to 4,629 in 2014.  
Of the 35,031 first-time prescriptions prescribed across all years of the study period, 25,208 
(72.0%) were formulations of gabapentin, with the remaining 9,823 (28.0%) prescriptions 
being pregabalin. Gabapentin was prescribed in each year of the study period, and the 
maximum number of first gabapentin prescriptions occurred in 2014 (n = 3,439). Pregabalin 
was first prescribed in this cohort in 2004, and the number of incident prescriptions peaked 
in 2010 (n = 1,197), where it accounted for 37.2% of gabapentinoids prescribed that year 
(Table 4.2). The ratio of gabapentin to pregabalin prescriptions was similar across age 
strata, lowest in the 40-49 years age group (where gabapentin accounted for 70.3% of first 
gabapentinoid prescriptions) and highest in the 70-79 years age group (72.6%). 
Eight different formulations of gabapentin were the first gabapentinoid prescribed to 
patients with OA. The most common formulation was 300mg capsules. There were nine 
different formulations of first pregabalin prescriptions during the study period, of which 
75mg capsules were the most common (Table 4.3).  
Of the 35,031 patients who received a gabapentinoid, 3,904 (11.1%) underwent a total 
knee arthroplasty (TKA) during the study period (prior to all censoring events except first 
gabapentinoid prescription). Of this subgroup, 2,587 (66.3%) were female and median age 
at operation was 69.0 years (IQR: 62.3, 76.0; range: 43, 94). 
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Table 4.2 Number of First Gabapentin and Pregabalin Prescriptions Issued, by Year, to Patients 
with OA 
 
 
 
 
 
 
 
 
 
 
Table 4.3 Formulations of the First Gabapentin or Pregabalin Prescribed to a Patient with OA, 
Ordered by Frequency22 
                                                     
22 Different formulations of gabapentin and pregabalin have been grouped by dose, for instance ‘Gabapentin 
300mg capsules’ includes 61 300mg Neurontin capsules and 2 gabapentin 300mg capsules produced by Teva 
UK Ltd. The full table is available in Appendix 3.1 on page 198. 
Year Gabapentin Pregabalin Total 
Number Percentage Number Percentage  
1995 2 100.0 0 0.0  2 
1996 4 100.0 0 0.0  4 
1997 2 100.0 0 0.0  2 
1998 8 100.0 0 0.0  8 
1999 21 100.0 0 0.0  21 
2000 87 100.0 0 0.0  87 
2001 164 100.0 0 0.0  164 
2002 321 100.0 0 0.0  321 
2003 514 100.0 0 0.0  514 
2004 690 96.1 28 3.9  718 
2005 838 72.1 325 27.9  1,163 
2006 910 64.2 507 35.8  1,417 
2007 1,294 70.0 554 30.0  1,848 
2008 1,584 68.7 721 31.3  2,305 
2009 1,828 67.2 891 32.8  2,719 
2010 2,017 62.8 1,197 37.2  3,214 
2011 2,504 67.9 1,184 32.1  3,688 
2012 2,814 72.4 1,075 27.6  3,889 
2013 3,218 73.7 1,146 26.3  4,364 
2014 3,439 74.3 1,190 25.7  4,629 
2015 2,949 74.6 1,005 25.4  3,954 
       
Total 25,208 72.0 9,823 28.0  35,031 
Gabapentin Pregabalin 
Formulation Frequency Formulation Frequency 
Gabapentin 300mg capsules 12,995 Pregabalin 75mg capsules 3,062 
Gabapentin 100mg capsules 11,467 Pregabalin 25mg capsules 2,958 
Gabapentin 600mg capsules 422 Pregabalin 50mg capsules 2,431 
Gabapentin 400mg capsules 241 Pregabalin 150mg capsules 562 
Gabapentin 800mg capsules 52 Pregabalin 100mg capsules 392 
Gabapentin 50mg/ml solution 14 Pregabalin 300mg capsules 281 
Gabapentin 250mg/5ml solution 10 Pregabalin 200mg capsules 103 
Gabapentin 400mg/5ml solution 7 Pregabalin 225mg capsules  29 
  Pregabalin 20mg/ml solution 5 
    
Total 25,208 Total 9,823 
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4.3 Incidence of First Gabapentinoid Prescriptions in the OA Population 
The crude annual incidence rate of first gabapentinoid prescriptions in patients diagnosed 
with OA increased through the study period (Table 4.4). In the period 1995-1999 the crude 
incidence rate of first gabapentinoid prescriptions in this cohort of patients with OA 
remained below 1.00 per 1,000 person-years. In the remaining period the incidence rate 
increased from 1.71 per 1,000 person-years (95% CI: 1.37, 2.11) in 2000 to 27.95 (95% CI: 
27.15, 28.77) per 1,000 person-years in 2014. The incidence rate of first gabapentinoid 
prescriptions remained similar in 2015 (27.92 (95% CI: 27.06, 28.81) per 1,000 person 
years). The largest annual increase on the multiplicative scale occurred between 1999 and 
2000 (crude incidence rate ratio: 3.29 (95% CI: 2.04, 5.30)), whilst the highest absolute rate 
difference occurred between years 2013 and 2014 (crude rate difference: 3.62 (95% CI: 
2.54, 4.70) per 1,000 person-years). 
Table 4.4 Events, Person-Time and Crude Incidence Rates, with 95% Confidence Intervals (CI) 
 
 
 
 
 
 
 
 
Year Events Person-Years Incidence Rate, per 1,000 
person-years (95% CI) 
1995 2 3,849.0 0.52 (0.06, 1.88) 
1996 4 12,080.6 0.33 (0.09, 0.85) 
1997 2 21,292.7 0.09 (0.01, 0.34) 
1998 8 30,888.4 0.26 (0.11, 0.51) 
1999 21 40,473.1 0.52 (0.32, 0.79) 
2000 87 50,968.4 1.71 (1.37, 2.11) 
2001 164 61,116.3 2.68 (2.29, 3.13) 
2002 321 72,403.4 4.43 (3.96, 4.95) 
2003 514 86,289.7 5.96 (5.45, 6.49) 
2004 718 103,448.1 6.94 (6.44, 7.47) 
2005 1,163 121,949.8 9.54 (9.00, 10.10) 
2006 1,417 138,098.9 10.26 (9.73, 10.81) 
2007 1,848 151,923.2 12.16 (11.62, 12.73) 
2008 2,305 164,688.2 14.00 (13.43, 14.58) 
2009 2,719 174,928.9 15.54 (14.96, 16.14) 
2010 3,214 181,003.7 17.76 (17.15, 18.38) 
2011 3,688 182,998.9 20.15 (19.51, 20.81) 
2012 3,889 185,227.1 21.00 (20.34, 21.67) 
2013 4,364 179,390.9 24.33 (23.61, 25.06) 
2014 4,629 165,619.5 27.95 (27.15, 28.77) 
2015 3,954 141,600.4 27.92 (27.06, 28.81) 
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The age-standardised incidence rate differed only marginally from the crude estimates and 
showed the same trend over time. The number of first gabapentinoid prescriptions 
remained below 1.00 per 1,000 person-years until the calendar year 2000, then increased 
annually to 27.57 (95% CI: 26.71, 28.43) in 2014. The incidence rate remained 27.57 (95% 
CI: 26.71, 28.43) first gabapentinoid prescriptions per 1,000 person-years in 2015 (Table 
4.5).
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Table 4.5 Crude Age-Stratified and Age-Standardised Rates of First Gabapentinoid Prescriptions, by Year  
N.B. All incidence rates are displayed per 1,000 person-years. (IR: annual incidence rate, CI: confidence interval) 
Year 
Age Group 
Age Standardised 
40-49 Years 50-59 Years 60-69 Years 70-79 Years 80 Years and Over 
IR 95% CI IR 95% CI IR 95% CI IR 95% CI IR 95% CI IR 95% CI 
1995 0.00 (0.00, 10.83) 2.61 (0.32, 9.42) 0.00 (0.00, 3.46) 0.00 (0.00, 3.37) 0.00  (0.00, 6.33) 0.36 (0.00, 0.85) 
1996 1.03  (0.03, 5.75) 0.42 (0.01, 2.33) 0.30  (0.01, 1.65) 0.30  (0.01, 1.66) 0.00  (0.00, 1.84) 0.26  (0.01, 0.51) 
1997 0.67  (0.02, 3.71) 0.24 (0.01, 1.33) 0.00 (0.00, 0.62) 0.00 (0.00, 0.61) 0.00 (0.00, 1.02) 0.05 (0.00, 0.12) 
1998 0.52  (0.01, 2.89) 0.50 (0.10, 1.45) 0.23  (0.03, 0.83) 0.11 (0.00, 0.62) 0.19  (0.00, 1.05) 0.23  (0.07, 0.39) 
1999 0.43 (0.01, 2.41) 0.51 (0.14, 1.30) 0.71  (0.31, 1.40) 0.50 (0.18, 1.09) 0.28  (0.03, 1.02) 0.50  (0.29, 0.72) 
2000 4.62 (2.46, 7.90) 1.72 (1.00, 2.76) 1.21 (0.70, 1.93) 1.70 (1.10, 2.50) 1.59  (0.89, 2.62) 1.61 (1.27, 1.95) 
2001 4.02 (2.14, 6.88) 2.70 (1.85, 3.82) 2.63 (1.91, 3.53) 2.35 (1.68, 3.18) 2.88 (1.99, 4.02) 2.66 (2.25, 3.06) 
2002 4.55 (2.65, 7.28) 4.60 (3.54, 5.87) 4.66 (3.76, 5.72) 4.65 (3.77, 5.68) 3.62 (2.70, 4.75) 4.38  (3.90, 4.86) 
2003 7.55 (5.17, 10.67) 6.20 (5.06, 7.51) 5.66  (4.74, 6.70) 6.39  (5.43, 7.48) 5.12  (4.11, 6.31) 5.86 (5.35, 6.37) 
2004 6.72  (4.63, 9.44) 6.87 (5.77, 8.13) 7.19  (6.24, 8.24) 7.28 (6.33, 8.33) 6.23 (5.20, 7.40) 6.92 (6.41, 7.42) 
2005 10.38  (7.90, 13.39) 9.23 (8.03, 10.55) 9.80 (8.78, 10.90) 9.40 (8.40, 10.49) 9.46 (8.28, 10.75) 9.53 (8.98, 10.08) 
2006 13.57 (10.84, 16.78) 10.62 (9.39, 11.97) 9.57 (8.63, 10.59) 10.79 (9.78, 11.88) 9.43 (8.32, 10.64) 10.14  (9.61, 10.67) 
2007 13.44  (10.81, 16.53) 11.79 (10.53, 13.17) 12.35 (11.34, 13.42) 12.67  (11.63, 13.78) 11.24  (10.09, 12.49) 12.11 (11.56, 12.66) 
2008 18.01 (15.01, 21.43) 15.11 (13.71, 16.62) 13.34 (12.33, 14.40) 14.86  (13.78, 16.01) 11.99 (10.85, 13.21) 13.80 (13.24, 14.37) 
2009 20.05 (16.92, 23.59) 16.56 (15.11, 18.10) 15.38 (14.34, 16.48) 16.03  (14.94, 17.18) 13.39 (12.22, 14.63) 15.34 (14.77, 15.92) 
2010 28.95 (25.18, 33.12) 19.89 (18.31, 21.56) 17.50 (16.41, 18.64) 17.45 (16.32, 18.63) 14.73 (13.54, 16.01) 17.40  (16.80, 18.00) 
2011 30.26 (26.36, 34.58) 23.98  (22.24, 25.81) 19.10 (17.97, 20.28) 20.70 (19.47, 21.98) 16.22 (14.98, 17.53) 19.79 (19.15, 20.43) 
2012 36.53 (32.16, 41.32) 26.42 (24.59, 28.35) 19.32 (18.19, 20.50) 20.90 (19.68, 22.18) 16.86 (15.61, 18.17) 20.57 (19.93, 21.22) 
2013 40.28 (35.51, 45.51) 29.04 (27.07, 31.11) 22.16 (20.93, 23.45) 24.53 (23.20, 25.93) 21.11 (19.69, 22.59) 24.00 (23.29, 24.71) 
2014 48.49 (42.89, 54.63) 35.11 (32.84, 37.49) 24.50 (23.14, 25.93) 28.51 (27.02, 30.05) 23.78 (22.23, 25.41) 27.57 (26.78, 28.37) 
2015 44.06 (38.20, 50.55) 34.89  (32.46, 37.46) 26.90 (25.36, 28.51) 26.61 (25.05, 28.23) 23.85 (22.18, 25.61) 27.57 (26.71, 28.43) 
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As demonstrated by Table 4.5, and further displayed in Figure 4.2, the absolute increase in 
the incidence rate of first gabapentinoid prescriptions was seen in all age groups, but from 
the mid-2000s onwards patients aged 40-49 years at the time of prescription were most 
likely to receive their first gabapentinoid prescription. In contrast, those aged 80 years or 
older were least likely to receive their first prescription. The incidence rate in those aged 
40-49 years increased from 4.62 (95% CI: 2.46, 7.90) first prescriptions per 1,000 person-
years in 2000 to 44.06 (95% CI: 38.20, 50.55) in 2015. The incidence rate in those aged 80 
years or older increased from 1.59 (95% CI: 0.89, 2.62) in 2000 to 23.85 (95% CI: 22.18, 
25.61) in 2015. Between these two age strata (40-49 and 80 years and older), the absolute 
rate difference in 2000 and 2015 was 3.03 and 20.20 prescriptions per 1,000 person-years, 
respectively. However, during the same period the rate ratio of gabapentinoid prescribing 
in those aged 40-49 compared to those aged 80 years or older decreased from 2.91 in 2000 
to 1.85 in 2015. 
 
Figure 4.2 Crude Annual Incidence Rate of First Gabapentinoid Prescriptions, Stratified by 
Attained Age 
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Over the course of the study period, the crude incidence rate of first gabapentinoid 
prescriptions was 16.86 (95% CI: 16.65, 17.08) per 1,000 person-years in females, 
compared to 13.13 (95% CI: 12.89, 13.37) in males. This resulted in a female to male rate 
ratio over the study period of 1.28 (95% CI: 1.25, 1.31). This ratio remained fairly constant 
between 2000 and 2015 (1.24 (95% CI: 0.79, 1.94) in 2000, 1.33 (95% CI: 1.24, 1.42) in 
2015). However, due to females being prescribed a gabapentinoid more frequently than 
males, the absolute rate difference increased from 0.35 more females per 1,000 person-
years being first prescribed a gabapentinoid in 2000 to 7.77 in 2015. The crude incidence 
rates for females increased from 1.84 (95% CI: 1.40, 2.37) per 1,000 person years in 2000 
to 31.02 (95% CI: 29.85, 32.22) in 2015. During the same period the crude incidence rate in 
males increased from 1.49 (95% CI: 0.99, 2.15) to 23.25 (95% CI: 22.01, 24.55). Age-
standardisation of the gender-stratified data resulted in very similar incidence rates (Figure 
4.3).  
 
Figure 4.3 Age-Standardised Incidence Rate (with 95% Confidence Intervals) of First 
Gabapentinoid Prescriptions, Stratified by Gender 
0
5
10
15
20
25
30
35
In
ci
d
en
ce
 R
at
e 
(p
er
 1
,0
0
0
 p
er
so
n
-y
ea
rs
)
Year
Females Males
88 
 
An increase in incidence rates across the study period was observed in all 13 geographical 
regions of the CPRD (Figure 4.4). Within the CPRD, there were at least 20 first 
gabapentinoid prescriptions issued to patients with OA (i.e. ≥20 patients with OA received 
their first gabapentinoid) annually from 2004 onwards.23 Similar to the data stratified by 
age group and gender, the increase in incidence rates in the majority of regions slowed or 
decreased in 2015. Over the course of the study period, Northern Ireland, followed by 
Scotland, had the highest rates of first gabapentinoid prescriptions per 1,000 person-years 
(Figure 4.5). It should be noted that Northern Ireland, Scotland and Wales are individual 
regions in the CPRD, and as a result displayed prescribing rates are equal within each area. 
Northern Ireland had the highest incidence rates of patients with OA receiving their first 
gabapentinoid each year between 2005 and 2014, before being overtaken by the North 
East of England in 2015. The rate of first gabapentinoid prescriptions in the North East in 
2015 was 44.46 (95% CI: 32.30, 59.69) per 1,000 person-years, the highest of any region 
during the study period. The second-highest rate of prescribing occurred in Northern 
Ireland in 2010 (44.18 (95% CI: 38.66, 50.26) per 1,000 person-years). During this year the 
next-highest rate of first gabapentinoid prescriptions was in Scotland (24.53 (95% CI: 21.97, 
27.3) per 1,000 person-years), which was the largest absolute rate difference between the 
highest and second-highest rates of first prescriptions in a calendar year. During the period 
2006 to 2012 South Central England consistently had the lowest rates of prescribing. The 
largest absolute change between years within a region occurred in the North East between 
years 2013 and 2014, an increase of 16.56 first prescriptions per 1,000 person-years. 
                                                     
23 This was with the exception of the East Midlands, which had a severe drop off in the number of first 
gabapentinoid prescriptions as well as total person-time from 2014 onwards, due to many practices in this 
region leaving the CPRD at this time. 
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Figure 4.4 Crude Incidence (per 1,000 Person-Years) of First Gabapentinoid Prescriptions in a Cohort of Patients with OA in 2005, 2010 and 2015. 
 
Maps created on www.mapchart.net. N.B East Midlands (in white) in 2015 had no data contributed to the CPRD, due to all cohort members being 
censored prior to this year.  
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Figure 4.5 Crude Incidence Rate of First Gabapentinoid Prescriptions, Between 1995 and 2015, by 
Geographical Region  
 
Crude incidence rates increased in all strata of time since diagnosis through the study 
period, but this was most pronounced in those prescribed their first gabapentinoid within 
five years of their OA diagnosis (Figure 4.6). Of the 22,093 first gabapentinoid prescriptions 
that occurred within 5 years of a patient’s index OA consultation, 5,841 (26.4%) occurred 
within 90 days of the OA diagnosis being given. This finding, perhaps unexpected from 
clinical experience, will be discussed further in Chapter 6. The pattern of higher incidence 
rates in the shortest duration was seen across all age strata. 
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Figure 4.6 Crude Incidence Rates of First Gabapentinoid Prescriptions, by Time Since Index OA 
Consultation 
 
4.4 Summary 
There has been an increase in the rate of first gabapentinoid prescriptions to patients 
diagnosed with OA. Incidence rates were highest in younger age groups, females, as well 
as the North of England, Northern Ireland and Scotland. Incidence rates were not higher in 
those with longer time since index OA consultation, but were instead highest within five 
years of diagnosis. The next chapter will further analyse the 35,031 patients with OA 
prescribed a gabapentinoid, by attributing these prescriptions to OA as well as to licensed 
and unlicensed indications.
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5 Results II 
 
5.1 Primary Analysis 
The primary attribution analysis explored the proportion of first gabapentinoid 
prescriptions prescribed to the study cohort that were attributable to OA, as well as to 
licensed and unlicensed indications, during the first specified time window (14 days before 
a cohort member’s gabapentinoid prescription to 90 days after). 
 
5.1.1 Attribution of First Gabapentinoid Prescriptions to Osteoarthritis 
Within window 1, 3,628 (10.4%; 95% CI: 10.0, 10.7) of the 35,031 cohort members 
prescribed a gabapentinoid had a diagnostic OA Read code recorded. 2,274 (62.7%) of 
these OA consultations were the patient’s index OA consultation. 1,082 (3.1%) of all 
patients prescribed a gabapentinoid had a Read code for OA recorded on the same day as 
the prescription was issued. 
Within the first time window studied, the proportion of first gabapentinoid prescriptions 
attributed to OA was similar by gender. 10.6% of first prescriptions in males were attributed 
to the condition, compared to 10.3% in females. The proportion of first prescriptions 
attributed to OA was also similar in each region of the CPRD. The proportion of first 
prescriptions attributed to OA was inversely associated with a patient’s age at prescription 
(Table 5.1). Across all years of the study, a first prescription of pregabalin (11.9%) was more 
likely to be attributed to OA than first gabapentin prescriptions (9.8%). This slight increase 
in pregabalin attribution remained even when data from only 2004 onwards, the year of 
94 
 
pregabalin approval, was analysed. First prescriptions could be attributed to OA in all years 
of the study period, except 1996, and from 2001 onwards (when there were more than 100 
first prescriptions annually to patients with OA in the CPRD), the proportion of first 
prescriptions attributed to OA was similar across all calendar years of the study (Table 5.2). 
Table 5.1 Attribution of First Gabapentinoid Prescriptions to OA, by Age Group 
  
 
 
Table 5.2 Attribution of First Gabapentinoid Prescriptions to OA, by Calendar Year 
 
 
 
 
 
 
 
 
Window 1: 14 days before gabapentinoid prescription to 90 days after 
Age Group Number of Prescriptions Attributed to OA (%) 
40-49 2,031 347 (17.1) 
50-59 6,603 836 (12.7) 
60-69 9,895 1,076 (10.9) 
70-79 10,111 864 (8.6) 
80+ 6,391 505 (7.9) 
   
Total 35,031 3,628 (10.4) 
Window 1: 14 days before gabapentinoid prescription to 90 days after 
Year Number of Prescriptions Attributed to OA (%) 
1995 2 1 (50.0) 
1996 4 0 (-) 
1997 2 1 (50.0) 
1998 8 1 (12.5) 
1999 21 4 (19.1) 
2000 87 6 (6.9) 
2001 164 17 (10.4) 
2002 321 37 (11.5) 
2003 514 65 (12.7) 
2004 718 100 (13.9) 
2005 1163 129 (11.1) 
2006 1417 167 (11.8) 
2007 1848 219 (11.9) 
2008 2305 223 (9.7) 
2009 2719 286 (10.5) 
2010 3214 300 (9.3) 
2011 3688 354 (9.6) 
2012 3889 403 (10.4) 
2013 4364 398 (9.1) 
2014 4629 506 (10.9) 
2015 3954 411 (10.4) 
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5.1.2 Attribution of First Gabapentinoid Prescriptions to Licensed or Unlicensed Indications 
During the first time window, 4,706 (13.4%; 95% CI: 13.1, 13.8) of the 35,031 cohort 
members prescribed a gabapentinoid had at least one Read code for a licensed or 
unlicensed indication. As patients could have a Read code for more than one condition 
during the same time window, there were 4,774 Read codes in this subgroup of the 
population.24 4,176 (87.5%) of these Read codes were of licensed indications.25 13 cohort 
members had two licensed indications present within the first window of their first 
gabapentinoid prescription. 594 (1.7%) patients had a Read code of an unlicensed 
indication, of which 51 also had a licensed indication recorded within window 1 (Table 
5.3).26 
 Table 5.3 Attribution of First Gabapentinoid Prescriptions to Licensed or Unlicensed Indications 
 
 
 
Of the licensed indications, neuropathic pain was the most common condition for a first 
prescription to be attributed to, followed by epilepsy and generalised anxiety disorder 
(GAD). Of the 4,058 neuropathic pain Read codes, over 50% were accounted for by sciatica 
                                                     
24 Whilst cohort members could only have one code of each condition, as the consultation date closest to 
prescription was taken, patients could have more than one licensed or unlicensed indication, for instance if 
they had Read codes for both epilepsy and neuropathic pain. Cohort members could also have both a licensed 
and unlicensed indication, and therefore the total number of Read codes exceeds the number of cohort 
members to which they were given. 
25 Licensed indications: Epilepsy, Generalised Anxiety Disorder, Neuropathic Pain. 
26 Unlicensed indications: Attention Deficit Disorder, Alcohol Withdrawal, Bipolar Disorder, Complex Regional 
Pain Syndrome, Fibromyalgia, Menopausal Hot Flushes, Migraine, Panic Disorder, Restless Legs Syndrome. 
Window 1: 14 days before gabapentinoid to 90 days after 
Indication Type Number % 
Only Licensed Indication(s) Present 4,112 11.7 
Only Unlicensed Indication(s) Present 543 1.6 
Licensed and Unlicensed Indication (s) Present 51 0.2 
   
Total 4,706 13.4 
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(1,291 (31.8%)), a non-specific neuropathic pain Read code (478 (11.8%)), and shingles (464 
(11.4%)).  
Of the unlicensed indications, fibromyalgia was the most commonly occurring Read code 
within window 1 of a cohort member’s first gabapentinoid prescription (Table 5.4). Fewer 
than 10 prescriptions were attributed to attention deficit disorder, alcohol withdrawal and 
bipolar disorder. For the remaining indications, the most common date for this condition 
to appear in a cohort member’s healthcare records was on the same date as their 
gabapentinoid prescription. 
 
Table 5.4 Attribution of First Gabapentinoid Prescriptions to Licensed and Unlicensed Indications, 
by Condition  
 
 
 
 
 
 
 
 
Stratification of prescriptions by calendar year demonstrated that the first gabapentinoid 
prescription to patients with OA attributed to a licensed indication occurred in 1999 
(neuropathic pain), and a year later for unlicensed indications (restless legs syndrome). 
Window 1: 14 days before gabapentinoid to 90 days after 
Condition Number % (95% CI) 
Epilepsy 71 0.2 (0.2, 0.3) 
GAD 47 0.1 (0.1, 0.2) 
Neuropathic Pain 4,058 11.6 (11.3, 11.9) 
    
Attention Deficit Disorder 0 - 
Alcohol Withdrawal 2 <0.1 (-) 
Bipolar Disorder 9 <0.1 (-) 
CRPS 37 0.1 (0.1, 0.1) 
Fibromyalgia 196 0.6 (0.5, 0.6) 
Menopausal Hot Flushes 67 0.2 (0.2, 0.2) 
Migraine 85 0.2 (0.2, 0.3) 
Panic Disorder 41 0.1 (0.1, 0.2) 
Restless Legs Syndrome 161 0.5 (0.4, 0.5) 
   
Total Read Codes 4,774 - 
   
Total Cohort Members 4,706 13.4 (13.1, 13.8) 
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Between 2005 and 2015 the proportion of patients receiving a gabapentinoid that could be 
attributed to a licensed or unlicensed indication remained fairly constant (between 12.0% 
and 14.8%).  
The proportion of first gabapentinoid prescriptions attributable to licensed or unlicensed 
indications (combined) was similar in males (1,493 (13.1%)) and females (3,213 (13.6%)) 
(Table 5.5). Females were more likely than males to have their first gabapentinoid 
prescription attributed to an unlicensed indication.  
 
 Table 5.5 Attribution of First Prescriptions to Licensed or Unlicensed Indications, by Gender 
(GAD: generalised anxiety disorder, CRPS: complex regional pain syndrome). Proportions are 
displayed as percentages with 95% confidence intervals (CIs) 
 
Window 1 Male Female 
 Prescriptions 11,424 Prescriptions 23,607 
Condition Number % (95% CI) Number % (95% CI) 
Epilepsy 22 0.2 (0.1, 0.3) 49 0.2 (0.2, 0.3) 
GAD 13 0.2 (0.1, 0.2) 34 0.1 (0.1, 0.2) 
Neuropathic Pain 1,359 11.9 (11.3, 12.5) 2,699 11.4 (11.0, 11.8) 
     
Attention Deficit Disorder 0 - 0 - 
Alcohol Withdrawal 1 <0.1 (-) 1 <0.1 (-) 
Bipolar Disorder 2 <0.1 (-) 7 <0.1 (-) 
CRPS 14 0.1 (0.1, 0.2) 23 0.1 (0.1, 0.1) 
Fibromyalgia 21 0.2 (0.1, 0.3) 175 0.7 (0.6, 0.9) 
Menopausal Hot Flushes 0 <0.1 (-) 67 0.3 (0.2, 0.4) 
Migraine 15 0.1 (0.1, 0.2) 70 0.3 (0.2, 0.4) 
Panic Disorder 10 0.1 (0.0, 0.1) 31 0.1 (0.1, 0.2) 
Restless Legs Syndrome 48 0.4 (0.3, 0.5) 113 0.5 (0.4, 0.6) 
     
Total Read Codes 1,505 - 3,269 - 
     
Total Cohort Members 1,493 13.1 (12.5, 13.7) 3,213 13.6 (13.2, 14.1) 
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Unlike in the attribution of first prescriptions to OA, the proportion of first prescriptions 
attributed to a licensed indication increased proportionally with patient’s age at 
prescription. 226 indication Read codes featured in the electronic health records of 219 
patients aged 40-49 years during window 1. This 10.8% of patients with a first prescription 
attributable to a licensed or unlicensed indication increased to 14.8% in those aged 80 years 
or older (Table 5.6). Through each of the age groups, the proportion of patients with a 
neuropathic pain Read code increased. 66.7% of prescriptions attributed to licensed or 
unlicensed indications in those aged 40-49 years were due to neuropathic pain, compared 
to 93.5% of prescriptions in those aged 80 years or older. Patients who had a gabapentinoid 
prescription that could be attributed to epilepsy or GAD were most commonly in the age 
group 60-69 years. The proportion of first prescriptions attributed to unlicensed conditions 
was highest in those aged 40-49 years at prescriptions, and lowest in those aged 80 years 
or older. 
There was a 1.4-fold variation in attribution of gabapentinoid prescriptions when stratified 
by the 13 geographical regions of the CPRD (Table 5.7). The lowest proportion of 
prescriptions attributed to a licensed or unlicensed indication occurred in Yorkshire and 
The Humber (11.4%) and the highest occurred in the East of England (16.1%). Perhaps due 
to the majority of attribution being to neuropathic pain, the regional variation specific to 
this condition was very similar. Within GAD and epilepsy, the other licensed indications, 
the highest proportion of attributed prescriptions occurred in the East Midlands. The 
highest and lowest proportions of prescriptions attributed to unlicensed indications 
occurred in the South West of England and London, respectively. 
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Table 5.6 Attribution of First Gabapentinoid Prescriptions to a Licensed or Unlicensed Indication, by Attained Age 
 
 
 
 
 
 
 
 
(GAD: generalised anxiety disorder, CRPS: complex regional pain syndrome)
Window 1 40-49 50-59 60-69 70-79 80+ 
 Prescriptions Prescriptions Prescriptions Prescriptions Prescriptions 
2,031 6,603 9,895 10,111 6,391 
Condition Number %  Number %  Number %  Number %  Number %  
Epilepsy 3 0.2 13 0.2 27 0.3 15 0.2 13 0.2 
GAD 1 0.1 9 0.1 17 0.2 12 0.1 8 0.1 
Neuropathic Pain 146 7.2 562 8.5 1,131 11.4 1,333 13.2 886 13.9 
           
Attention Deficit Disorder 0 - 0 - 0 - 0 - 0 - 
Alcohol Withdrawal 1 0.1 1 <0.1 0 - 0 - 0 - 
Bipolar Disorder 1 0.1 1 <0.1 2 <0.1 3 <0.1 2 <0.1 
CRPS 2 0.1 17 0.3 8 0.1 8 0.1 2 <0.1 
Fibromyalgia 36 1.8 83 1.3 56 0.6 18 0.2 3 0.1 
Menopausal Hot Flushes 11 0.5 24 0.4 22 0.2 9 0.1 1 <0.1 
Migraine 12 0.6 25 0.4 27 0.3 13 0.1 8 0.1 
Panic Disorder 4 0.2 10 0.2 7 0.1 13 0.1 7 0.1 
Restless Legs Syndrome 9 0.4 19 0.3 47 0.5 54 0.5 32 0.5 
           
Total Read Codes 226 - 764 - 1,344 - 1,478 - 962 - 
           
Total Cohort Members 219 10.8 747  11.3 1,329 13.4
3 
1,463  14.4
7 
948 14.8 
(95% CI) (9.4, 12.1) (10.6, 12.1) (12.8, 14.1) (13.8, 15.2) (14.0, 15.7) 
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Table 5.7 Attribution of First Gabapentinoid Prescriptions to Licensed or Unlicensed Indications, 
by Geographical Region 
 
Stratification by gabapentinoid type demonstrated that, whilst some indications were 
present in the first time window surrounding both gabapentin and pregabalin equally, 
there were some differences in certain conditions. For instance GAD, which is a licensed 
indication for pregabalin but not of gabapentin, appeared more frequently around the time 
of a cohort member’s first pregabalin prescription compared to those prescribed 
gabapentin. Attributed prescriptions of gabapentin were more likely to be due to Read 
codes of neuropathic pain, menopausal hot flushes and restless legs syndrome. In total, 
gabapentin prescriptions were more likely to be attributed to a licensed or unlicensed 
indication than pregabalin (Table 5.8).  
 
 
                                                     
27 Patients with licensed and unlicensed indications may have been mutually exclusive (such as in the North 
East), but could have had Read codes of both licensed and unlicensed indications, resulting in the attribution 
of first prescriptions to licensed or unlicensed conditions not totalling the individual attribution, such as in 
the North West. 
Window 1 Prescriptions 
in Cohort 
Licensed Unlicensed Licensed or Unlicensed27 
Region Number (%) Number (%) Number (%) 
North East  801 99 (12.4) 12 (1.5) 111 (13.9) 
North West 5,979 789 (13.2) 107 (1.8) 886 (14.8) 
Yorkshire & The Humber 1,140 113 (9.9) 21 (1.8) 130 (11.4) 
East Midlands 958 121 (12.6) 16 (1.7) 137 (14.3) 
West Midlands 3,396 420 (12.4) 73 (2.2) 486 (14.3) 
East of England 2,518 374 (14.9) 35 (1.4) 406 (16.1) 
South West 2,547 280 (11.0) 59 (2.3) 333 (13.1) 
South Central 2,604 328 (12.6) 41 (1.6) 364 (14.0) 
London 2,179 240 (11.0) 30 (1.4) 268 (12.3) 
South East Coast 2,933 325 (11.1) 55 (1.9) 376 (12.8) 
Northern Ireland 1,889 218 (11.5) 31 (1.6) 249 (13.2) 
Scotland 3,855 404 (10.5) 54 (1.4) 453 (11.8) 
Wales 4,232 452 (10.7) 60 (1.4) 507 (12.0) 
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 Table 5.8 Attribution of First Gabapentin or Pregabalin Prescriptions to Licensed or Unlicensed 
Indications 
 
 
5.1.3 Attribution of First Gabapentinoid Prescriptions Solely to OA 
As patients may have had Read codes of both OA and a licensed or unlicensed indication in 
the first time window studied, the 10.4% of first gabapentinoids attributed to OA may be 
the upper limit of prescriptions attributable to OA based on the presence of a Read code 
for the condition. 3,303 (9.4%; 95% CI: 9.1, 9.7) of all patients prescribed a gabapentinoid 
had an OA Read code within the first time window, with no licensed or unlicensed 
indication code recorded. Of these OA Read codes, 2,111 (63.9%) were their initial OA 
diagnosis. When stratified by patient age, gender and region, the proportion of attribution 
to patients solely with OA were similar to those attributed to OA with or without a licensed 
or unlicensed indication. 
 
 
Window 1 Gabapentin Pregabalin 
 Prescriptions: 25,208 Prescriptions: 9,823 
Condition Number % Number % 
Epilepsy 55 0.2 16 0.2 
GAD 8 <0.1 39 0.4 
Neuropathic Pain 3,117 12.4 941 9.6 
     
Attention Deficit Disorder 0 - 0 - 
Alcohol Withdrawal 1 <0.1 1 <0.1 
Bipolar Disorder 6 <0.1 3 <0.1 
CRPS 22 0.1 15 0.2 
Fibromyalgia 132 0.5 64 0.7 
Menopausal Hot Flushes 57 0.2 10 0.1 
Migraine 70 0.3 15 0.2 
Panic Disorder 29 0.1 12 0.1 
Restless Legs Syndrome 140 0.6 21 0.2 
     
Total (95% CI) 3,637 14.4 (14.0, 14.9) 1,137 11.6 (10.9, 12.2) 
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5.1.4 Unattributed Prescriptions 
8,009 patients had a Read code within the first time window of OA or at least one of the 
identified licensed or unlicensed indications. As a result, 27,022 (77.1%; 95% CI: 76.7, 77.6) 
first gabapentinoid prescriptions issued to patients with OA were unattributed to OA or the 
other identified indications. 
As seen in the attribution of first gabapentinoid prescriptions to OA and the licensed or 
unlicensed indications, the proportion of unattributed first prescriptions was similar 
between patient gender and region, as well as by calendar year and gabapentinoid type. 
Those aged 40-49 years at prescription had the lowest proportion of unattributed 
prescriptions, but the proportion in all other age groups was similar. 
 
5.2 Sensitivity Analyses 
As one may expect, expansion of the time window studied around the date of prescription 
resulted in an increased number of first gabapentinoid prescriptions being attributed to OA 
and licensed or unlicensed indications, resulting in a subsequent decrease in the proportion 
of unattributed prescriptions. The percentage of patients with a gabapentinoid prescription 
attributed to OA increased from 10.4% in window 1 to 28.4% in window 2 (180 days either 
side of prescription). In window 3 (365 days before gabapentinoid to 180 days after) the 
percentage of cohort members with an OA Read code was 37.1% (Table 5.9). As window 4 
(365 days before OA diagnosis to 180 days after gabapentinoid prescription) spanned a 
patient’s index date, this was not included in the analysis of OA attribution (as all patients’ 
index dates would appear in this time window, and thus attribution would be 100%). 
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 Table 5.9 Attribution of First Gabapentinoid Prescriptions to OA, by Time Window 
 
N. B. G: Gabapentinoid, d: days (i.e. -14d→G = 14 days before gabapentinoid prescription date). 
This does not exclude patients who also have a licensed or unlicensed indication 
As in the first time window studied, during the other time windows analysed the attribution 
of first gabapentinoid prescriptions to OA was similar between males and females. The 
proportion of first prescriptions attributed to OA was also similar between regions, 
although Scotland had the highest rates of attribution in windows 2 and 3. Pregabalin was 
more commonly attributed to OA than gabapentin in all time windows analysed, and 
attribution to OA was again inversely proportional to a patient’s attained age. During 
window 3, the attribution of first gabapentinoid prescriptions to OA gradually decreased 
over the course of the study period (Figure 5.1). 
 
Figure 5.1 Attribution of First Gabapentinoid Prescriptions in Window 3 to OA (With No Presence 
of Licensed or Unlicensed Indications) and Licensed or Unlicensed Indications 
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Window Definition Number % (95% CI) 
1 -14d→G→+90 3,628 10.4 (10.0, 10.7) 
2 -180d→G→+180 9,959 28.4 (28.0, 28.9) 
3 -365d→G→+180 12,986 37.1 (36.6, 37.6) 
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The percentage of cohort members with a licensed or unlicensed indication increased from 
13.4% in window 1 to 22.3% in window 2, 26.1% in window 3 and 41.0% in window 4. The 
proportion of first gabapentinoid prescriptions in patients with OA attributed to licensed 
or unlicensed indications, whilst similar in window 1, was higher in women throughout all 
windows studied. This difference increased as the time window surrounding a cohort 
member’s first gabapentinoid prescription was expanded (Table 5.10). First prescriptions 
were also more likely to be attributed to an unlicensed indication in females in all time 
periods analysed. Differences between the original time window and the expanded time 
periods occurred in the analysis of the licensed indications. In windows 1 to 3, males who 
received a gabapentinoid were more likely to have a Read code for a licensed indication. 
However, in window 4 females had a higher proportion of attributed prescriptions, likely 
due to the same pattern seen with neuropathic pain. Epilepsy Read codes were more likely 
to be seen in the healthcare records of female patients in window 1, although males had a 
higher proportion of attribution in the remaining time windows studied.  
 
Table 5.10 Attribution of First Gabapentinoid Prescriptions to Licensed or Unlicensed Indications, 
by Gender and Time Window 
N.B. d: days, G: gabapentinoid, OA: osteoarthritis 
As in window 1, the majority of licensed or unlicensed indication Read codes identified in 
all time windows studied were codes of neuropathic pain, although the proportion of codes 
that were neuropathic pain progressively decreased in each window (85.0% of all licensed 
Window Definition Males Females Total 
Number (%) Number (%) Number (%; 95% CI) 
1 -14d→G→+90d 1,493 (13.1) 3,213 (13.6) 4,706 (13.4; 13.1, 13.8) 
2 -180d→G→+180d 2,468 (21.6) 5,331 (22.6) 7,799 (22.3; 21.8, 22.7) 
3 -365d→G→+180d 2,825 (24.7) 6,302 (26.7) 9,127 (26.1; 25.6, 26.5) 
4 -365d→OA, G→+180d 4,162 (36.4) 10,197 (43.2) 14,359 (41.0; 40.5, 41.5) 
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or unlicensed indication Read codes in window 1, 66.84% of Read codes in window 4). With 
the exception of attention deficit disorder, which first appeared in window 3, the 
attribution of prescriptions to all other conditions increased with each expansion of the 
window studied. Fibromyalgia remained the most common indication of the unlicensed 
conditions in windows 2 and 3, before being overtaken by migraine and menopausal hot 
flushes in the final time window (Table 5.11).  
 
Table 5.11 Attribution of First Gabapentinoid Prescriptions to Licensed and Unlicensed Conditions, 
by Time Window 
N.B. Percentages use the total number of gabapentinoid prescriptions (n = 35,031) as the 
denominator. (d: days, G: gabapentinoid, OA: osteoarthritis, GAD: generalised anxiety disorder, 
CRPS: complex regional pain syndrome) 
In all time windows studied, the proportion of first gabapentinoid prescriptions attributable 
to licensed or unlicensed indications was higher in gabapentin than pregabalin. 
Stratification by region demonstrated that, similar to the initial analysis, the East of England 
Condition 
Window 1 Window 2 Window 3 Window 4 
-14d→G→+90d -180d→G→+180d -365d→G→+180d 
-365d→OA,  
G→+180d 
Number (%) Number (%) Number (%) Number (%) 
Epilepsy 71 (0.2) 179 (0.5) 211 (0.6) 291 (0.8) 
GAD 47 (0.1) 78 (0.2) 92 (0.3) 189 (0.5) 
Neuropathic Pain 4,058 (11.6) 6465 (18.5) 7,404 (21.1) 11,164 (31.9) 
      
Attention Deficit Disorder 0 (-) 0 (-) 2 (<0.1) 7 (<0.1) 
Alcohol Withdrawal 2 (<0.1) 8 (<0.1) 11 (<0.1) 33 (0.1) 
Bipolar Disorder 9 (<0.1) 23 (0.1) 31 (0.1) 101 (0.3) 
CRPS 37 (0.1) 71 (0.2) 83 (0.2) 114 (0.3) 
Fibromyalgia 196 (0.6) 355 (1.0) 443 (1.3) 820 (2.3) 
Menopausal Hot Flushes 67 (0.2) 186 (0.5) 293 (0.8) 1,169 (3.3) 
Migraine 85 (0.2) 251 (0.7) 365 (1.0) 1,183 (3.4) 
Panic Disorder 41 (0.1) 129 (0.4) 206 (0.6) 692 (2.0) 
Restless Legs Syndrome 161 (0.5) 318 (0.9) 441 (1.3) 939 (2.7) 
     
Total Read Codes 4,774  8,063  9,582  16,702 
     
Total Cohort Members 4,706 (13.4) 7,799 (22.3) 9,127 (26.1) 14,359 (41.0) 
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had the highest proportion of prescriptions attributed to licensed conditions in all time 
periods analysed. However, after the first time window, the area with the lowest 
proportion of attributed prescriptions was Scotland. During windows 1 to 3, the attribution 
of first gabapentinoid prescriptions to licensed or unlicensed indications remained fairly 
constant between 2005 and 2015. Analysis of window 4 demonstrated that the attribution 
of first gabapentinoids has increased during this period (Table 5.12).  
 
 Table 5.12 Attribution of First Gabapentinoid Prescriptions to Licensed or Unlicensed Indication, 
by Year 
d: days, G: gabapentinoid, OA: osteoarthritis 
 
Year Prescriptions 
Window 1 Window 2 Window 3 Window 4 
-14d→G→+90d -180d→G→+180d -365d→G→+180d 
-365d→OA,  
G→+180d 
Number (%) Number (%) Number (%) Number (%) 
1995 2 0 (-) 0 (-) 1 (50.0) 1 (50.0) 
1996 4 0 (-) 0 (-) 0 (-) 1 (25.0) 
1997 2 0 (-) 0 (-) 0 (-) 0 (-) 
1998 8 0 (-) 1 (12.5) 1 (12.5) 1 (12.5) 
1999 21 2 (9.5) 5 (23.8) 5 (23.8) 8 (38.1) 
2000 87 10 (11.5) 17 (19.5) 23 (26.4) 32 (36.8) 
2001 164 10 (6.1) 23 (14.0) 34 (20.7) 46 (28.1) 
2002 321 40 (12.5) 57 (17.8) 63 (19.6) 98 (30.5) 
2003 514 36 (7.0) 82 (16.0) 99 (19.3) 152 (29.6) 
2004 718 70 (9.8) 138 (19.2) 163 (22.7) 218 (30.4) 
2005 1,163 147 (12.6) 243 (20.9) 280 (24.1) 415 (35.7) 
2006 1,417 175 (12.4) 292 (20.6) 346 (24.4) 505 (35.6) 
2007 1,848 271 (14.7) 433 (23.4) 512 (27.7) 709 (38.4) 
2008 2,305 283 (12.3) 501 (21.7) 590 (25.6) 840 (36.4) 
2009 2,719 360 (13.2) 585 (21.5) 681 (25.1) 1,043 (38.4) 
2010 3,214 415 (12.9) 684 (21.3) 796 (24.8) 1,268 (39.5) 
2011 3,688 534 (14.5) 826 (22.4) 973 (26.4) 1,530 (41.5) 
2012 3,889 467 (12.0) 830 (21.3) 981 (25.2) 1,597 (41.1) 
2013 4,364 622 (14.3) 1,011 (23.2) 1,169 (26.8) 1,940 (44.5) 
2014 4,629 686 (14.8) 1,138 (24.6) 1,304 (28.2) 2,102 (45.4) 
2015 3,954 578 (14.6) 933 (23.6) 1,106 (28.0) 1,853 (46.9) 
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In all time windows studied, the highest proportion of attribution to licensed or unlicensed 
indications occurred in those aged 80 years or older. First prescriptions were least likely to 
be attributed in cohort members aged 40-49 years in windows 1 and 4, with attribution of 
prescriptions in those aged 50-59 years lowest in the other time windows studied.  
Similar results of the proportion of prescriptions attributed to other indications when 
stratified by gabapentinoid type remained upon expansion of the time period studied 
around the date of prescription. In all time windows studied the proportion of first 
pregabalin prescriptions attributed to GAD was higher than gabapentin. Within window 4 
the proportion of pregabalin attributed to bipolar disorder and fibromyalgia was also larger 
than gabapentin prescriptions. Similar to the initial analysis, first gabapentin prescriptions 
were attributed to neuropathic pain and restless legs syndrome at a higher rate than those 
of pregabalin. In all windows studied, the proportion of gabapentin prescriptions attributed 
to licensed or unlicensed indications was higher than that of pregabalin. 
Naturally, as the proportion of first gabapentinoid prescriptions attributed to OA and 
licensed or unlicensed indications increased in the more sensitive time windows used, the 
proportion of prescriptions that were unattributed fell. 77.1% of first prescriptions 
remained unattributed in window 1, compared to 54.8% in window 2 and 45.8% in window 
3 (Table 5.13).28 
 Table 5.13 Number, Percentage and 95% Confidence Intervals of Unattributed First 
Gabapentinoid Prescriptions in Patients with OA, by Time Window 
 
 
 
 
 
 
 
 
 
 
 
d: days, G: gabapentinoid 
                                                     
28 Again, the proportion of unattributed prescriptions during window 4 was not analysed as this time window 
incorporated a patient’s initial OA diagnosis, and therefore the number of unattributed prescriptions would 
be zero. 
Window Definition Number % (95% CI) 
1 -14d→G→+90 27,022 77.1 (76.7, 77.6) 
2 -180d→G→+180 19,198 54.8 (54.3, 55.3) 
3 -365d→G→+180 16,042 45.8 (45.3, 46.3) 
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The proportion of unattributed first gabapentinoid prescriptions was similar in males and 
females in windows 1 and 2, although males did have a higher proportion of unattributable 
prescriptions in window 3. The proportion of unattributed prescriptions remained fairly 
constant over the study period as well as between gabapentin and pregabalin.  
The proportion of unattributed prescriptions was lowest in those aged 40-49 years and 
highest in patients aged 80 years or older in all time windows studied. 32.8% of first 
gabapentinoid prescriptions were unattributed to OA or licensed or unlicensed indications 
in window 3 in those aged 40-49 years, compared to 49.7% of first prescriptions in the 
oldest age group. The proportion of unattributed prescriptions was highest in Wales in all 
time windows studied. 
 
5.3 Summary 
Based on the primary attribution analysis, over the course of the study period 9.4% of first 
gabapentinoid prescriptions issued to patients with OA could be attributed to OA, with no 
evidence of other indications. An additional 13.4% of first prescriptions could be attributed 
to licensed or unlicensed indications. Of the identified indications, neuropathic pain was 
the most common cause of attribution. In all time windows studied, the proportion of first 
prescriptions attributed to OA or to a licensed or unlicensed indication was similar between 
genders, regions, calendar years and gabapentinoid type. Those aged 40-49 years had the 
lowest proportion of first gabapentinoid prescriptions that were unattributed to OA or a 
licensed or unlicensed indication. Despite expansion of the time window studied in the 
following sensitivity analyses, a large number of first gabapentinoid prescriptions (16,042 
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(45.8%) in window 3) remained unattributed to OA or to the other identified licensed and 
unlicensed indications. 
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6 Discussion 
 
6.1 Summary of Key Findings 
The hypothesis of the research presented in this thesis was that the marked rise in the 
number of gabapentin and pregabalin (gabapentinoid) prescriptions issued within the UK 
has been driven, in part, by increased off-label prescribing for common painful conditions. 
Furthermore, there is anecdotal evidence that the gabapentinoids may be being used for 
the joint pain experienced by patients with OA. The purpose of this thesis was to examine 
the specific role of osteoarthritis in the increasing numbers of gabapentinoids prescribed 
in the UK. To investigate this, I explored the possible rationale for and efficacy of their use 
in OA by conducting a series of scoping reviews of the published literature regarding the 
gabapentinoids and the epidemiology and current management of OA. I then undertook 
an original analysis to explore this hypothesis using the CPRD, an electronic UK primary care 
dataset. 
Literature reviews demonstrated that OA is a highly prevalent condition, which has a large 
impact on patients, health services and wider society. The relevance of this high prevalence 
and presentation to health services is that even a small proportion of patients prescribed a 
gabapentinoid would result in a large number of prescriptions being issued, and could thus 
contribute to the observed increase in prescribing. The undertaking of scoping reviews 
highlighted that reasons for gabapentinoid prescribing in OA may include the concerns of 
clinicians with the currently recommended treatment options. Another factor may be the 
growing body of literature suggesting that some patients with OA may have central 
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mechanisms contributing to their pain, which can result in features of neuropathic pain, for 
which the gabapentinoids are recommended. 
To date, there have been four randomised controlled trials of the gabapentinoids in 
patients with OA, each with fewer than 100 participants. The first trial was conducted by 
Ohtori et al. (2013), who demonstrated that a combination of pregabalin and an NSAID in 
patients with knee OA was more effective than either as monotherapy by the end of the 
four week study period. Since then, there has been a 13 week trial of pregabalin in hand 
OA (Sofat et al., 2017), which demonstrated that pregabalin was more effective than 
duloxetine compared to placebo, and two trials of knee OA with evidence of a neuropathic 
component (Filatova et al., 2018; Wright et al., 2017). In the trial conducted by Wright et 
al. (2017), pregabalin was more effective than paracetamol at 28 days. Although the five 
week trial by Filatova et al. (2018) demonstrated that patient’s pain and function scores 
improved with pregabalin, no between-group outcomes were reported. As all trial data is 
currently limited to small trials with short periods of follow-up, there is very limited 
evidence of the long-term efficacy of the gabapentinoids in OA. On the contrary, there has 
been an increasing awareness of the risks associated with gabapentinoid use. Whilst 
adverse effects have increasingly been reported by studies, there are serious concerns with 
their potential to be misused and diverted, and the number of gabapentinoid-related 
overdoses and deaths has risen substantially. These concerns have culminated in the likely 
implementation of the control of gabapentinoid prescribing, and this proposal is currently 
under review. 
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My original analysis of UK primary care electronic health records, using the CPRD, 
estimated that between 1995 and 2015 the age-standardised number of patients with OA 
receiving their first gabapentinoid prescription increased from less than one per 1,000 
person-years to over 27 per 1,000 person-years. Over the course of the study period, the 
increase in rate of first gabapentinoid prescriptions was observed in all stratifications. 
However, higher rates of first gabapentinoid prescriptions were observed in females, 
younger patients, patients who had more recently received their initial OA diagnosis, and 
those in the North of England, Scotland and Northern Ireland. 
The majority (77.1%) of first gabapentinoid prescriptions to patients with OA were not 
attributed to OA or other identified licensed or unlicensed indications. 10.4% of first 
gabapentinoid prescriptions could be attributed to OA, although a more cautious estimate 
of first prescriptions attributable to OA may be 9.4%, once prescriptions in patients with 
Read codes of licensed or unlicensed indications were attributed to these conditions. The 
proportion of first gabapentinoid prescriptions attributed to OA remained fairly constant 
throughout the study period. Prescriptions were more commonly attributed to OA in 
younger patients. 13.4% of patients prescribed a first gabapentinoid had at least one 
licensed or unlicensed indication. The proportion of first prescriptions attributed to OA or 
other licensed or unlicensed indications did increase as the time window around 
prescription was expanded. However, a large number of first prescriptions did remain 
unattributed. 
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6.2 Comparison to Current Literature 
The analysis of this study has built on knowledge provided by prior literature of OA and 
gabapentinoid prescribing, whilst also contributing novel information. 
Firstly, the cohort of patients used in this analysis is comparable to previous literature of 
OA using the CPRD. The proportion of patients who received an OA diagnosis (based on a 
definitive OA Read code) that were female was very similar to a prior study of the CPRD 
during the period 1992-2013 (Yu et al., 2017). The earlier, albeit overlapping, time period 
used in this study may explain the different total number of cases identified and the slight 
difference in average age at diagnosis compared to the analysis in this thesis, reflecting a 
slight change in the use of the diagnostic Read code of OA by clinicians over time. Indeed, 
it should be highlighted that the absolute number of patients identified as incident cases, 
for instance by year or region, is not necessarily indicative of the incidence of OA, rather it 
portrays the number of patients given a code of diagnostic OA in the CPRD, which can be 
affected by the number of practices contributing data (which has decreased from a peak of 
597 in 2008 and 2009 to 433 in 2015, displayed in Appendix 3.2 on page 199). Another 
factor in the number of incident OA cases identified is the behaviour, in terms of the Read 
codes used, of the practitioners in practices contributing data to the CPRD. It has been 
demonstrated by prior studies that the incidence of OA has continued to increase, and is 
expected to continue doing so, but there appears to have been a gradual shift away from 
the use of diagnostic OA Read codes in the CPRD (Yu et al., 2017, 2018). This may also 
explain why, in sensitivity analyses, there was a slight decrease in the attribution of first 
gabapentinoid prescriptions to OA over the course of the study period, particularly from 
2008 onwards. This would therefore render the proportions of first prescriptions attributed 
to OA in more recent years as conservative estimates.  
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This analysis of gabapentinoid prescribing, although in a cohort of patients with OA, 
contributes new information to the understanding of gabapentinoid prescribing in relation 
to prior studies. Whilst the dependence forming medications report (Cartagena et al., 2017) 
and the study of gabapentinoid use prior to arthroplasty in Australia (Inacio et al., 2018) 
included the prescribing of gabapentin, in both instances it was studied as part of a group 
of medications (with lamotrigine as GABAergic medications and amitriptyline as 
neuropathic pain drugs, respectively). As a result, to the best of my knowledge, this analysis 
was the first to explore the individual trends in gabapentin prescribing, as prior drug 
utilisation studies have only studied pregabalin (Asomaning et al., 2016; Viñas-Bastart et 
al., 2017). Compared to these two studies, the analysis within this thesis also provides a 
longer study period and a more up-to-date investigation of gabapentinoid prescribing 
compared to the 2014 cross-sectional study design of the Catalonian study (Viñas-Bastart 
et al., 2017) and the 6-year study of the THIN database which concluded in 2009 
(Asomaning et al., 2016). The nature of this incidence analysis also means it can provide an 
indication of the risk of a patient with OA receiving a gabapentinoid, both over calendar 
time and for instance by a patient’s age, and this has not been reported previously. 
The higher rates of first gabapentinoid prescriptions in younger patients with OA in this 
study cohort (those aged 40-49 years), have also been documented by a study of opioid 
prescribing in OA conducted in the US (DeMik et al., 2017). Possible reasons for the higher 
rate of initiation of pharmacological options such as opioids and the gabapentinoids in 
those aged 40-49 may include fewer safety concerns in this group of patients due to lower 
rates of comorbidities and the associated reduction in the concomitant prescribing of other 
medications. This group of patients may also have increased expectations, potentially 
linked to a possible loss of quality of life or employment. Furthermore, clinicians may be 
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reluctant to suggest surgical options in such young patients, due to the current average 
longevity of prostheses. As this was an analysis of incident prescribing, if every member of 
the study cohort were to receive their initial OA code aged younger than 45 years and their 
first gabapentinoid within five years of this date, this could explain a higher rate in this age 
group and lower rates in subsequent age groups (i.e. depletion of susceptibles). However, 
this cohort was open to recruitment from a dynamic population (patients registered with 
general practices contributing to the CPRD), and the median age when a cohort member 
entered the study due to receiving their first diagnostic OA Read code was 66.0 years. 
This was the first analysis of incident gabapentinoid prescribing. However, the higher 
likelihood of females with OA receiving a first gabapentinoid prescription is comparable to 
the higher proportion of females prescribed pregabalin in the cross-sectional Spanish study 
(Viñas-Bastart et al., 2017), providing rates of discontinuation are equal between genders. 
Females tend to have higher rates of prescribing in all classes of medications compared to 
males, including pain medications in those aged 40-44 years (Roe et al., 2002). Higher rates 
of prescribing in females has also been reported in both NSAID use in OA (Dominick et al., 
2003) and opioids in chronic non-cancer pain (Campbell et al., 2010). The higher incidence 
rates of prescribing in females may be due to an increased willingness to take medications 
and higher expectations, which are potentially reflected in their higher consultation rates 
compared to males (Hobbs et al., 2016). The higher rate of first gabapentinoid prescriptions 
in females remained following age-standardisation, and thus a different age distribution of 
patients with a diagnostic Read code of OA does not account for the increased rate. The 
attribution analysis demonstrated that the higher incidence of first gabapentinoid 
prescriptions in females is not accounted for by higher rates of comorbidities that are 
licensed or unlicensed indications for the gabapentinoids. The fairly constant rate ratio 
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between the two genders demonstrates that although the rate of first gabapentinoid 
prescriptions in females has not increased compared to males on a multiplicative scale, the 
absolute risk difference of a woman with OA receiving her first gabapentinoid has 
increased, particularly in the period 2010-2014. 
The regional variation of first gabapentinoid prescriptions in this cohort of patients with OA 
has also been noted by other literature and reports of the gabapentinoids. Public Health 
England, in their 2014 ‘Advice for prescribers’ document, reported that there was a higher 
number of gabapentin and pregabalin items prescribed in the North of England. This higher 
rate of prescribing compared to the Midlands or South of England was not felt to be due to 
social or demographic factors alone (Public Health England, 2014). The dependence 
forming medications report demonstrated that the proportion of gabapentin, pregabalin 
and lamotrigine prescriptions that are short versus long term varied greatly in the North 
East of England. Although this discrepancy may reflect a misclassification in short and long 
term prescribing, it appears that patients in the North East of England were less likely to be 
prescribed a gabapentinoid long-term than in other regions in England (Cartagena et al., 
2017). Whilst this may be due to differences in the OA population versus those with any 
condition prescribed a dependence forming medication, it is possible that these differences 
are due to incidence versus prevalence prescribing analysis. It is possible that within the 
North East there are a large number of patients that receive gabapentinoids (and thus the 
incidence rate in the analysis in this thesis was high), but do not remain on them for long 
periods of time, and therefore this region has a relatively low average length of prescribing 
(Cartagena et al., 2017). The higher rates of prescribing in the North of England compared 
to the South have also been reported in opioid studies. Published in 2018, a study of 
prescribing in England found that nine out of the ten Clinical Commissioning Groups (CCGs) 
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with the highest rates of prescribing (based on opioid dose per head) were based in the 
North of England (Mordecai et al., 2018). 
Whilst the region-level estimates presented in this thesis were not age or sex-standardised, 
there did not appear to be large differences between the distributions of the different 
regions’ populations. Analysis at an individual practice or practitioner level was not 
performed in this analysis due to concerns regarding increasingly small cell sizes, although 
it is possible that the higher rates of prescribing in certain areas are driven by certain 
practitioners, practices or areas. This may particularly be the case in the North East of 
England. As of July 2013, the number of practices in this region was low in comparison to 
other areas (Herrett et al., 2015). Whilst the number of practices within the UK contributing 
to the CPRD has since increased (The Farr Institute, 2017), it is not clear how well the North 
East is currently represented. This lack of practices may be a source of selection bias if those 
contributing data to the CPRD during the study period were not representative of the wider 
region, for instance if practices in the CPRD were more (or less) likely to prescribe a 
gabapentinoid. 
The use of gabapentinoids post-operatively following a patient’s arthroplasty has been 
explored by previous literature (Fabritius et al., 2017; Li et al., 2017). Gabapentin or 
pregabalin may be used in this context either as an analgesic in the immediate post-
operative phase or for the iatrogenic neuropathic pain induced by the procedure. However, 
of the 35,031 patients prescribed a gabapentinoid in the CPRD, 557 (1.6%) patients 
received their prescription during the one year period following their total knee 
arthroplasty and therefore this does not seem to represent a substantial proportion of their 
use in this study. 1,331 (3.8%) patients received their first gabapentinoid (as documented 
in primary care records) following their procedure. In these cohort members who received 
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their first gabapentinoid following their TKA, the median time between the procedure and 
their first gabapentinoid prescription was 2.9 (IQR: 1.2, 5.4) years.  
The attribution analysis performed within this thesis also contributes to prior 
understanding of gabapentinoid prescribing. The dependence forming medications report 
and the cross-sectional study of pregabalin prescribing in Catalonia, Spain, did present 
common diagnoses of patients who are prescribed a gabapentinoid. However, as the report 
only presented groups of diagnoses, such as ‘pain’, it was not possible to understand the 
contribution of individual conditions, such as OA, or to appreciate the proportion of off-
label prescribing, as neuropathic pain is a licensed indication (Cartagena et al., 2017). 
Equally, whilst the study of pregabalin prescribing in Catalonia did present the proportion 
of patients with specific conditions, such as fibromyalgia or epilepsy, a common diagnosis 
featured in the health records of patients prescribed pregabalin was ‘bone and joint pain’. 
The conditions accounting for this diagnosis were not presented and therefore, again, it 
was not possible to appreciate the individual contribution of conditions such as OA.  
The analysis of the THIN dataset did include attribution of pregabalin prescriptions by 
individual conditions. However, the analysis in this thesis builds on this prior work by also 
assessing the proportion of first prescriptions attributed to unlicensed indications. The 
differences in the proportion of first prescriptions attributed to licensed indications 
between this work and the THIN study may be due to the different populations and time 
periods studied, but are most likely due to the techniques used, particularly in the 
sensitivity analyses. For instance the 61.1% of prescriptions that could not be attributed to 
a licensed indication in their primary analysis rapidly reduced when these analyses were 
performed. The classification of all back pain in patients prescribed pregabalin as 
neuropathic, as performed in their sensitivity analyses, could be viewed as extreme, as back 
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pain is a common cause of patients presenting to primary care, and it is known that only a 
small minority of these patients display features of neuropathic pain (Enthoven et al., 
2013). Another factor resulting in different attribution estimates between the THIN study 
and the analysis within this thesis may be that all authors of the study are employees of 
Pfizer, and thus may have had a conflict of interest to conclude that prescribing was in line 
with recommendations (Asomaning et al., 2016). 
In summary, the analyses presented within this thesis contribute novel information to the 
current understanding of gabapentinoid prescribing. This work provides an original 
contribution exploring the incidence of gabapentinoid prescribing among patients with a 
common painful condition for which their use would be off-label, in which the role of a 
neuropathic pain component is unclear and for which there is limited efficacy. The 
stratifications of the incidence rate in this cohort provide a new depth of understanding of 
gabapentinoid prescribing in this population of patients. The analysis also has consistencies 
with prior work of OA in the CPRD and prior research of the gabapentinoids, as well as other 
dependence forming medications, such as opioids. 
 
6.3 Strengths and Limitations 
A full understanding of the results contributed by this thesis, including their interpretation 
and potential implications, requires an appreciation of the study’s strengths and 
limitations. 
The predominant strengths of this study originate with the dataset used. The CPRD is a 
large, UK-wide database that provided a substantial number of events and person-time for 
the analysis of incident gabapentinoid prescribing in the OA population. Due to the design 
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of the software used by general practitioners, coding of prescriptions is an automated 
procedure and therefore the number of gabapentinoids identified in this cohort should be 
accurate. Secondly, Read codes used in this study have been used in prior studies, 
whenever possible.  
The potential limitations of this analysis are those related to the data and design of 
analyses. Whilst the CPRD was representative of the 2011 UK census in mid-2013 (Herrett 
et al., 2015), it is possible that this is no longer the case. Possible reasons for this may 
include the gradual shift of practices from the VISION software system to EMIS, resulting in 
them no longer contributing data to the CPRD GOLD dataset. Specific to this study, this shift 
would have had to affect the incidence of gabapentinoid prescribing or the attribution of 
first prescriptions. Whilst this seems unlikely, it is possible, for instance if practices that 
have moved to the newer system are more likely to provide Read codes alongside 
prescriptions. Another limitation with the choice of using the CPRD is the potential lack of 
secondary care information. Whilst the majority of prescriptions initiated in secondary care 
will feature in the CPRD, especially if they are repeat prescriptions, there is the potential 
for some prescriptions to be missed. As most consultations for OA occur in primary care 
within the community (Peat et al., 2001), this potential limitation should affect only a small 
number of gabapentinoid prescriptions prescribed to a patient for OA. However, it is 
important to be aware of such potential limitations, especially for the number of first 
prescriptions attributed to other conditions (if they are commonly treated in secondary 
care), and the number of gabapentinoid prescriptions issued acutely after arthroplasty. 
However, linkage of the CPRD to secondary care data may not have had a pronounced 
effect. Whilst the benefit of secondary care data linkage to the CPRD has been 
demonstrated for identifying acute hospitalisations (Rothnie et al., 2016) and mortality 
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following venous thromboembolism (Gallagher et al., 2016), linkage is less useful for more 
chronic conditions such as hepatic injury (Wing et al., 2016). 
Another limitation of the CPRD is the ability to assess dosages and adherence. Whilst dose 
and prescription length are included in the CPRD, patients may be advised to taper their 
dose by changing the number of tablets taken daily, as recommended by NICE (National 
Institute for Health and Care Excellence, 2013). As a result the analysis of dosage and 
duration of prescription may not be an accurate representation of real-world practice. 
Secondly, it is not possible to understand how patients are taking these medications 
(regular versus as and when required (PRN)), or whether they are taking the gabapentinoids 
at all. This lack of adherence may reduce the risks of potential dependence in these 
patients, but raises concerns regarding the possibility of the diversion of unused 
gabapentinoids. 
Limitations of this research may also arise from the OA population used in this study. Firstly, 
it is known that patients who receive a Read code of diagnostic OA differ from the large 
number of patients who are recorded using ‘clinical OA’ Read codes. The decision was made 
to use the diagnostic definition to increase the likelihood that cohort members would have 
the condition (i.e. minimise false-positives). The use of ‘clinical OA’ Read codes, such as 
‘joint pain’, may also have made distinguishing between OA and other conditions used in 
the attribution analysis (for instance fibromyalgia), more challenging. However, prior 
studies have demonstrated that the diagnostic definition is more likely to be used in older 
patients and those with more severe disease (Jordan et al., 2016). The median age of 66.0 
years at time of index OA diagnosis reinforces this. Firstly, this indicates the need for 
caution when attempting to generalise the findings to all patients presenting with OA to 
primary care in the UK. Secondly, it is important not to interpret the time since index OA 
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diagnosis as being the duration of symptomatic disease. As patients tend to be older than 
those managed under clinical OA Read codes, this may explain the short period of time 
between a cohort member’s initial OA diagnosis (using this definition) and their first 
gabapentinoid prescription. Indeed, this does not solely apply to pharmacological 
management such as the gabapentinoids, as the time between initial OA diagnosis and 
arthroplasty is also much shorter than one would expect if the onset of disease was the 
initial presentation of symptoms (Yu et al., 2017). Use of the diagnostic definition of OA 
may have also affected the age-stratified analyses, if more severe disease is a risk factor for 
receiving a gabapentinoid. Although one may expect that older patients would be more 
likely to receive their first prescription due to also having high levels of disease severity, 
the risk in the older age groups may have been diluted by those patients who receive their 
code of definitive OA due to being older but, due to low disease severity, are not at risk of 
receiving a gabapentinoid. In contrast, the reason for younger patients receiving a code of 
definitive OA may be purely due to disease severity, and as a result the incidence rates 
observed in younger patients may be higher than those of older ages. It should also be 
noted that, as the diagnostic definition is often recorded for patients with more severe 
disease, this may be used as the justification for the prescription of a gabapentinoid, 
resulting in relatively low rates of prescribing in those with clinical OA. However, as almost 
four times as many patients receive an initial diagnosis of clinical OA compared to those 
that receive a diagnosis based on the presence of a diagnostic Read code (Yu et al., 2017), 
a low rate of prescribing may still result in a large absolute number of prescriptions. 
The exclusion of patients with prevalent disease may be criticised as limiting 
generalisability to all OA consulters. However, the design of a fixed cohort with recruitment 
open across 21 years inevitably means that follow-up (median: 5.1 years) spanned several 
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years after diagnosis. Whilst patients included in a certain year of the study can be viewed 
as cases with either incident or prevalent OA during that calendar year, patients who 
consulted in the first three years of the study period would have been excluded if they also 
had a Read code of diagnostic OA in the three year period prior to the study period 
beginning. As a result there may have been patients with OA not included in this cohort 
study, although one could expect this to be a very small minority. Other patients not 
included in this analysis (as demonstrated by Figure 3.1 in Chapter 3) include those with 
prevalent disease who did not receive a diagnostic OA code during the study period, either 
due to not consulting or due to the choice of codes used by the practitioner. As patients 
who receive codes of clinical OA tend to have milder disease, and the same could be 
assumed of those who do not regularly consult, the incidence rate of gabapentinoid 
prescriptions in patients with OA found in this study may not be representative of all 
patients with the condition. As a result, the figures can be viewed as more representative 
of the OA population who receive a diagnostic Read code of OA, and who consult at least 
once during a 20 year period.  
It is possible that the length of the study period used may also be a limitation if patients 
received their gabapentinoid prescription more than 20 years after their initial diagnosis, 
although the age-stratified and time since diagnosis results mean that this is unlikely be the 
case. Equally, as patients were often censored from the cohort due to other criteria, such 
as deregistering from their practice, expansion of the study period using the existent design 
is unlikely to significantly alter the number of incident gabapentinoid prescriptions 
identified. Due to the structure of the CPRD, the incidence rate of gabapentinoid 
prescribing was not assessed by specific joint sites. It is also therefore possible that a 
patient with OA of a certain joint was excluded, irrespective of whether they since 
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developed OA at a different joint site. The use of arthroplasty as exclusion criteria could 
also be viewed as a potential limitation. Arthroplasty was used to identify prevalent 
disease, as this is a common endpoint for patients with severe OA, and OA represents the 
most common indication for both hip and knee arthroplasty (National Joint Registry, 2017). 
However, it is possible that the patient since developed OA in another joint, or that they 
were excluded erroneously if the procedure was not for OA, and instead was for another 
indication, such as a hip fracture. 
The method used to attribute gabapentinoid prescriptions has limitations, partly imposed 
by the nature of the data and coding behaviour in general practice, and partly related to 
the potential for misclassification of morbidities using Read codes. The technique for 
attributing prescriptions, including the corresponding sensitivity analyses, was felt to be 
the best way to attribute prescriptions to indications in electronic health records such as 
the CPRD, and had been used by prior studies (Asomaning et al., 2016; Bedson et al., 2016). 
It is clear that practitioners have reasons to prescribe gabapentinoids to patients with OA, 
due to the condition itself or comorbidities. Limitations of the method used to attribute 
gabapentinoid prescriptions may arise due to either an under-recording of the identified 
possible indications, including OA, or due to a failure of the study design to identify all 
possible indications and their respective Read codes. For instance, whilst all patients with 
a diagnostic Read code of OA were included in this cohort, a gabapentinoid prescription 
would not have been attributed to OA if the condition was subsequently recorded using 
more clinical codes, even if OA was their only morbidity. As a result an unknown proportion 
of the unattributed prescriptions may be attributable to OA due to clinical OA codes being 
used around the time of first prescription, rendering this estimate conservative. Equally, 
although all Read codes of identified indications were previously used codes and from 
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validated code lists whenever feasible, it is possible that, much like OA, conditions are 
coded using different terms. An example may include generalised anxiety disorder being 
recorded more generally as anxiety. Use of free text from a patient’s electronic health 
record may have provided more information regarding diagnoses, as approximately 40% of 
information can be recorded this way rather than as Read codes. Unfortunately however 
this is an expensive, complex method and free text data is not available from 2013 onwards 
(Price et al., 2016).  
It was decided that all identified indications should be included in the analyses, and whilst 
the lack of attribution to certain conditions may have been predicted, particularly in this 
age group of patients, all possible indications were included to gain the greatest 
understanding of the use of the gabapentinoids in patients with OA. Whilst this study has 
assessed the use of the gabapentinoids in OA, a common source of pain, they could equally 
be used in other, unidentified, painful conditions not mentioned in the reviewed literature, 
such as back pain. If the gabapentinoids are being used in this condition for neuropathic 
pain, such as in sciatica, then one could assume that the prescriptions in these patients 
would be attributed to this licensed indication. There may however be use in patients with 
no neuropathic pain, resulting in the number of first prescriptions left unattributed being 
an overestimate. 
Other limitations of this method resulting in a conservative figure of the proportion of first 
prescriptions attributed to OA may be that the presence of a comorbidity Read code may 
not equate to the first gabapentinoid being used purely for this condition. For instance if a 
patient with both epilepsy and OA were to be prescribed a gabapentinoid, their OA may be 
a factor in the clinician’s decision to prescribe. Equally, prescriptions attributed to 
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neuropathic pain may have been a result of neuropathic pain features arising as a 
consequence of the patient’s OA. 
In conclusion, this analysis demonstrated that approximately 9-10% of first gabapentinoid 
prescriptions in patients with OA are attributable to the condition. However, due to 
potential limitations with the approach to attribute a first gabapentinoid prescription to 
OA, it is likely that, whilst some prescriptions may have been used for other conditions, 
such as back pain, there is an unknown proportion of unattributed prescriptions that were 
also prescribed for OA. This would therefore result in the current estimate being 
conservative. 
 
6.4 Implications 
In light of the study’s strengths and limitations, areas of this work may need to be viewed 
as cautious estimates. However, the analysis in this thesis is a basis of work for future 
research and has implications for clinicians and policy makers. 
One could argue that the fairly constant proportion of first prescriptions attributed to OA 
compared to the increasing incidence rates in this population may point to OA not being 
responsible for their use in this condition. However, it is important to highlight that, 
irrespective of the proportion, the absolute number of first prescriptions attributed to OA 
(and no other licensed or unlicensed indication) increased from 6 in 2000 to 191 in 2007 
and to 454 in 2014. Possible reasons for the steady proportion of first prescriptions 
attributed to OA may be that the gabapentinoid was prescribed due to rationale that has 
not recently changed. For instance, based on studies included in the 2017 systematic 
review, the first articles assessing for the presence of neuropathic pain features in OA were 
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published in 2011 (French et al., 2017). With the latest NICE guidelines for the management 
of neuropathic pain being published in 2013 (National Institute for Health and Care 
Excellence, 2013), an increase in the proportion of first prescriptions attributed to OA may 
have been expected to increase around this time if this was a factor in their use. Equally, 
as concerns with the safety of medications such as paracetamol have increased in recent 
years, it seems more likely that the gabapentinoids are being used for OA due to the lack 
of efficacy of the currently recommended medications, which one may suspect has always 
posed an issue for clinicians, leading them to resort to non-guideline medications, such as 
the gabapentinoids. Due to the predicted increase in the absolute number of patients with 
OA, clinicians will increasingly be required to manage the pain arising due to the condition. 
There will, consequently, be a larger number of patients who do not respond to, or are not 
suitable for, the currently recommended therapies. Unless changes are made to the current 
guidelines, clinicians may increasingly rely on medications such as the gabapentinoids. 
However, limited evidence of the efficacy of the off-label use of the gabapentinoids in OA, 
coupled with severe concerns with their potential risks, means that their use requires 
careful justification. It should, however, be acknowledged that whilst it is easy to highlight 
the concerns with the use of medications such as paracetamol, NSAIDs and the 
gabapentinoids, this leaves clinicians with very few options to treat patients who have 
increasing expectations. It is critical therefore that raising concerns does not simply push 
clinicians from one pharmacological option to another, particularly problematic whilst 
potentially effective non-pharmacological and core treatments, such as exercise, remain 
inaccessible and underfunded. 
The decreasing use of the diagnostic code of OA, as reported by Yu et al. (2017, 2018), may 
also be a factor in the flat trend observed in the proportion of first prescriptions attributed 
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to OA. Whilst this decrease in use will also have affected recruitment into the cohort, the 
median time of 3.4 years between a patient’s index date and them receiving their first 
gabapentinoid demonstrates that these events may occur amid different rates of use of the 
diagnostic codes of OA. As a result, a gabapentinoid prescribed for the patient’s OA pain 
may have not been coded or coded using more clinical OA codes such as joint pain, resulting 
in a conservative estimate of attribution to OA, and a relatively flat trend in attribution 
compared to the increasing incidence rate of gabapentinoid prescribing in the condition. 
The difference in the proportion of first gabapentinoid prescriptions attributed to OA 
(almost three times larger in window 3 compared to window 1) as well as the identified 
licensed or unlicensed indications in the sensitivity analyses has further demonstrated the 
effect the time window chosen can have on the results of studies using electronic 
healthcare databases. Furthermore, with approximately 45% of first prescriptions 
remaining unattributed even in window 4, a window one could classify as an extremely 
sensitive time period to identify indications in the CPRD, this analysis has highlighted a 
potential lack of coding by clinicians, an important finding for researchers of similar studies 
using the CPRD. As discussed, this may be due to limitations of this analysis in identifying 
the codes used or conditions for which the gabapentinoids are prescribed. However, the 
apparent lack of coding raises the question whether coding guidelines, such as a code being 
given upon management changes in chronic conditions, are being adhered to by 
participating practices. To understand whether this lack of coding is specific to OA or the 
gabapentinoids requires further work, however researchers should be aware that a 
potential lack of coding may be responsible for a lack of attribution in similarly designed 
studies. 
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Scoping reviews of the literature demonstrate that it is imperative that clinicians are 
particularly wary of the prescribing of a gabapentinoid to patients with a history of 
substance use disorders. Equally, patients with access (either prescribed or via diversion) 
to other sedative medications, including opioids, which are commonly prescribed in OA, 
should be viewed as high risk – largely due to the potential for synergistic adverse effects. 
As reported by many trials studying the efficacy of the gabapentinoids, they do appear to 
confer benefit in some patients, although this does appear to be a small minority. As a 
result gabapentinoids may prove effective for the pain of some patients with OA. To 
maximise their potential efficacy, and to reduce risk, it is imperative that the dose of 
gabapentin or pregabalin is titrated as recommended. A regular review of patients taking 
gabapentinoids, particularly for off-label conditions, should also be encouraged, with 
prescriptions stopped if there is no demonstrable evidence of efficacy. Not only is this 
important to reduce potential harms, but may reduce diversion, as the diversion of opioids 
is more common in patients that gain no benefit from their use (Han et al., 2017). Finally, 
whilst it is likely that a proportion of unattributed gabapentinoid prescriptions are due to 
OA or other comorbidities, it is likely that a large number of prescriptions that were issued 
to this cohort of OA patients had no associated Read code entered. Clinicians should 
therefore be encouraged to record their reasoning for the prescription of a gabapentinoid, 
particularly when prescribing for off-label conditions such as OA. 
The novel contribution of this work provides a platform for future research of the 
gabapentinoids. Firstly, there remains scope for further work using the CPRD to provide 
further insight into gabapentinoid prescribing in patients with OA. Performing the same 
analyses in patients with ‘clinical OA’, as done by prior studies, would provide more 
sensitivity to the definition used. This may also provide a greater understanding of the 
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number of gabapentinoid prescriptions issued to the wider population of patients with OA 
who do not receive a diagnostic Read code. As demonstrated by prior studies, the use of 
clinical OA as a definition of the disease results in a younger group of patients, who are 
earlier in their disease progression. This earlier window may allow a greater opportunity to 
analyse other prescriptions prescribed to patients with OA before they receive their first 
gabapentinoid, further allowing the exploration of the hypothesis that clinicians resort to 
the gabapentinoids due to the ineffectiveness of recommended options. Due to the larger 
number of patients in a cohort of clinical OA, more detailed analysis beyond a region level 
would also be possible. Rates of gabapentinoid prescribing could be performed at a practice 
or practitioner level, which would demonstrate whether rates of prescribing are driven by 
certain areas, practices or individuals. 
It should be noted that this study of the CPRD has other research objectives not included 
in this thesis (presented in the ISAC protocol, Appendix 1.1, page 158). Stratification of the 
incidence rates of first gabapentinoid prescriptions by socioeconomic class could not be 
included in this thesis due to the tight deadline of the MPhil for which it was completed 
and the lapsing of the Institute’s CPRD GOLD license during this time. Use of the Index of 
Multiple Deprivation (IMD), as performed in a study of opioids (Foy et al., 2016), would 
allow the exploration of the relationship between a patient’s deprivation and rates of 
gabapentinoid prescribing in patients with OA. As noted by Cartagena et al. (2017, p. 11), 
GABAergic is “slightly more likely to patients living in deprived areas”. This may explain 
some of the variation seen by geographical region. Research objectives in the ISAC protocol 
separate to the three included in this thesis include rates of opioid co-prescribing in the OA 
population and a more detailed analysis of gabapentinoid prescribing in the period before 
and after a patient’s arthroplasty.  
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Studies beyond the analysis in this thesis may also be possible using electronic health 
records. For instance assessing the significance of factors for a patient receiving a 
gabapentinoid prescription or having a prescription attributed to OA or a licensed or 
unlicensed indication using regression analysis would provide further insight by adjusting 
for confounding. Finally, an alternative approach may be to study the conditions of patients 
prescribed a gabapentinoid, however, without condition specific information it would not 
be possible to identify the risk to a patient with a certain condition, such as OA in this study. 
As it is imperative for clinicians that the potential efficacy and risks of gabapentinoids can 
be assessed, further studies of their use are warranted. Whilst trials tend to be small, with 
short follow-up, the role of different research designs should be explored. An example may 
include interviewing clinicians or patients. Surveying clinicians may provide a greater 
understanding of the rationale for the use of the gabapentinoids as well as who initiates 
the medications. This would not only allow a better understanding of reasons for use (for 
instance if started in a pain clinic), but would also allow a more targeted approach to reduce 
gabapentinoid prescribing at the source of initial prescription, if warranted. Questionnaires 
issued to patients could be used to ascertain whether they take the gabapentinoids as 
indicated, and the long-term efficacy and harms of their use. The CPRD allows the 
possibility to survey clinicians or patients, and the dataset could still be used to identify 
gabapentinoid prescriptions. An interventional study design could also be used, for 
example to assess the impact of screen notifications on the rate of gabapentinoid 
prescribing. For instance GPs who are considering the prescription of a gabapentinoid for 
off-label conditions such as OA could be alerted to the possible risks. However, the likely 
control of gabapentinoid prescribing probably supersedes this.  
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This work may also serve as a basis of information to policy makers and others in public 
health. A crude estimate of the absolute number of patients with OA being started on a 
gabapentinoid within the UK can be derived by applying the incidence rate of first 
gabapentinoid prescription from this thesis to the estimated total number of prevalent 
cases consulting in the UK with osteoarthritis. The seven-year prevalence rate of 651 
patients with OA consulting per 10,000 person-years in 2010 (Jordan et al., 2014), applied 
to the estimated mid-2010 UK population (Office for National Statistics, 2017c), results in 
an estimate of just over four million patients with OA living in the UK. Applying the 2010 
incidence rate of first gabapentinoid prescriptions from this thesis provides an estimate of 
72,000 patients with OA receiving a gabapentinoid during this year. Using the proportions 
of attributed prescriptions in 2010, more than 6,000 of the total number of first 
prescriptions may be attributed with some confidence to being specifically for OA. A further 
9,000 can be attributed to licensed or unlicensed indications. Such crude estimates give a 
rough approximation of the likely numbers affected in a calendar year but should be 
interpreted with caution. Firstly, whilst the regional primary care dataset used to estimate 
the prevalence of OA has been found to be representative of wider national and 
international datasets (Jordan et al., 2007), there may be slight differences. Secondly, 
whilst the population of incident cases used in the analysis in this thesis differs from the 
prevalence figures provided in this article, patients included in this study of the CPRD in 
2010 can be viewed as those with incident and prevalent disease during this year. Although 
caution is required, the scaling up to the UK population does, however, provide useful 
information to policy makers and demonstrates that a substantial number of prescriptions 
(over 55,000) were prescribed to patients with OA but were not attributable to OA or other 
licensed or unlicensed indications (Table 6.1). Whilst this is a large volume of initial 
prescriptions, the total number of prescriptions will be greater, and both values will have 
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increased in recent years, due to the increased incidence rate of gabapentinoid prescribing, 
and the rise in the number of patients with OA. 
Table 6.1 First Gabapentinoid Prescriptions in Patients with OA, Scaled to the 2010 UK Population 
 
In the context of the possible dependence-forming nature of the gabapentinoids, this 
analysis of incident prescribing provides useful information. With the exception of the 
recent report of dependence forming medications (Cartagena et al., 2017), literature 
commonly presents gabapentinoid prescriptions as the total number of items prescribed. 
Whilst duration of treatment is important, incidence analysis can provide a greater 
appreciation of the number of patients newly prescribed and exposed to these medications 
and their potential risks. Do the concerns surrounding the gabapentinoids, particularly 
regarding misuse and diversion, result in a drive by policy makers and clinicians to reduce 
the length of time patients are prescribed them, or to reduce the number of patients who 
receive them? Using the benzodiazepines (a class of potentially dependence-forming 
medications) as an example, it would appear that the length of prescribing is a cause for 
concern in dependence forming medications such as the gabapentinoids as in the early 
2000s NICE set targets to reduce the average length of benzodiazepine prescribing 
(Cartagena et al., 2017). The distinction between the 2015 data in this thesis and the 
prevalence data further highlights this. The slowing down of the increase in incident 
gabapentinoid prescribing demonstrated in this thesis differs from the continued increase 
in total items prescribed within the UK. One interpretation of this discrepancy may be that 
the increase in the number of patients starting a gabapentinoid has slowed, and as 
 This study of CPRD: 2010 UK Estimates: 2010 
Gabapentinoid prescriptions in OA  3,214 72,561 
Attributed to OA 277 6,254 
Attributed to other indications 415 9,369 
Unattributed prescriptions 2,522 56,938 
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prevalence has continued to rise, this must therefore be due to an increase in the average 
length of prescribing. Another influence could be that external factors, such as Public 
Health England’s ‘Advice for Prescribers’ had a greater impact on unlicensed conditions 
such as OA compared to other indications. However, caution should be noted with the 
interpretation of this finding, and further work is required. Firstly, the differences observed 
may be due to differences between the cohort of patients with OA in this thesis compared 
to the general population in national prescribing data. Secondly, as this occurred in the last 
year of the study, it is not possible to fathom whether this is a one-off (potentially linked 
to the decrease in practices contributing to data CPRD GOLD), or whether this is the start 
of a longer trend. As a result, further work to assess average duration of prescribing, as well 
as prescribing rates in future years, repeating these analyses, is required. This is also 
important to observe the effect the likely implementation of the control of gabapentin and 
pregabalin prescribing has on prescribing trends within the UK.  
Whilst the trends in this thesis can be evaluated against the general increase in prescribing, 
the distinction between incidence and prevalence data, whereby one must assume that the 
duration of treatment has remained constant and that each patient would receive only one 
prescription, is too great to make a meaningful comparison. As a result, the current lack of 
incident prescribing data for the gabapentinoids across all conditions means that 
comparing the data in this study to more general trends is challenging. The availability of 
this data, whilst not only providing an indication of the duration of use of the 
gabapentinoids, may further illustrate whether use in OA is in-line with or exceeding 
general trends, which, if the latter, may further point to use for this common condition. 
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6.5 Conclusion 
Between 1995 and 2015, the proportion of patients with diagnosed OA being issued a first 
gabapentinoid prescription within UK primary care has risen sharply. Approximately 1 in 10 
prescriptions appear to be for the control of OA pain, although the reason for many more 
prescriptions could not be confidently identified, and thus the estimate of OA attribution 
may be conservative. The off-label use of medicines is common and the rationale for the 
use of the gabapentinoids for OA pain may include the lack of efficacy with the currently 
recommended pharmacological therapies, safety concerns with their use, as well as a 
potential neuropathic component to the pain experienced by patients with OA. However, 
there is a lack of trial evidence of their efficacy, and given concerns with their potential for 
misuse and diversion, the prescribing of the gabapentinoids for a condition as prevalent as 
OA may require more careful justification by clinicians. The likely future implementation of 
controls on the prescribing of the gabapentinoids may result in changes in practice, and the 
effects on the management and outcomes of OA should be evaluated.
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Appendix 1.2 Linkage Form submitted to the ISAC Secretariat for use of Index of Multiple Deprivation Data (not included in this thesis) 
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Appendix 2.1 Read Codes of Diagnostic Osteoarthritis 
Read Code Read term 
N05..11 Osteoarthritis 
N05z211 Elbow osteoarthritis NOS 
N05z400 Osteoarthritis NOS, of the hand 
N05z611 Knee osteoarthritis NOS 
N053512 Hip osteoarthitis NOS 
N053611 Patellofemoral osteoarthritis 
N05z712 Foot osteoarthritis NOS 
N05z.11 Joint degeneration 
N05z412 Thumb osteoarthritis NOS 
N05z511 Hip osteoarthritis NOS 
N05zB00 Osteoarthritis NOS, of acromioclavicular joint 
N05zL00 Osteoarthritis NOS, of knee 
N05..00 Osteoarthritis and allied disorders 
N05z100 Osteoarthritis NOS, of shoulder region 
N05zA00 Osteoarthritis NOS, of sternoclavicular joint 
N050111 Heberdens' nodes 
N050.00 Generalised osteoarthritis - OA 
N053700 Localised osteoarthritis, unspecified, of the ankle and foot 
N05z411 Finger osteoarthritis NOS 
N05z713 Toe osteoarthritis NOS 
N05z500 Osteoarthritis NOS, pelvic region/thigh 
N05z.00 Osteoarthritis NOS 
N05z900 Osteoarthritis NOS, of shoulder 
N05zJ00 Osteoarthritis NOS, of hip 
N05zS00 Osteoarthritis NOS, of 1st MTP joint 
N05zF00 Osteoarthritis NOS, of MCP joint 
N05zN00 Osteoarthritis NOS, of ankle 
N05zT00 Osteoarthritis NOS, of lesser MTP joint 
N05zE00 Osteoarthritis NOS, of wrist 
N05zH00 Osteoarthritis NOS, of DIP joint of finger 
N05zG00 Osteoarthritis NOS, of PIP joint of finger 
N050500 Secondary multiple arthrosis 
N05z800 Osteoarthritis NOS, other specified site 
N05z600 Osteoarthritis NOS, of the lower leg 
N05z311 Wrist osteoarthritis NOS 
N053100 Localised osteoarthritis, unspecified, of shoulder region 
N05z700 Osteoarthritis NOS, of ankle and foot 
N051500 Localised, primary osteoarthritis of the pelvic region/thigh 
N053400 Localised osteoarthritis, unspecified, of the hand 
N053800 Localised osteoarthritis, unspecified, of other spec site 
N051F00 Localised, primary osteoarthritis of elbow 
N05zC00 Osteoarthritis NOS, of elbow 
N051800 Localised, primary osteoarthritis of other specified site 
N053500 Localised osteoarthritis, unspecified, pelvic region/thigh 
N051z00 Localised, primary osteoarthritis NOS 
N051600 Localised, primary osteoarthritis of the lower leg 
N053900 Arthrosis of first carpometacarpal joint, unspecified 
N051400 Localised, primary osteoarthritis of the hand 
N054.00 Oligoarticular osteoarthritis, unspecified 
N052400 Localised, secondary osteoarthritis of the hand 
N050400 Primary generalized osteoarthrosis 
N050200 Generalised osteoarthritis of multiple sites 
N051100 Localised, primary osteoarthritis of the shoulder region 
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N051B00 Primary gonarthrosis, bilateral 
N05z300 Osteoarthritis NOS, of the forearm 
N051200 Localised, primary osteoarthritis of the upper arm 
N051900 Primary coxarthrosis, bilateral 
N052A00 Post-traumatic gonarthrosis, bilateral 
N050700 Heberden's nodes with arthropathy 
N051D00 Localised, primary osteoarthritis of the wrist 
N051700 Localised, primary osteoarthritis of the ankle and foot 
N051A00 Coxarthrosis resulting from dysplasia, bilateral 
N05zU00 Osteoarthritis NOS, of IP joint of toe 
N05zz00 Osteoarthritis NOS 
N051E00 Localised, primary osteoarthritis of toe 
N053z00 Localised osteoarthritis, unspecified, NOS 
N051.00 Localised, primary osteoarthritis 
N052800 Localised, secondary osteoarthritis of other specified site 
N052600 Localised, secondary osteoarthritis of the lower leg 
N052100 Localised, secondary osteoarthritis of the shoulder region 
N05zK00 Osteoarthritis NOS, of sacro-iliac joint 
N052700 Localised, secondary osteoarthritis of the ankle and foot 
N053.00 Localised osteoarthritis, unspecified 
N053600 Localised osteoarthritis, unspecified, of the lower leg 
N051300 Localised, primary osteoarthritis of the forearm 
N050z00 Generalised osteoarthritis NOS 
N05z000 Osteoarthritis NOS, of unspecified site 
N050112 Bouchards' nodes 
N051C00 Primary arthrosis of first carpometacarpal joints, bilateral 
N050100 Generalised osteoarthritis of the hand 
N050300 Bouchard's nodes with arthropathy 
N050600 Erosive osteoarthrosis 
N050000 Generalised osteoarthritis of unspecified site 
N05zP00 Osteoarthritis NOS, of subtalar joint 
N052200 Localised, secondary osteoarthritis of the upper arm 
N054600 Oligoarticular osteoarthritis, unspecified, of lower leg 
N054800 Oligoarticular osteoarthritis, unspecified, other spec sites 
N052.00 Localised, secondary osteoarthritis 
N052500 Localised, secondary osteoarthritis of pelvic region/thigh 
N052300 Localised, secondary osteoarthritis of the forearm 
N054000 Oligoarticular osteoarthritis, unspec, of unspecified sites 
N053000 Localised osteoarthritis, unspecified, of unspecified site 
N052C00 Post-traumatic gonarthrosis, unilateral 
N05z200 Osteoarthritis NOS, of the upper arm 
N054100 Oligoarticular osteoarthritis, unspecified, of shoulder 
N05z711 Ankle osteoarthritis NOS 
N053511 Otto's pelvis 
N054z00 Osteoarthritis of more than one site, unspecified, NOS 
N051000 Localised, primary osteoarthritis of unspecified site 
N05zR00 Osteoarthritis NOS, of other tarsal joint 
N05zQ00 Osteoarthritis NOS, of talonavicular joint 
N054900 Oligoarticular osteoarthritis, unspecified, multiple sites 
N052z00 Localised, secondary osteoarthritis NOS 
N054400 Oligoarticular osteoarthritis, unspecified, of hand 
N053200 Localised osteoarthritis, unspecified, of the upper arm 
N052B00 Post-traumatic arthrosis of first carpometacarpal jt bilat 
N053300 Localised osteoarthritis, unspecified, of the forearm 
N052900 Post-traumatic coxarthrosis, bilateral 
N05zD00 Osteoarthritis NOS, of distal radio-ulnar joint 
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N054500 Oligoarticular osteoarthritis, unspecified, of pelvis/thigh 
N052000 Localised, secondary osteoarthritis of unspecified site 
N05zM00 Osteoarthritis NOS, of tibio-fibular joint 
N054700 Oligoarticular osteoarthritis, unspecified, of ankle/foot 
N054200 Oligoarticular osteoarthritis, unspecified, of upper arm 
N052511 Coxae malum senilis 
N051G00 Osteoarthritis of spinal facet joint 
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Appendix 2.2 Product Codes of the Gabapentinoids 
BNF Code Drug Name Product Name 
04030000/04070300/04080100 Pregabalin Pregabalin 100mg capsules 
04030000/04070300/04080100 Pregabalin Pregabalin 150mg capsules 
04030000/04070300/04080100 Pregabalin Pregabalin 150mg/5ml oral solution 
04030000/04070300/04080100 Pregabalin Pregabalin 150mg/5ml oral suspension 
04030000/04070300/04080100 Pregabalin Pregabalin 200mg capsules 
04030000/04070300/04080100 Pregabalin Pregabalin 225mg capsules 
04030000/04070300/04080100 Pregabalin Pregabalin 25mg capsules 
04030000/04070300/04080100 Pregabalin Pregabalin 300mg capsules 
04030000/04070300/04080100 Pregabalin Pregabalin 50mg capsules 
04030000/04070300/04080100 Pregabalin Pregabalin 50mg capsules (Accord Healthcare) 
04030000/04070300/04080100 Pregabalin Pregabalin 50mg capsules (Sandoz) 
04030000/04070300/04080100 Pregabalin Pregabalin 75mg capsules 
04030000/04070300/04080100 Pregabalin Pregabalin 75mg/5ml oral solution 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 100mg capsules (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 150mg capsules (Lexon (UK)) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 150mg capsules (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 150mg capsules (Sigma Pharmaceuticals Plc) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 200mg capsules (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 20mg/ml oral solution (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 225mg capsules (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 25mg capsules (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 300mg capsules (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 50mg capsules (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 50mg capsules (Waymade Healthcare Plc) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 75mg capsules (Pfizer) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 75mg capsules (Stephar (U.K.)) 
04030000/04070300/04080100/06010500 Pregabalin Lyrica 75mg capsules (Waymade Healthcare Plc) 
04030000/04070300/04080100/06010500 Pregabalin Pregabalin 20mg/ml oral solution sugar free 
04030000/04080100 Pregabalin Alzain 100mg capsules (Dr Reddy's Laboratories (UK)) 
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04030000/04080100 Pregabalin Alzain 150mg capsules (Dr Reddy's Laboratories (UK)) 
04030000/04080100 Pregabalin Alzain 200mg capsules (Dr Reddy's Laboratories (UK)) 
04030000/04080100 Pregabalin Alzain 225mg capsules (Dr Reddy's Laboratories (UK)) 
04030000/04080100 Pregabalin Alzain 25mg capsules (Dr Reddy's Laboratories (UK)) 
04030000/04080100 Pregabalin Alzain 300mg capsules (Dr Reddy's Laboratories (UK)) 
04030000/04080100 Pregabalin Alzain 50mg capsules (Dr Reddy's Laboratories (UK)) 
04030000/04080100 Pregabalin Alzain 75mg capsules (Dr Reddy's Laboratories (UK)) 
04030000/04080100 Pregabalin Lecaent 50mg capsules (Actavis UK) 
04030000/04080100 Pregabalin Pregabalin 100mg capsules (A A H Pharmaceuticals) 
04030000/04080100 Pregabalin Pregabalin 25mg capsules (Teva UK) 
04030000/04080100 Pregabalin Pregabalin 50mg capsules (A A H Pharmaceuticals) 
04030000/04080100 Pregabalin Pregabalin 75mg capsules (Teva UK) 
04030000/04080100 Pregabalin Rewisca 100mg capsules (Consilient Health) 
04030000/04080100 Pregabalin Rewisca 150mg capsules (Consilient Health) 
04030000/04080100 Pregabalin Rewisca 200mg capsules (Consilient Health) 
04030000/04080100 Pregabalin Rewisca 225mg capsules (Consilient Health) 
04030000/04080100 Pregabalin Rewisca 25mg capsules (Consilient Health) 
04030000/04080100 Pregabalin Rewisca 300mg capsules (Consilient Health) 
04030000/04080100 Pregabalin Rewisca 50mg capsules (Consilient Health) 
04030000/04080100 Pregabalin Rewisca 75mg capsules (Consilient Health) 
04070300/04080100 Gabapentin Gabapentin 100mg capsules 
04070300/04080100 Gabapentin Gabapentin 100mg capsules (A A H Pharmaceuticals) 
04070300/04080100 Gabapentin Gabapentin 100mg capsules (Actavis UK) 
04070300/04080100 Gabapentin Gabapentin 100mg capsules (Mylan) 
04070300/04080100 Gabapentin Gabapentin 100mg capsules (Sandoz) 
04070300/04080100 Gabapentin Gabapentin 100mg capsules (Teva UK) 
04070300/04080100 Gabapentin Gabapentin 100mg capsules (Zentiva) 
04070300/04080100 Gabapentin Gabapentin 100mg/5ml oral solution 
04070300/04080100 Gabapentin Gabapentin 250mg/5ml oral solution 
04070300/04080100 Gabapentin Gabapentin 250mg/5ml Oral solution (Boots Pharmaceuticals) 
04070300/04080100 Gabapentin Gabapentin 250mg/5ml oral suspension 
04070300/04080100 Gabapentin Gabapentin 300mg capsules 
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04070300/04080100 Gabapentin Gabapentin 300mg capsules (A A H Pharmaceuticals) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Actavis UK) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Alliance Healthcare (Distribution)) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Arrow Generics) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Bristol Laboratories) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Creo Pharma) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Mylan) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Ranbaxy (UK)) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Sandoz) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Teva UK) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Waymade Healthcare Plc) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Zentiva) 
04070300/04080100 Gabapentin Gabapentin 300mg/5ml oral solution 
04070300/04080100 Gabapentin Gabapentin 300mg/5ml oral suspension 
04070300/04080100 Gabapentin Gabapentin 400mg capsules 
04070300/04080100 Gabapentin Gabapentin 400mg capsules (Almus Pharmaceuticals) 
04070300/04080100 Gabapentin Gabapentin 400mg/5ml oral solution 
04070300/04080100 Gabapentin Gabapentin 400mg/5ml oral suspension 
04070300/04080100 Gabapentin Gabapentin 50mg/ml oral solution sugar free 
04070300/04080100 Gabapentin Gabapentin 50mg/ml oral solution sugar free (Alliance Healthcare (Distribution)) 
04070300/04080100 Gabapentin Gabapentin 600mg tablets 
04070300/04080100 Gabapentin Gabapentin 600mg tablets (A A H Pharmaceuticals) 
04070300/04080100 Gabapentin Gabapentin 600mg tablets (DE Pharmaceuticals) 
04070300/04080100 Gabapentin Gabapentin 600mg tablets (Teva UK) 
04070300/04080100 Gabapentin Gabapentin 600mg tablets (Zentiva) 
04070300/04080100 Gabapentin Gabapentin 600mg/5ml oral solution 
04070300/04080100 Gabapentin Gabapentin 800mg tablets 
04070300/04080100 Gabapentin Neurontin 100mg capsules (Pfizer) 
04070300/04080100 Gabapentin Neurontin 300mg capsules (Dowelhurst) 
04070300/04080100 Gabapentin Neurontin 300mg capsules (Pfizer) 
04070300/04080100 Gabapentin Neurontin 400mg capsules (Pfizer) 
04070300/04080100 Gabapentin Neurontin 600mg tablets (Pfizer) 
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04070300/04080100 Gabapentin Neurontin 800mg tablets (Pfizer) 
4070300 Gabapentin Gabapentin 6% gel 
4080100 Gabapentin Gabapentin 600mg tablets and Gabapentin 300mg capsules 
04070300/04080100 Gabapentin Gabapentin 100mg capsules (Generics (UK) Ltd) 
04070300/04080100 Gabapentin Gabapentin 300mg capsules (Generics (UK) Ltd) 
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Appendix 2.3 Read Codes of Hip and Knee Arthroplasty 
Read Code Read Term 
7K20.16 Freeman total replacement of hip joint using cement 
7K20000 Primary cemented total hip replacement 
7K20.1G THR - Total prosthetic replacement of hip joint using cement 
7K21.13 Lord total replacement of hip joint not using cement 
7K21.15 Monk total replacement of hip joint not using cement 
7K20.1C Muller total replacement of hip joint using cement 
7K22.12 THR - Other total prosthetic replacement of hip joint 
7K22000 Primary total prosthetic replacement of hip joint NEC 
7K20.17 Furlong total replacement of hip joint using cement 
7K21.16 Ring total replacement of hip joint not using cement 
7K20.11 Arthroplasty of hip joint using cement 
7K21.12 Furlong total replacement of hip joint not using cement 
7K21.11 Freeman total replacement of hip joint not using cement 
7K20.1F Turner total replacement of hip joint using cement 
7K20.1A McKee total replacement of hip joint using cement 
7K20.12 Aufranc total replacement of hip joint using cement 
7K21.17 THR - Total prosthetic replacement hip joint without cement 
7K21.00 Total prosthetic replacement of hip joint not using cement 
7K20.14 Exeter total replacement of hip joint using cement 
7K20.1D Pretoria total replacement of hip joint using cement 
7K20.19 Ilch total replacement of hip joint using cement 
7K21.14 Madreporique total replacement of hip joint not using cement 
7K20.18 Howse total replacement of hip joint using cement 
7K20.1E Stanmore total replacement of hip joint using cement 
7K22.00 Other total prosthetic replacement of hip joint 
7K20300 Primary hybrid total replacement of hip joint NEC 
7K20.1B Monk total replacement of hip joint using cement 
7K20.13 Charnley total replacement of hip joint using cement 
7K20.00 Total prosthetic replacement of hip joint using cement 
7K20.15 Farrer total replacement of hip joint using cement 
7K20011 Charnley cemented total hip replacement 
7K21y00 Other specified total prosthetic replacement of hip joint not using cement 
7K20y00 Other specified total prosthetic replacement of hip joint using cement 
7K21000 Primary uncemented total hip replacement 
7K21z00 Total prosthetic replacement of hip joint not using cement NOS 
7K20z00 Total prosthetic replacement of hip joint using cement NOS 
7K22z00 Total prosthetic replacement of hip joint NOS 
7K30.00 Total prosthetic replacement of knee joint using cement 
7K30.11 Anametric total replacement of knee joint using cement 
7K30.13 Attenborough total replacement of knee joint using cement 
7K30.15 Cavendish total replacement of knee joint using cement 
7K30.16 Charnley total replacement of knee joint using cement 
7K30.17 Deane total replacement of knee joint using cement 
7K30.18 Denham total replacement of knee joint using cement 
7K30.19 Freeman total replacement of knee joint using cement 
7K30.1A Geomedic total replacement of knee joint using cement 
7K30.1B Geometric total replacement of knee joint using cement 
7K30.1C Guepar hinge replacement of knee joint using cement 
7K30.1D Gunston total replacement of knee joint using cement 
7K30.1E Herbert total replacement of knee joint using cement 
7K30.1F Ilch total replacement of knee joint using cement 
7K30.1G Irving total replacement of knee joint using cement 
7K30.1H Liverpool total replacement of knee joint using cement 
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7K30.1I Manchester total replacement of knee joint using cement 
7K30.1J Marmor total replacement of knee joint using cement 
7K30.1L Melbourne total replacement of knee joint using cement 
7K30.1N Polycentric total replacement of knee joint using cement 
7K30.1P Sheehan total replacement of knee joint using cement 
7K30.1Q Shiers total replacement of knee joint using cement 
7K30.1R Stanmore total replacement of knee joint using cement 
7K30.1S Swanson total replacement of knee joint using cement 
7K30.1T Uci total replacement of knee joint using cement 
7K30.1V TKR -Total prosthetic replacement of knee joint using cement 
7K31.00 Total prosthetic replacement of knee joint not using cement 
7K31.12 TKR - Total prosthetic replacement knee joint without cement 
7K32.00 Other total prosthetic replacement of knee joint 
7K32.12 TKR - Other total prosthetic replacement of knee joint 
7K32000 Primary total knee replacement NEC 
7K32011 Primary hybrid total knee replacement NEC 
K812 TOTAL KNEE REPLACEMENT 
7K30000 Primary cemented total knee replacement 
7K30y00 Total prosthetic replacement of knee joint using cement OS 
7K30z00 Total prosthetic replacement of knee joint using cement NOS 
7K31000 Primary uncemented total knee replacement 
7K31y00 Total prosthetic replacement knee joint not using cement OS 
7K31z00 Total prosthetic replacement knee joint not using cement NOS 
7K32y00 Other total prosthetic replacement of knee joint OS 
7K32z00 Other total prosthetic replacement of knee joint NOS 
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Appendix 2.4 Read Codes of Identified Licensed and Unlicensed Gabapentinoid Indications 
Epilepsy 
Read Code Read Term 
2126000 Epilepsy resolved 
F132100 Progressive myoclonic epilepsy 
F25..00 Epilepsy 
F250.00 Generalised nonconvulsive epilepsy 
F250000 Petit mal (minor) epilepsy 
F250011 Epileptic absences 
F250100 Pykno-epilepsy 
F250200 Epileptic seizures - atonic 
F250300 Epileptic seizures - akinetic 
F250400 Juvenile absence epilepsy 
F250500 Lennox-Gastaut syndrome 
F250y00 Other specified generalised nonconvulsive epilepsy 
F250z00 Generalised nonconvulsive epilepsy NOS 
F251.00 Generalised convulsive epilepsy 
F251000 Grand mal (major) epilepsy 
F251011 Tonic-clonic epilepsy 
F251100 Neonatal myoclonic epilepsy 
F251111 Otohara syndrome 
F251200 Epileptic seizures - clonic 
F251300 Epileptic seizures - myoclonic 
F251400 Epileptic seizures - tonic 
F251500 Tonic-clonic epilepsy 
F251y00 Other specified generalised convulsive epilepsy 
F251z00 Generalised convulsive epilepsy NOS 
F252.00 Petit mal status 
F253.00 Grand mal status 
F253.11 Status epilepticus 
F254.00 Partial epilepsy with impairment of consciousness 
F254000 Temporal lobe epilepsy 
F254100 Psychomotor epilepsy 
F254200 Psychosensory epilepsy 
F254300 Limbic system epilepsy 
F254400 Epileptic automatism 
F254500 Complex partial epileptic seizure 
F254z00 Partial epilepsy with impairment of consciousness NOS 
F255.00 Partial epilepsy without impairment of consciousness 
F255000 Jacksonian; focal or motor epilepsy 
F255011 Focal epilepsy 
F255012 Motor epilepsy 
F255100 Sensory induced epilepsy 
F255200 Somatosensory epilepsy 
F255300 Visceral reflex epilepsy 
F255311 Partial epilepsy with autonomic symptoms 
F255400 Visual reflex epilepsy 
F255500 Unilateral epilepsy 
F255600 Simple partial epileptic seizure 
F255y00 Partial epilepsy without impairment of consciousness OS 
F255z00 Partial epilepsy without impairment of consciousness NOS 
F256.00 Infantile spasms 
F256000 Hypsarrhythmia 
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F256100 Salaam attacks 
F256.11 Lightning spasms 
F256.12 West syndrome 
F256z00 Infantile spasms NOS 
F257.00 Kojevnikov's epilepsy 
F258.00 Post-ictal state 
F259.00 Early infant epileptic encephalopathy wth suppression bursts 
F259.11 Ohtahara syndrome 
F25A.00 Juvenile myoclonic epilepsy 
F25B.00 Alcohol-induced epilepsy 
F25C.00 Drug-induced epilepsy 
F25D.00 Menstrual epilepsy 
F25E.00 Stress-induced epilepsy 
F25F.00 Photosensitive epilepsy 
F25X.00 Status epilepticus; unspecified 
F25y.00 Other forms of epilepsy 
F25y000 Cursive (running) epilepsy 
F25y100 Gelastic epilepsy 
F25y200 Locl-rlt(foc)(part)idiop epilep&epilptic syn seiz locl onset 
F25y300 Complex partial status epilepticus 
F25y400 Benign Rolandic epilepsy 
F25y500 Panayiotopoulos syndrome 
F25yz00 Other forms of epilepsy NOS 
F25z.00 Epilepsy NOS 
SC20000 Traumatic epilepsy 
1B1W.00 Transient epileptic amnesia  
1O30.00 Epilepsy confirmed  
2824.11 O/E - Jacksonian fit  
667B.00 Nocturnal epilepsy  
667N.00 Epilepsy severity 
Eu05212 [X]Schizophrenia-like psychosis in epilepsy 
Eu05y11 [X]Epileptic psychosis NOS 
Eu06013 [X]Limbic epilepsy personality 
Eu80300 [X]Acquired aphasia with epilepsy [Landau - Kleffner]  
F132200 Myoclonic encephalopathy 
F251600 Grand mal seizure 
F25G.00 Severe myoclonic epilepsy in infancy 
Fyu5000 [X]Other generalized epilepsy and epileptic syndromes  
Fyu5100 [X]Other epilepsy  
Fyu5200 [X]Other status epilepticus 
Fyu5900 [X]Status epilepticus; unspecified 
ZS82.00  Acquired epileptic aphasia 
ZS82.11 Landau-Kleffner syndrome  
212J.00 Epilepsy resolved 
667..00 Epilepsy monitoring 
667A.00 Epilepsy treatment stopped 
667C.00 Epilepsy control good 
667D.00 Epilepsy control poor 
667E.00 Epilepsy care arrangement 
667F.00 Seizure free >12 months 
667G.00 Epilepsy restricts employment 
667H.00 Epilepsy prevents employment 
667J.00 Epilepsy impairs education 
667K.00 Epilepsy limits activities 
667L.00 Epilepsy does not limit activities 
667M.00 Epilepsy management plan given 
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667P.00 No seizures on treatment 
667Q.00 1 to 12 seizures a year 
667R.00 2 to 4 seizures a month 
667S.00 1 to 7 seizures a week 
667T.00 Daily seizures 
667V.00 Many seizures a day 
667W.00 Emergency epilepsy treatment since last appointment 
667X.00 No epilepsy drug side effects 
8BIF.00 Epilepsy medication review 
8BL3.00 Patient on maximal tolerated anticonvulsant therapy 
9N0r.00 Seen in epilepsy clinic 
9N4V.00 DNA - Did not attend epilepsy clinic 
F25z.11 Fit (in known epileptic) NOS 
F25G.11 Dravet syndrome 
F25H.00 Generalised seizure 
 
Generalised Anxiety Disorder 
 
 
Neuropathic Pain 
Read Code Read Term 
C106.00 Diabetes mellitus with neurological manifestation 
C106100 Diabetes mellitus; adult onset; + neurological manifestation 
C106.12 Diabetes mellitus with neuropathy 
C106.13 Diabetes mellitus with polyneuropathy 
C106y00 Other specified diabetes mellitus with neurological comps 
C106z00 Diabetes mellitus NOS with neurological manifestation 
C108200 Insulin-dependent diabetes mellitus with neurological comps 
C108211 Type I diabetes mellitus with neurological complications 
C108212 Type 1 diabetes mellitus with neurological complications 
C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
C108B11 Type I diabetes mellitus with mononeuropathy 
C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
C109211 Type II diabetes mellitus with neurological complications 
C109212 Type 2 diabetes mellitus with neurological complications 
C109A00 Non-insulin dependent diabetes mellitus with mononeuropathy 
C109A11 Type II diabetes mellitus with mononeuropathy 
C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
C109B11 Type II diabetes mellitus with polyneuropathy 
C10E200 Type 1 diabetes mellitus with neurological complications 
C10E212 Insulin-dependent diabetes mellitus with neurological comps 
C10EB00 Type 1 diabetes mellitus with mononeuropathy 
C10EC00 Type 1 diabetes mellitus with polyneuropathy 
C10EC11 Type I diabetes mellitus with polyneuropathy 
C10EC12 Insulin dependent diabetes mellitus with polyneuropathy 
Read Code Read Term 
E200200 Generalised anxiety disorder 
Eu41100 [X]Generalized anxiety disorder 
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C10F200 Type 2 diabetes mellitus with neurological complications 
C10F211 Type II diabetes mellitus with neurological complications 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C10FA11 Type II diabetes mellitus with mononeuropathy 
C10FB00 Type 2 diabetes mellitus with polyneuropathy 
C10FB11 Type II diabetes mellitus with polyneuropathy 
F345000 Diabetic mononeuritis multiplex 
F35z000 Diabetic mononeuritis NOS 
F372000 Acute painful diabetic neuropathy 
F372100 Chronic painful diabetic neuropathy 
F372.11 Diabetic polyneuropathy 
F372.12 Diabetic neuropathy 
F372200 Asymptomatic diabetic neuropathy 
F3y0.00 Diabetic mononeuropathy 
C106.11 Diabetic amyotrophy 
C109H00 Non-insulin dependent d m with neuropathic arthropathy 
C109H11 Type II diabetes mellitus with neuropathic arthropathy 
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
F374z00 Polyneuropathy in disease NOS 
F381300 Myasthenic syndrome due to diabetic amyotrophy 
F381311 Diabetic amyotrophy 
F171100 Autonomic neuropathy due to diabetes 
F372.00 Polyneuropathy in diabetes 
C106000 Diabetes mellitus, juvenile, + neurological manifestation 
C108J00 Insulin dependent diab mell with neuropathic arthropathy 
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy 
C108J11 Type I diabetes mellitus with neuropathic arthropathy 
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy 
C109B12 Type 2 diabetes mellitus with polyneuropathy 
C10FH11 Type II diabetes mellitus with neuropathic arthropathy 
F171z00 Peripheral autonomic neuropathy due to disease NOS 
C10EB00 Type 1 diabetes mellitus with mononeuropathy 
C10FA00 Type 2 diabetes mellitus with mononeuropathy 
C108211 Type I diabetes mellitus with neurological complications 
M271100 Neuropathic diabetic ulcer - foot 
A531.11 Post-herpetic neuralgia 
A531100 Geniculate herpes zoster 
A531111 Ramsey - Hunt syndrome 
A531300 Postherpetic polyneuropathy 
A531500 Postzoster neuralgia 
A531511 Postherpetic neuralgia 
F311.00 Geniculate ganglionitis 
F374400 Polyneuropathy in herpes zoster 
A531.11 Post-herpetic neuralgia 
A531200 Postherpetic trigeminal neuralgia 
A531300 Postherpetic polyneuropathy 
A531500 Postzoster neuralgia 
A531511 Postherpetic neuralgia 
F300.00 Post-herpetic trigeminal neuralgia 
F374400 Polyneuropathy in herpes zoster 
A53..00 Herpes zoster 
A53..11 Shingles 
A530.00 Herpes zoster with meningitis 
A531z00 Herpes zoster with other CNS complication NOS 
A532.00 Herpes zoster with ophthalmic complication 
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A532000 Herpes zoster with dermatitis of eyelid 
A532100 Herpes zoster with keratoconjunctivitis 
A532200 Herpes zoster iridocyclitis 
A532300 Ophthalmic herpes zoster infection 
A532400 Herpes zoster ophthalmicus 
A532z00 Herpes zoster with other ophthalmic complication 
A53x.00 Herpes zoster with other specified complication 
A53x000 Herpes zoster otitis externa 
A53x100 Disseminated zoster 
A53xz00 Herpes zoster with other specified complication NOS 
A53y.00 Herpes zoster with unspecified complication 
A53z.00 Herpes zoster NOS 
AyuA500 [X]Zoster without complications 
F501600 Infective otitis externa due to herpes zoster 
F501611 Herpes zoster - otitis externa 
F366.00 Polyneuropathy 
F367.00 Peripheral neuropathy 
F370100 Postinfectious polyneuritis 
F374.00 Polyneuropathy in disease EC 
F374z00 Polyneuropathy in disease NOS 
F37z.11 Polyneuropathy unspecified 
Fyu6A00 [X]Other mononeuropathies of upper limb 
Fyu6B00 [X]Other mononeuropathies of lower limb 
Fyu6C00 [X]Other specified mononeuropathies 
Fyu6D00 [X]Other mononeuropathies in diseases classified elsewhere 
Fyu7.00 [X]Polyneuropathies & other disord of peripheral nerv syst 
Fyu7200 [X]Other specified polyneuropathies 
Fyu7500 [X]Polyneuropathy/other endocrine+metabolic diseases CE 
Fyu7C00 [X] Polyneuropathy, unspecified 
N035.00 Neuropathic arthropathy 
N035.11 Charcot's arthropathy 
N035.12 Neuropathic arthritis 
N242.00 Neuralgia, neuritis and radiculitis unspecified 
N242000 Neuralgia unspecified 
N242z00 Neuralgia, neuritis or radiculitis NOS 
N242z11 Policeman's disease 
N242300 Neuropathic pain 
A531200 Postherpetic trigeminal neuralgia 
F300.00 Post-herpetic trigeminal neuralgia 
F301.00 Other specified trigeminal neuralgia 
F301000 Tic douloureux 
F301z00 Trigeminal neuralgia NOS 
F30y.00 Other trigeminal nerve disorder 
1475 H/O: trigeminal neuralgia 
F30..00 Trigeminal nerve disorders 
F336000 Phantom limb syndrome with pain 
F336100 Phantom limb syndrome without pain 
F336.00 Phantom limb syndrome 
F262100 Horton's (histamine) neuralgia 
F262500 Periodic migrainous neuralgia 
F321.00 Glossopharyngeal neuralgia 
F356100 Morton's neuralgia 
FyuJ100 [X]Retrobulbar neuritis in diseases classified elsewhere 
N142000 Lumbago with sciatica 
N143.00 Sciatica 
N143.11 Acute back pain with sciatica 
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F256000 Hypsarrhythmia 
F371200 Polyneuropathy in rheumatoid arthritis 
F375.00 Alcoholic polyneuropathy 
29B2.00 O/E - anaesthesia present 
29B2000 O/E - anaesthesia in legs 
29B2100 O/E - anaesthesia of extremities 
29B2.11 O/E - loss of touch sensation 
29B3.00 O/E - hypoaesthesia present 
29B4.00 O/E - hyperaesthesia present 
29B8.00 10g monofilament sensation absent 
29B9.00 10g monofilament sensation R foot abnormal 
29BA.00 10g monofilament sensation L foot abnormal 
29H2.00 O/E - vibration sense reduced 
29H3.00 O/E - vibration sense absent 
29H4.00 O/E - Vibration sense of right foot abnormal 
29H6.00 O/E - Vibration sense of left foot abnormal 
29H8.00 O/E - vibration sense left foot reduced 
29H9.00 O/E - vibration sense right foot reduced 
29HA.00 O/E - Vibration sense of right foot absent 
29HB.00 O/E - Vibration sense of left foot absent 
F161400 Subacute necrotic myelopathy 
F163.00 Myelopathy due to disease EC 
F163000 Myelopathy due to intervertebral disc disease 
F163200 Myelopathy due to spondylosis 
F163z00 Myelopathy due to disease NOS 
F16y.00 Other myelopathy 
F16y000 Drug induced myelopathy 
F16y100 Radiation induced myelopathy 
F16yz00 Other myelopathy NOS 
F16z.00 Myelopathy NOS 
F16z.11 Cord compression NOS 
F16z.12 Spinal cord compression NOS 
F246.00 Cauda equina syndrome 
F246000 Cauda equina syndrome not affecting bladder 
F246100 Cauda equina syndrome with cord bladder 
F246z00 Cauda equina syndrome NOS 
F29y400 Cord compression 
F29y411 Spinal cord compression 
F337100 Nerve root and plexus compressions in intervert disc disord 
F337200 Nerve root and plexus compressions in spondylosis 
F337300 Nerve root and plexus compressions in other dorsopathies 
F350.00 Sciatic nerve lesion 
F378.00 Intercostal neuropathy 
N113.00 Thoracic spondylosis with myelopathy 
N113000 Single-level thoracic spondylosis with myelopathy 
N113200 Multiple-level thoracic spondylosis with myelopathy 
N115.00 Lumbosacral spondylosis with myelopathy 
N115000 Single-level lumbosacral spondylosis with myelopathy 
N115100 Two-level lumbosacral spondylosis with myelopathy 
N115200 Multiple-level lumbosacral spondylosis with myelopathy 
N11B.00 Thoracic spondylosis with radiculopathy 
N11B000 Single-level thoracic spondylosis with radiculopathy 
N11B100 Two-level thoracic spondylosis with radiculopathy 
N11B200 Multiple-level thoracic spondylosis with radiculopathy 
N11C.00 Lumbosacral spondylosis with radiculopathy 
N11C000 Single-level lumbosacral spondylosis with radiculopathy 
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N11C100 Two-level lumbosacral spondylosis with radiculopathy 
N11C200 Multiple-level lumbosacral spondylosis with radiculopathy 
N11y200 Neuropathic spondylopathy 
N11z100 Spondylosis with myelopathy, NOS 
N129.00 Disc disorder with myelopathy 
N129.11 Prolapsed intervertebral disc with associated myelopathy 
N129000 Unspecified disc disorder with myelopathy 
N129200 Thoracic disc disorder with myelopathy 
N129300 Lumbar disc disorder with myelopathy 
N129z00 Disc disorder with myelopathy NOS 
N12B.00 Disc prolapse with myelopathy 
N12B100 Thoracic disc prolapse with myelopathy 
N12B200 Lumbar disc prolapse with myelopathy 
N12C400 Prolapsed lumbar intervertebral disc with sciatica 
N134.11 Brachial radiculitis 
N144.00 Thoracic and lumbosacral neuritis 
N144000 Thoracic neuritis, unspecified 
N144100 Lumbosacral neuritis, unspecified 
N144z00 Thoracic and lumbosacral neuritis NOS 
Nyu6200 [X]Other spondylosis with myelopathy 
Nyu6300 [X]Other spondylosis with radiculopathy 
Nyu7300 [X]Lumbar + other intervertebral disc disorders with myelopathy 
Nyu7400 [X]Lumbar + other intervertebral disc disorders with radiculopathy 
F330300 Thoracic Outlet Syndrome 
N111.00 Cervical spondylosis with myelopathy 
N111000 Single-level cervical spondylosis with myelopathy 
N111100 Two-level cervical spondylosis with myelopathy 
N111200 Multiple-level cervical spondylosis with myelopathy 
N111300 Cervical myelopathy 
N119.00 Cervical spondylosis with radiculopathy 
N119000 Single-level cervical spondylosis with radiculopathy 
N119100 Two-level cervical spondylosis with radiculopathy 
N119200 Multiple-level cervical spondylosis with radiculopathy 
N129100 Cervical disc disorder with myelopathy 
N12B000 Cervical disc prolapse with myelopathy 
N12zH00 Cervical disc disorder with radiculopathy 
N134.00 Brachial (cervical) neuritis 
N134.12 Cervical radiculitis 
F337000 Nerve root and plexus compressions in neoplastic disease 
F373.00 Polyneuropathy in malignant disease 
F344.00 Causalgia 
N337.12 Reflex sympathetic dystrophy 
N337111 Reflex sympathetic dystrophy 
F302.00 Atypical face pain 
1B46.00 C/O paraesthesia 
29B5.00 O/E - paraesthesia present 
29B5000 O/E - paraesthesia in hands 
A72x100 Mumps polyneuropathy 
C262300 Burning feet syndrome 
C34y400 Gouty neuritis 
F335.00 Neuralgia amyotrophy 
F335.11 Parsonage - Aldren - Turner syndrome 
F342.11 Neuritis ulnar nerve 
F342000 Cubital tunnel syndrome 
F370z00 Acute infective polyneuritis NOS 
FyuAE00 [X]Myelopathy in diseases classified elsewhere 
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G73y400 Acroparaesthesia - Schultze's type 
G73y500 Acroparaesthesia - Nothnagel's type 
G73y511 Nothnagel's vasomotor acroparaesthesia 
G73y600 Acroparaesthesia - unspecified 
R020700 [D]Paraesthesia 
E011100 Korsakov's alcoholic psychosis with peripheral neuritis 
F33..00 Nerve root and plexus disorders 
F337.00 Nerve root and plexus compressions in diseases EC 
F33y.00 Other nerve root or plexus disorder 
F33z.00 Nerve root or plexus disorder NOS 
F34..00 Mononeuritis of upper limb and mononeuritis multiplex 
F340.00 Carpal tunnel syndrome 
F340.12 CTS- Carpal tunnel syndrome 
F341000 Median nerve neuritis 
F341100 Median nerve compression in forearm 
F345.00 Mononeuritis multiplex 
F34y.00 Other upper limb mononeuritis 
F34z.00 Mononeuritis upper limb NOS 
F35..00 Mononeuritis lower limb 
F351.00 Meralgia paraesthetica 
F355.00 Tarsal tunnel syndrome 
F356000 Morton's metatarsalgia 
F35x.00 Other mononeuritis lower limb 
F35y.00 Unspecified mononeuritis lower limb 
F35z.00 Mononeuritis of unspecified site NOS 
F35z.11 Peripheral neuropathy - hereditary or idiopathic 
F36..00 Hereditary and idiopathic peripheral neuropathy 
F360.00 Hereditary peripheral neuropathy 
F360z00 Hereditary peripheral neuropathy NOS 
F362.00 Hereditary sensory neuropathy 
F364.00 Idiopathic progressive polyneuropathy 
F365.00 Neuropathy in association with hereditary ataxia 
F36y.00 Other idiopathic peripheral neuropathy 
F36yz00 Other idiopathic peripheral neuropathy NOS 
F36z.00 Hereditary or idiopathic peripheral neuropathy NOS 
F37..00 Inflammatory and toxic neuropathy 
F37..11 Toxic neuropathy 
F370.00 Acute infective polyneuritis 
F371.00 Polyneuropathy in collagen vascular disease 
F371000 Polyneuropathy in disseminated lupus erythematosus 
F371100 Polyneuropathy in polyarteritis nodosa 
F371z00 Polyneuropathy in collagen vascular disease NOS 
F374000 Polyneuropathy in amyloidosis 
F374100 Polyneuropathy in beriberi 
F374200 Polyneuropathy in vitamin B deficiency 
F374300 Polyneuropathy in diphtheria 
F374500 Polyneuropathy in hypoglycaemia 
F374600 Polyneuropathy in mumps 
F374800 Polyneuropathy in porphyria 
F374900 Polyneuropathy in sarcoidosis 
F374A00 Polyneuropathy in uraemia 
F376.00 Polyneuropathy due to drugs 
F377.00 Other toxic agent polyneuropathy 
F37y.00 Other toxic or inflammatory neuropathy 
F37y000 Serum neuropathy 
F37z.00 Toxic or inflammatory neuropathy NOS 
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Fyu1300 [X]Paraneoplastic neuromyopathy and neuropathy 
Fyu6.00 [X]Nerve, nerve root and plexus disorders 
Fyu6500 [X]Other nerve root and plexus disorders 
Fyu7100 [X}Other inflammatory polyneuropathies 
Fyu7800 [X]Polyneuropathy/other musculoskeletal disorders CE 
Fyu7B00 [X]Inflammatory polyneuropathy, unspecified 
FyuAC00 [X]Autonomic neuropathy/endocrine+metabolic disease 
L164.00 Peripheral neuritis in pregnancy 
N134.14 Ulnar neuritis 
N1y0.00 Recurrent atlantoaxial subluxation with myelopathy 
N242100 Neuritis unspecified 
N242200 Radiculitis unspecified 
F37y100 Axonal sensorimotor neuropathy 
F330.00 Brachial plexus lesions 
F330000 Cervical rib syndrome 
 
Alcohol Withdrawal 
Read Code Read Term 
Eu10800 [X]Alcohol withdrawal-induced seizure 
E01y000 Alcohol withdrawal syndrome 
 
Attention Deficit Disorder 
Read Code Read Term 
Eu90000 [X]Disturbance of activity and attention 
Eu90011 [X]Attention deficit hyperactivity disorder 
E2E0.00 Child attention deficit disorder 
Eu9y700 [X]Attention deficit disorder 
E2E0100 Attention deficit with hyperactivity 
6A61.00 Attention deficit hyperactivity disorder annual review 
ZS91.11 ADD - Attention deficit disorder 
ZS91.00 Attention deficit disorder 
Eu90.00 [X]Hyperkinetic disorders 
Ry13.00 [D]Overactivity 
E2E0z00 Child attention deficit disorder NOS 
E2E2.00 Hyperkinetic conduct disorder 
ZS91.12 [X]Attention deficit disorder 
Eu90100 [X]Hyperkinetic conduct disorder 
ZS9..00 Disorders of attention and motor control 
E2E0000 Attention deficit without hyperactivity 
Eu90z00 [X]Hyperkinetic disorder, unspecified 
E2Ez.00 Hyperkinetic syndrome NOS 
ZS94.00 Minimal brain dysfunction 
E2E1.00 Hyperkinesis with developmental delay 
Eu90111 [X]Hyperkinetic disorder associated with conduct disorder 
Eu90y00 [X]Other hyperkinetic disorders 
Eu90z12 [X]Hyperkinetic syndrome NOS 
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Bipolar Disorder 
Read Code Read Term 
146D.00 H/O: manic depressive disorder 
1S42.00 Manic mood 
6657.11 Lithium monitoring 
6657.12 Started lithium 
E11..00 Affective psychoses 
E110.00 Manic disorder; single episode 
E110000 Single manic episode; unspecified 
E110100 Single manic episode; mild 
E110.11 Hypomanic psychoses 
E110200 Single manic episode; moderate 
E110300 Single manic episode; severe without mention of psychosis 
E110400 Single manic episode; severe; with psychosis 
E110600 Single manic episode in full remission 
E110z00 Manic disorder; single episode NOS 
E111.00 Recurrent manic episodes 
E111000 Recurrent manic episodes; unspecified 
E11..11 Bipolar psychoses 
E111100 Recurrent manic episodes; mild 
E111200 Recurrent manic episodes; moderate 
E11..13 Manic psychoses 
E111300 Recurrent manic episodes; severe without mention psychosis 
E111400 Recurrent manic episodes; severe; with psychosis 
E111500 Recurrent manic episodes; partial or unspecified remission 
E111600 Recurrent manic episodes; in full remission 
E111z00 Recurrent manic episode NOS 
E114.00 Bipolar affective disorder; currently manic 
E114000 Bipolar affective disorder; currently manic; unspecified 
E114100 Bipolar affective disorder; currently manic; mild 
E114.11 Manic-depressive - now manic 
E114200 Bipolar affective disorder; currently manic; moderate 
E114300 Bipolar affect disord; currently manic; severe; no psychosis 
E114400 Bipolar affect disord; currently manic;severe with psychosis 
E114500 Bipolar affect disord;currently manic; part/unspec remission 
E114600 Bipolar affective disorder; currently manic; full remission 
E114z00 Bipolar affective disorder; currently manic; NOS 
E115.00 Bipolar affective disorder; currently depressed 
E115000 Bipolar affective disorder; currently depressed; unspecified 
E115100 Bipolar affective disorder; currently depressed; mild 
E115.11 Manic-depressive - now depressed 
E115200 Bipolar affective disorder; currently depressed; moderate 
E115300 Bipolar affect disord; now depressed; severe; no psychosis 
E115400 Bipolar affect disord; now depressed; severe with psychosis 
E115500 Bipolar affect disord; now depressed; part/unspec remission 
E115600 Bipolar affective disorder; now depressed; in full remission 
E115z00 Bipolar affective disorder; currently depressed; NOS 
E116.00 Mixed bipolar affective disorder 
E116000 Mixed bipolar affective disorder; unspecified 
E116100 Mixed bipolar affective disorder; mild 
E116200 Mixed bipolar affective disorder; moderate 
E116300 Mixed bipolar affective disorder; severe; without psychosis 
E116400 Mixed bipolar affective disorder; severe; with psychosis 
E116500 Mixed bipolar affective disorder; partial/unspec remission 
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E116600 Mixed bipolar affective disorder; in full remission 
E116z00 Mixed bipolar affective disorder; NOS 
E117.00 Unspecified bipolar affective disorder 
E117000 Unspecified bipolar affective disorder; unspecified 
E117100 Unspecified bipolar affective disorder; mild 
E117200 Unspecified bipolar affective disorder; moderate 
E117300 Unspecified bipolar affective disorder; severe; no psychosis 
E117400 Unspecified bipolar affective disorder;severe with psychosis 
E117500 Unspecified bipolar affect disord; partial/unspec remission 
E117600 Unspecified bipolar affective disorder; in full remission 
E117z00 Unspecified bipolar affective disorder; NOS 
E11y.00 Other and unspecified manic-depressive psychoses 
E11y000 Unspecified manic-depressive psychoses 
E11y100 Atypical manic disorder 
E11y300 Other mixed manic-depressive psychoses 
E11yz00 Other and unspecified manic-depressive psychoses NOS 
Eu3..00 [X]Mood - affective disorders 
Eu30.00 [X]Manic episode 
Eu30000 [X]Hypomania 
Eu30100 [X]Mania without psychotic symptoms 
Eu30.11 [X]Bipolar disorder; single manic episode 
Eu30200 [X]Mania with psychotic symptoms 
Eu30211 [X]Mania with mood-congruent psychotic symptoms 
Eu30212 [X]Mania with mood-incongruent psychotic symptoms 
Eu30y00 [X]Other manic episodes 
Eu30z00 [X]Manic episode; unspecified 
Eu30z11 [X]Mania NOS 
Eu31.00 [X]Bipolar affective disorder 
Eu31000 [X]Bipolar affective disorder; current episode hypomanic 
Eu31100 [X]Bipolar affect disorder cur epi manic wout psychotic symp 
Eu31.11 [X]Manic-depressive illness 
Eu31.12 [X]Manic-depressive psychosis 
Eu31.13 [X]Manic-depressive reaction 
Eu31200 [X]Bipolar affect disorder cur epi manic with psychotic symp 
Eu31300 [X]Bipolar affect disorder cur epi mild or moderate depressn 
Eu31400 [X]Bipol aff disord; curr epis sev depress; no psychot symp 
Eu31500 [X]Bipolar affect dis cur epi severe depres with psyc symp 
Eu31600 [X]Bipolar affective disorder; current episode mixed 
Eu31700 [X]Bipolar affective disorder; currently in remission 
Eu31y00 [X]Other bipolar affective disorders 
Eu31y11 [X]Bipolar II disorder 
Eu31y12 [X]Recurrent manic episodes 
Eu31z00 [X]Bipolar affective disorder; unspecified 
Eu33213 [X]Manic-depress psychosis;depressd;no psychotic symptoms 
Eu33312 [X]Manic-depress psychosis;depressed type+psychotic symptoms 
Eu34.00 [X]Persistent mood affective disorders 
Eu34000 [X]Cyclothymia 
Eu34y00 [X]Other persistent mood affective disorders 
Eu34z00 [X]Persistent mood affective disorder; unspecified 
Eu3y.00 [X]Other mood affective disorders 
Eu3y000 [X]Other single mood affective disorders 
Eu3y011 [X]Mixed affective episode 
Eu3y100 [X]Other recurrent mood affective disorders 
Eu3yy00 [X]Other specified mood affective disorders 
Eu3z.00 [X]Unspecified mood affective disorder 
Eu3z.11 [X]Affective psychosis NOS 
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ZV11111 [V]Personal history of manic-depressive psychosis 
ZV11112 [V]Personal history of manic-depressive psychosis 
 
Complex Regional Pain Syndrome 
Read Code Read Term 
F369.00 Complex Regional Pain Syndrome 
F369.11 Chronic Regional Pain Syndrome 
N33C.00 Complex regional pain syndrome type I 
F347.00 Complex regional pain syndrome type II 
N337.00 Algoneurodystrophy 
N337.11 Algodystrophy 
N337.12 Reflex sympathetic dystrophy 
N337111 Reflex Sympathetic dystrophy 
 
Fibromyalgia 
Read Code Read Term 
N239.00  Fibromyalgia 
N248.00 Fibromyalgia 
 
Menopausal Hot Flushes 
Read Code Read Term 
K5A2000 Menopausal flushing 
K5A2011 Hot flushes - menopausal 
 
Migraine  
Read Code Read Term 
1474000 H/O migraine with aura 
8B6N.00 Migraine prophylaxis 
F26..00 Migraine 
F260.00 Classical migraine 
F260.11 Migraine with aura 
F261.00 Common migraine 
F261000 Atypical migraine 
F261.11 Migraine without aura 
F261z00 Common migraine NOS 
F262.00 Migraine variants 
F262200 Abdominal migraine 
F262300 Basilar migraine 
F262400 Ophthalmic migraine 
F262500 Periodic migrainous neuralgia 
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F262800 Migraine induced by oestrogen contraceptive 
F262z00 Migraine variant NOS 
F26y.00 Other forms of migraine 
F26y000 Hemiplegic migraine 
F26y100 Ophthalmoplegic migraine 
F26y111 Moebius' ophthalmoplegic migraine 
F26y200 Status migrainosus 
F26y300 Complicated migraine 
F26yz00 Other forms of migraine NOS 
F26z.00 Migraine NOS 
Fyu5300 [X]Other migraine 
K584.11 Migraine - menstrual 
R090D00 [D]Abdominal migraine 
 
Panic Disorder 
 
 
Restless Legs Syndrome 
Read Code Read Term 
F13z200 Restless Legs Syndrome 
 
  
Read Code Read Term 
225J.00 O/E - panic attack 
E200100 Panic disorder 
E200111 Panic attack 
E202.11 Social phobic disorders 
E202300 Social phobia; fear of eating in public 
E202400 Social phobia; fear of public speaking 
E202500 Social phobia; fear of public washing 
E280.00 Acute panic state due to acute stress reaction 
Eu40100 [X]Social phobias 
Eu41000 [X]Panic disorder [episodic paroxysmal anxiety] 
Eu41011 [X]Panic attack 
Eu41012 [X]Panic state 
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Appendix 3 Surplus Results
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Appendix 3.1 First Gabapentinoids Prescribed to Patients with OA, All Formulations 
 
  
Gabapentin Pregabalin 
Formulation Frequency Formulation Frequency 
Gabapentin 300mg capsules 12,932 Pregabalin 75mg capsules 2,871 
Gabapentin 100mg capsules 11,433 Pregabalin 25mg capsules 2,733 
Gabapentin 600mg capsules 413 Pregabalin 50mg capsules 2,273 
Gabapentin 400mg capsules 238 Pregabalin 150mg capsules 517 
Neurontin 300mg capsules 61 Pregabalin 100mg capsules 378 
Gabapentin 800mg capsules 51 Pregabalin 300mg capsules 267 
Neurontin 100mg capsules 33 Lyrica 25mg capsules 222 
Gabapentin 50mg/ml solution 14 Lyrica 75mg capsules 191 
Gabapentin 250mg/5ml solution 10 Lyrica 50mg capsules 158 
Neurontin 600mg capsules 9 Pregabalin 200mg capsules 98 
Gabapentin 400mg/5ml solution 7 Lyrica 150mg capsules 44 
Neurontin 400mg capsules 3 Pregabalin 225mg capsules  29 
Gabapentin 300mg capsules (Teva UK Ltd) 2 Lyrica 300mg capsules 14 
Neurontin 800mg capsules 1 Lyrica 100mg capsules 14 
Gabapentin 100mg capsules (Teva UK Ltd) 1 Lyrica 200mg capsules 5 
  Pregabalin 20mg/ml solution 4 
  Rewisca 25mg capsules (Consilient Health Ltd) 2 
  Lyrica 20mg/ml solution 1 
  Alzain 25mg capsules (Dr Reddy’s Laboratories (UK) Ltd) 1 
  Alzain 150mg capsules (Dr Reddy’s Laboratories (UK) Ltd) 1 
    
Total 25,208 Total 9,823 
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Appendix 3.2 Number of Practices Contributing Patients Newly Diagnosed with OA to the CPRD, by Calendar Year 
Region Calendar Year 
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
North East 4 4 4 5 7 7 9 8 9 9 10 10 10 10 10 10 10 9 8 6 4 
North West 28 29 31 32 37 41 46 51 61 70 75 75 76 77 77 75 72 69 67 62 49 
Yorkshire & The 
Humber 
16 16 16 16 19 20 23 22 21 22 24 24 22 21 17 15 14 9 6 4 4 
East Midlands 13 13 14 14 14 17 18 21 21 22 21 20 21 20 18 15 10 8 5 1 0 
West Midlands 18 18 19 19 23 31 33 36 44 47 49 50 53 53 55 54 53 52 49 44 35 
East of England 15 16 17 19 20 22 30 35 38 43 46 48 47 44 42 40 36 33 29 25 21 
South West 19 19 20 22 26 28 31 39 41 44 49 51 52 52 54 54 51 49 46 37 27 
South Central 11 11 12 12 13 15 20 31 39 45 46 48 48 48 48 51 51 50 48 47 41 
London 13 14 18 19 20 21 24 31 40 48 52 54 58 61 63 63 62 64 66 63 48 
South East Coast 15 18 18 20 22 24 25 31 36 42 50 54 56 58 58 57 58 57 55 53 50 
Northern Ireland 5 5 5 6 6 7 9 11 13 13 15 20 22 21 21 21 22 22 22 22 22 
Scotland 10 11 12 12 14 17 19 24 28 38 48 61 71 71 73 71 72 69 70 70 69 
Wales 16 16 17 17 19 22 25 31 38 42 45 56 60 61 61 62 64 65 66 65 63 
                      
Total 183 190 203 213 240 272 312 371 429 485 530 571 596 597 597 588 575 556 537 499 433 
 
